WO2023072297A1 - Nitrogen-containing tetracyclic compound, and preparation method therefor and use thereof in medicine - Google Patents

Nitrogen-containing tetracyclic compound, and preparation method therefor and use thereof in medicine Download PDF

Info

Publication number
WO2023072297A1
WO2023072297A1 PCT/CN2022/128914 CN2022128914W WO2023072297A1 WO 2023072297 A1 WO2023072297 A1 WO 2023072297A1 CN 2022128914 W CN2022128914 W CN 2022128914W WO 2023072297 A1 WO2023072297 A1 WO 2023072297A1
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
group
pharmaceutically acceptable
alkyl
heterocyclyl
Prior art date
Application number
PCT/CN2022/128914
Other languages
French (fr)
Chinese (zh)
Inventor
李心
沈峰
董怀德
贺峰
陶维康
Original Assignee
江苏恒瑞医药股份有限公司
上海恒瑞医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司, 上海恒瑞医药有限公司 filed Critical 江苏恒瑞医药股份有限公司
Publication of WO2023072297A1 publication Critical patent/WO2023072297A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Definitions

  • the disclosure belongs to the field of medicine, and relates to a nitrogen-containing tetracyclic compound, its preparation method and its application in medicine.
  • the present disclosure relates to a nitrogen-containing tetracyclic compound represented by general formula (I), its preparation method, a pharmaceutical composition containing the compound, and its use as a therapeutic agent, especially as a KRAS G12C inhibitor and its use in the preparation of medicines for treating and/or preventing tumors.
  • the RAS (Rat Sarcoma Viral Oncogene Homolog) family belongs to the small GTPase superfamily and is widely expressed in various eukaryotes. There are three RAS genes in humans (HRAS, KRAS, and NARS), which can be expressed as four highly related RAS small GTPases (HRAS, KRAS4A, KARS4B, and NRAS). It functions as a binary switch for GDP-GTP regulation. Normally, they have two forms: the GDP (guanosine diphosphate)-bound form in the inactive state and the GTP (guanosine triphosphate)-bound form in the activated state.
  • RAS protein regulates multiple downstream pathways including RAF-MEK-ERK, PI3K/Akt/mTOR by switching between two active states, thereby affecting cell growth, proliferation and differentiation (Nat Rev Cancer, 2007, 7, 295 -308).
  • the RAS gene has a high mutation rate in various tumors such as pancreatic cancer, colorectal cancer, and non-small cell lung cancer.
  • the activated mutant RAS protein will promote abnormal signal transduction, leading to the occurrence and development of cancer, as well as resistance to targeted drugs. Medicinal properties.
  • KRAS mutation is the gene with the highest mutation rate among human oncogenes, accounting for 20-30% of all tumors.
  • KRAS mutations are mainly point mutations, including 12, 13 and 61 amino acid mutations.
  • the mutation of glycine to cysteine (G12C) at position 12 is the most common, and this mutation has a large proportion (14%) in lung cancer, especially non-small cell lung cancer, and also in some colorectal cancer (4%), pancreatic cancer Expressed in cancer (2%) patients.
  • the incidence of mutations in this gene is even greater than the sum of mutations in ALK, RET, and TRK genes.
  • KRAS G12C small molecule inhibitor ARS-1620 can effectively inhibit tumor growth in a variety of KRAS G12C mutant tumor models, and even completely regress the tumor. Since KRAS G12C is a mutant protein in tumor cells, and wild-type KRAS does not have this mutation site, it provides a perfect tumor-selective target (Cell, 2018, 572, 578-589).
  • KRAS G12C has attracted many well-known new drug research and development companies at home and abroad to participate.
  • Amgen s fastest-growing small-molecule KRAS G12C inhibitor Sotorasib (AMG510) was approved by the FDA on May 28, 2021, it is used for patients with non-small cell lung cancer who have received at least one systemic therapy and carry a KRAS G12C mutation , but Eli Lilly's new generation KRAS G12C inhibitor LY3537982 has attracted more attention.
  • Eli Lilly reported the preclinical data of LY3537982 at the annual meeting of the American Association for Cancer Research (AACR) in April 2021. The data showed that LY3537982 inhibited cell activity more than 10 times higher than Sotorasib, and entered the clinic in July 2021 Phase one. It can be seen that highly selective, safe and effective KRAS G12C inhibitors are still needed clinically.
  • Patent applications for KRAS G12C inhibitors have been published, including WO2014152588A1, WO2015054572A1, WO2016164675A1, WO2017087528A1, WO2017201161A1, WO2018119183A2, WO2018206539A1, WO2018217 651A1, WO2019099524A1, WO2019215203A1, WO2020081282A1, WO2020178282A1, WO2021118877A1, etc.
  • X is selected from CR a R b , NR s and an oxygen atom
  • Y is selected from ( CRcRd ) r , NRt - CReRf , CReRf - NRt , O - CReRf and CReRf - O ;
  • Z 1 and Z 2 are the same or different, and are each independently CR u or a nitrogen atom;
  • Ring A is aryl or heteroaryl
  • R a , R b , R c , R d , R e and R f are the same or different, and each independently selected from hydrogen atom, halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, hydroxyl and cyano;
  • R s and R t are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkenyl group and an alkynyl group;
  • R 1 is selected from cyano
  • Each R is the same or different, and is independently selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkoxy group, a hydroxyl group, and an amino group, wherein each of the alkyl and alkoxy groups is independently selected from One or more substituents in halogen, cyano, amino and hydroxyl;
  • R 3 , R 4 , R 5 and R u are the same or different, and each independently selected from hydrogen atom, halogen, cyano, alkyl, alkenyl, alkynyl, -NR 7a R 7b , -C(O)R 8 , -OR 8 , -S(O) p R 8 , cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl Each group is independently selected from one or more of halogen, alkyl, haloalkyl, cyano, -NR 7c R 7d , -OR 8a , cycloalkyl, heterocyclyl, aryl and heteroaryl Substituents are substituted;
  • Each R 6 is the same or different, and each independently selected from hydrogen atom, halogen, cyano, alkyl, alkenyl, alkynyl, -NR 9a R 9b , -C(O)NR 9a R 9b , -C(O )R 10 , -C(O)OR 10 , -OC(O)R 10 , -OR 10 , -S(O) p R 10 , -S(O) p NR 9a R 9b , cycloalkyl, heterocycle radical, aryl and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently selected from halogen, alkyl, haloalkyl, cyano, - NR 9c R 9d , -OR 10a , cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
  • R 11 , R 12 , R 13 and R 14 are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, -NR 15a R 15b , -OR 16 , cyano, cycloalkyl, heterocyclyl, Aryl and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently selected from halogen, oxo, alkyl, haloalkyl, alkoxy One or more substituents in radical, haloalkoxy, cyano, -NR 15c R 15d , hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
  • R 8 , R 8a , R 10 , R 10a and R 16 are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein The alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, oxo, alkoxy, haloalkyl, One or more substituents in haloalkoxy, cyano, -NR 17a R 17b , hydroxyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
  • R 7a , R 7b , R 7c , R 7d , R 9a , R 9b , R 9c , R 9d , R 15a , R 15b , R 15c , R 15d , R 17a and R 17b are the same or different, and each independently selected From a hydrogen atom, an alkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are independently optionally substituted by one or more substituents selected from halogen, oxo, hydroxy, cyano, alkyl, alkoxy, haloalkyl and haloalkoxy;
  • R 7a and R 7b together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
  • R 7c and R 7d together with the attached nitrogen atom form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
  • R 9a and R 9b form a heterocyclic group together with the connected nitrogen atom, wherein the heterocyclic group is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
  • R 9c and R 9d form a heterocyclic group together with the connected nitrogen atom, wherein the heterocyclic group is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
  • R 15a and R 15b together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
  • R 15c and R 15d together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
  • R 17a and R 17b together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
  • r is 1 or 2;
  • s 0, 1, 2, 3, 4, 5 or 6;
  • t 0, 1, 2, 3, 4 or 5;
  • p 0, 1 or 2.
  • the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof wherein Y is (CR c R d ) r , wherein R c and R d are the same or different, and Each is independently selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl, r is 1 or 2; preferably, Y is CH 2 or CH 2 -CH 2 .
  • the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof wherein each R 2 is the same or different, and each independently selected from a hydrogen atom, a halogen, a cyano group, C 1-6 alkyl, C 1-6 alkoxy, hydroxyl and amino, wherein said C 1-6 alkyl is optionally substituted by one or more substituents selected from halogen and cyano; preferably Ground, R 2 is a hydrogen atom.
  • the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof wherein s is 0, 1 or 2; preferably, s is 0.
  • the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof:
  • n 0 or 1
  • Ring A, Z 1 , Z 2 , R 1 , R 3 , R 4 , R 5 , R 6 and t are as defined in the general formula (I).
  • the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof wherein ring A is 6 to 10 membered aryl or 5 to 10 membered hetero Aryl; preferably, ring A is a 5 to 10 membered heteroaryl; more preferably, ring A is an 8 to 10 membered bicyclic heteroaryl group containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulfur in the ring Aryl; more preferably, ring A is benzothienyl.
  • the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof wherein for W is CR 6 or N, t is 0, 1, 2, 3 or 4, R 6 is as defined in general formula (I); preferably, for W is C(CN) or N, t is 0, 1, 2 or 3, R 6 is as defined in general formula (I).
  • the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof wherein R 1 is wherein R 11 , R 12 , R 13 and R 14 are as defined in general formula (I); preferably, R 1 is wherein R 11 , R 12 and R 13 are as defined in the general formula (I).
  • the compound represented by the general formula (I), the general formula (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof the salt:
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
  • the compound represented by general formula (I), general formula (II), general formula (III) or a pharmaceutically acceptable salt thereof is represented by general formula (III-1).
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
  • the compound represented by general formula (I), general formula (II), general formula (III) or a pharmaceutically acceptable salt thereof is represented by general formula (III-2).
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
  • the compound represented by general formula (I), general formula (II), general formula (III), general formula (III-1) or a pharmaceutically acceptable salt thereof is Compounds represented by general formula (III-1-A) or pharmaceutically acceptable salts thereof:
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
  • the compound represented by general formula (I), general formula (II), general formula (III), general formula (III-1) or a pharmaceutically acceptable salt thereof is Compounds represented by general formula (III-1-B) or pharmaceutically acceptable salts thereof:
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
  • the compound represented by general formula (I), general formula (II), general formula (III), general formula (III-2) or a pharmaceutically acceptable salt thereof is A compound represented by general formula (III-2-A) or a pharmaceutically acceptable salt thereof:
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
  • the compound represented by general formula (I), general formula (II), general formula (III), general formula (III-2) or a pharmaceutically acceptable salt thereof is Compounds represented by general formula (III-2-B) or pharmaceutically acceptable salts thereof:
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
  • the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof wherein each R 6 is the same or different, and each independently selected from a hydrogen atom , halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl; preferably, each R 6 is the same or different, and each independently selected from a hydrogen atom, halogen, cyano and -NH 2 .
  • the general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1- B), compounds represented by general formula (III-2-A), general formula (III-2-B) or pharmaceutically acceptable salts thereof wherein each R is the same or different, and each independently selected from a hydrogen atom , halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl; preferably, each R 6 is the same or different, and each independently is a hydrogen atom or halogen; more preferably, each R 6 are the same or different, and are each independently a hydrogen atom or fluorine; most preferably, R 6 is fluorine.
  • the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof wherein t is 0, 1, 2 or 3; preferably, t is 3.
  • the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof wherein t is 0, or each R 6 is the same or different, and each independently is selected from halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl, and t is 1, 2 or 3.
  • R 6 is fluorine and t is 1.
  • the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof wherein X is an oxygen atom; Y is CH 2 or CH 2 -CH 2 ; Z 1 and Z 2 Both are nitrogen atoms; ring A is 5 to 10 membered heteroaryl; R 1 is R 3 , R 4 and R 5 are the same or different, and are independently selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; s is 0; t is 0, or each R 6 is the same or different, and each independently selected from halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl, and t is 1, 2 or 3; R 11 is selected from hydrogen atom, halogen and C 1-6 alkyl; R 12 is selected from hydrogen atom, halogen and C 1-6 alkyl; R 13 is selected from hydrogen atom, halogen and C 1-6 alkyl; and R 14 is selected
  • the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof wherein ring A contains 1, 2 or 3 hetero Atoms of 8 to 10 membered bicyclic heteroaryl; m is 0 or 1; Z 1 and Z 2 are nitrogen atoms; R 1 is R 3 , R 4 and R 5 are the same or different, and are each independently selected from a hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; t is 0, or each R 6 is the same or different, and each independently selected from halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl, and t is 1, 2 or 3; R 11 is selected from hydrogen atom, halogen and C 1-6 Alkyl; R 12 is selected from hydrogen atom, halogen and C 1-6 alkyl; and R 13 is selected from hydrogen atom, halogen and C 1-6 alkyl.
  • Typical compounds of the present disclosure include, but are not limited to:
  • Rings A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , s and t are as defined in general formula (I).
  • Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (II).
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III).
  • Another aspect of the present disclosure relates to a compound represented by general formula (III-1a) or a salt thereof:
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1).
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2).
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1-A).
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1-B).
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2-A).
  • Another aspect of the present disclosure relates to a compound or a salt thereof represented by general formula (III-2-Ba):
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2-B).
  • Typical intermediate compounds of the present disclosure include, but are not limited to:
  • R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
  • Rings A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , s and t are as defined in general formula (Ia).
  • R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
  • Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIa).
  • R W1 and R W2 are the same or different, and each independently is an amino protecting group; preferably, both R W1 and R W2 are tert-butoxycarbonyl;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIIa).
  • R W1 and R W2 are the same or different, and each independently is an amino protecting group; preferably, both R W1 and R W2 are tert-butoxycarbonyl;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1a).
  • R W1 and R W2 are the same or different, and each independently is an amino protecting group; preferably, both R W1 and R W2 are tert-butoxycarbonyl;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2a).
  • Typical intermediate compounds of the present disclosure include, but are not limited to:
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, comprising:
  • L is halogen; preferably, L is Cl;
  • Ring A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 , s and t are as in general formula (I) defined.
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, comprising:
  • L is halogen; preferably, L is Cl;
  • n 0 or 1
  • Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 and t are as defined in the general formula (II).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, comprising:
  • L is halogen; preferably, L is Cl;
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-1) or a pharmaceutically acceptable salt thereof, comprising:
  • L is halogen; preferably, L is Cl;
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III-1).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-2) or a pharmaceutically acceptable salt thereof, comprising:
  • L is halogen; preferably, L is Cl;
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III-2).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-1-A) and general formula (III-1-B) or a pharmaceutically acceptable salt thereof, comprising:
  • the compound of general formula (III-1) or its pharmaceutically acceptable salt is obtained by resolution of general formula (III-1-A) and general formula (III-1-B) compound or its pharmaceutically acceptable salt;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , m and t are as defined in the general formula (III-1).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-2-A) and general formula (III-2-B) or a pharmaceutically acceptable salt thereof, comprising:
  • General formula (III-2) compound or its pharmaceutically acceptable salt obtains general formula (III-2-A) and general formula (III-2-B) compound or its pharmaceutically acceptable salt through resolution;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , m and t are as defined in the general formula (III-2).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (Ia) or a pharmaceutically acceptable salt thereof, comprising:
  • R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
  • Rings A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , s and t are as defined in general formula (Ia).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IIa) or a pharmaceutically acceptable salt thereof, comprising:
  • R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
  • Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIa).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IIIa) or a pharmaceutically acceptable salt thereof, comprising:
  • Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIIa).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-1a) or a pharmaceutically acceptable salt thereof, comprising:
  • Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1a).
  • Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-2a) or a pharmaceutically acceptable salt thereof, comprising:
  • Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2a).
  • compositions which contains the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula ( III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and Table A
  • the present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or its pharmaceutically acceptable salt or the pharmaceutical composition comprising it in preparation Use in a medicament for inhibiting KRAS G12C.
  • the present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or its pharmaceutically acceptable salt or the pharmaceutical composition comprising it in preparation Use in a medicament for treating and/or preventing a disease or condition mediated by KRAS G12C.
  • the present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or its pharmaceutically acceptable salt or the pharmaceutical composition comprising it in preparation Use in medicines for treating and/or preventing tumors.
  • the present disclosure also relates to a method for inhibiting KRAS G12C, which comprises administering a therapeutically effective dose of general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it.
  • the present disclosure also relates to a method for treating and/or preventing a disease or condition mediated by KRAS G12C, which comprises administering a therapeutically effective amount of the general formula (I), general formula (II), general formula (III) to the patient in need , general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula ( III-2-B) and a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it.
  • the present disclosure also relates to a method for treating and/or preventing tumors, which comprises administering an effective dose of general formula (I), general formula (II), general formula (III), general formula ( III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2- B) and a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it.
  • the present disclosure further relates to a general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), Compounds shown in general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and Table A or pharmaceutically acceptable salts thereof, or pharmaceutical combinations comprising them substances, which are used as medicines.
  • the present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it, It acts as a KRAS G12C inhibitor.
  • the present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it, It is used for the treatment and/or prevention of diseases or conditions mediated by KRAS G12C.
  • the present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it, It is used in the treatment and/or prevention of tumors.
  • the disease or condition mediated by KRAS G12C as described above in the present disclosure is preferably a tumor.
  • the tumor as described above in the present disclosure is cancer; said cancer is preferably selected from lung cancer (such as non-small cell lung cancer and small cell lung cancer), pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer , colorectal cancer (such as colon and rectal cancer), liver cancer, breast cancer, prostate cancer, thyroid cancer, stomach cancer, urothelial cancer, testicular cancer, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, bladder cancer , head and neck cancer, renal cancer, nasopharyngeal cancer, bone cancer, lymphoma, melanoma, sarcoma, peripheral neuroepithelial tumor, glioma (such as astrocytoma and glioblastoma), brain tumor and myeloma; More preferably selected from lung cancer (such as non-small cell lung cancer), pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer
  • the active compound may be presented in a form suitable for administration by any suitable route, preferably in unit dosage form, or in such a form that the patient can self-administer a single dose.
  • a unit dosage form of a compound or composition of the present disclosure may be presented as a tablet, capsule, cachet, bottle, powder, granule, lozenge, suppository, reconstituted powder or liquid.
  • a suitable unit dose may be 0.1 to 1000 mg.
  • the pharmaceutical composition of the present disclosure may contain one or more auxiliary materials selected from the following components: fillers (diluents), binders, wetting agents, disintegrants or excipients wait.
  • auxiliary materials selected from the following components: fillers (diluents), binders, wetting agents, disintegrants or excipients wait.
  • the compositions may contain from 0.1 to 99% by weight of active compound.
  • the pharmaceutical composition containing the active ingredient may be in a form suitable for oral administration, such as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixir.
  • Oral compositions can be prepared according to any method known in the art for the preparation of pharmaceutical compositions, and such compositions can contain one or more ingredients selected from the group consisting of sweeteners, flavoring agents, coloring agents and preservatives, To provide pleasing and palatable medicinal preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients suitable for the manufacture of tablets.
  • excipients may be inert excipients, granulating agents, disintegrants, binders and lubricants. These tablets may be uncoated or may be coated by known techniques to mask the taste of the drug or to delay disintegration and absorption in the gastrointestinal tract, thus providing sustained release over an extended period of time.
  • Oral formulations can also be provided in soft gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, or where the active ingredient is mixed with a water-soluble carrier or an oil vehicle.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending, dispersing or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.
  • Oily suspensions can be formulated by suspending the active ingredient in a vegetable or mineral oil.
  • the oily suspensions may contain a thickening agent.
  • Sweetening and flavoring agents as mentioned above may be added to provide a palatable preparation. These compositions can be preserved by adding antioxidants.
  • compositions of the present disclosure may also be in the form of oil-in-water emulsions.
  • the oily phase may be vegetable oil, mineral oil or mixtures thereof.
  • Suitable emulsifiers may be naturally occurring phospholipids, and the emulsions may also contain sweetening agents, flavoring agents, preservatives and antioxidants.
  • Such formulations may also contain a demulcent, a preservative, coloring agents and antioxidants.
  • compositions of the present disclosure may be in the form of sterile injectable aqueous solutions.
  • acceptable vehicles or solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • the sterile injectable preparation can be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oily phase, and the injection or microemulsion can be injected into the patient's bloodstream by local bulk injection.
  • solutions and microemulsions are preferably administered in a manner that maintains a constant circulating concentration of the disclosed compounds.
  • a continuous intravenous delivery device can be used.
  • An example of such a device is the Deltec CADD-PLUS.TM. Model 5400 IV pump.
  • compositions of the present disclosure may be in the form of sterile injectable aqueous or oily suspensions for intramuscular and subcutaneous administration.
  • This suspension may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension prepared in a parenterally acceptable non-toxic diluent or solvent.
  • sterile fixed oils are conveniently employed as a solvent or suspending medium. For this purpose, any blended and fixed oil may be used.
  • fatty acids are also used in the preparation of injectables.
  • the disclosed compounds may be administered in the form of suppositories for rectal administration.
  • These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and will therefore melt in the rectum to release the drug.
  • the dosage of the drug to be administered depends on many factors, including but not limited to the following factors: the activity of the specific compound used, the age of the patient, the weight of the patient, the state of health of the patient, the behavior of the patient , patient's diet, administration time, administration method, rate of excretion, combination of drugs, severity of disease, etc.; in addition, the optimal treatment mode such as the mode of treatment, the daily dosage of the compound or the content of the pharmaceutically acceptable saltkinds can be validated against traditional treatment regimens.
  • alkyl refers to a saturated linear or branched aliphatic hydrocarbon group having 1 to 20 (for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (ie C 1-20 alkyl).
  • the alkyl group is preferably an alkyl group having 1 to 12 carbon atoms (ie, a C 1-12 alkyl group), more preferably an alkyl group having 1 to 6 carbon atoms (ie, a C 1-6 alkyl group).
  • Non-limiting examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl , 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl- 2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1 ,3-Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl , 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methyl
  • Alkyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, ring One or more of alkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • alkenyl refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein the definition of the alkyl group is as described above, and it has 2 to 12 (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (ie C 2-12 alkenyl).
  • the alkenyl group is preferably an alkenyl group having 2 to 6 carbon atoms (ie, a C 2-6 alkenyl group).
  • Non-limiting examples include: vinyl, propenyl, isopropenyl, butenyl, and the like.
  • Alkenyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, the substituents being preferably selected from D atoms, alkoxy, halogen, haloalkyl, haloalkoxy, ring One or more of alkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • alkynyl refers to an alkyl group containing at least one carbon-carbon triple bond in the molecule, wherein the definition of the alkyl group is as described above, and it has 2 to 12 (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (ie C 2-12 alkynyl).
  • the alkynyl group is preferably an alkynyl group having 2 to 6 carbon atoms (ie, a C 2-6 alkynyl group).
  • Non-limiting examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
  • Alkynyl groups may be substituted or unsubstituted, and when substituted, they may be substituted at any available point of attachment, the substituents being preferably selected from the group consisting of D atom, alkoxy, halogen, haloalkyl, haloalkoxy, ring One or more of alkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • alkoxy refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples include: methoxy, ethoxy, propoxy, and butoxy, and the like. Alkoxy may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, One or more of cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic full carbocycle (ie monocyclic cycloalkyl) or polycyclic ring system (ie polycyclic cycloalkyl) having 3 to 20 (eg 3, 4 , 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (ie 3 to 20 membered cycloalkyl).
  • the cycloalkyl group is preferably a cycloalkyl group having 3 to 12 ring atoms (i.e. a 3 to 12 membered cycloalkyl group), more preferably a cycloalkyl group having 3 to 8 ring atoms (i.e. a 3 to 8 membered cycloalkyl group). ), most preferably a cycloalkyl group having 3 to 6 ring atoms (ie a 3 to 6 membered cycloalkyl group).
  • Said monocyclic cycloalkyl non-limiting examples include: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl , cycloheptatrienyl and cyclooctyl, etc.
  • the polycyclic cycloalkyl includes: spirocycloalkyl, condensed cycloalkyl and bridged cycloalkyl.
  • spirocycloalkyl refers to a polycyclic ring system that shares one carbon atom (called a spiro atom) between the rings, which may contain one or more double bonds in the ring, or may contain one or more rings selected from nitrogen, Oxygen and sulfur heteroatoms (the nitrogen may be optionally oxidized, i.e. form nitrogen oxides; the sulfur may be optionally oxo, i.e.
  • the spirocycloalkyl is preferably a spirocycloalkyl having 6 to 14 ring atoms (i.e.
  • spirocycloalkyl a 6 to 14 membered spirocycloalkyl, more preferably a spirocycloalkyl having 7 to 10 ring atoms (i.e. 7 to 10 member spirocycloalkyl).
  • the spirocycloalkyl group includes single spirocycloalkyl and polyspirocycloalkyl (such as double spirocycloalkyl, etc.), preferably single spirocycloalkyl or double spirocycloalkyl, more preferably 3-membered/4-membered, 3-membered Yuan/5 yuan, 3 yuan/6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan, 5 yuan/5 yuan, 5 yuan/ 6
  • connection point can be anywhere; also includes: wait.
  • fused cycloalkyl refers to a polycyclic ring system in which two adjacent carbon atoms are shared between the rings, which is a monocyclic cycloalkyl fused to one or more monocyclic cycloalkyls, or a monocyclic cycloalkyl to a heterocyclic
  • cyclic groups, aryl groups or heteroaryl groups are condensed, wherein the point of attachment is on the monocyclic cycloalkyl group, which can contain one or more double bonds in the ring, and have 5 to 20 (for example, 5 , 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (ie 5 to 20 membered fused cycloalkyl).
  • the condensed cycloalkyl group is preferably a fused cycloalkyl group having 6 to 14 ring atoms (i.e. a 6 to 14 membered fused cycloalkyl group), more preferably a fused cycloalkyl group having 7 to 10 ring atoms (i.e. 7 to 10 fused cycloalkyl).
  • the fused cycloalkyl includes bicyclic fused cycloalkyl and polycyclic fused cycloalkyl (such as tricyclic fused cycloalkyl, tetracyclic fused cycloalkyl, etc.), preferably bicyclic fused cycloalkyl or tricyclic fused cycloalkyl , more preferably 3 yuan/4 yuan, 3 yuan/5 yuan, 3 yuan/6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan , 5 yuan/5 yuan, 5 yuan/6 yuan, 5 yuan/7 yuan, 6 yuan/3 yuan, 6 yuan/4 yuan, 6 yuan/5 yuan, 6 y
  • connection point can be anywhere; also includes:
  • bridged cycloalkyl refers to an all-carbon polycyclic ring system which shares two carbon atoms not directly connected between the rings, which may contain one or more double bonds in the ring, and has 5 to 20 (for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (ie, 5 to 20 membered bridged cycloalkyl).
  • the bridged cycloalkyl group is preferably a bridged cycloalkyl group having 6 to 14 carbon atoms (i.e. a 6 to 14 membered bridged cycloalkyl group), more preferably a bridged cycloalkyl group having 7 to 10 carbon atoms (i.e.
  • the bridged cycloalkyl includes bicyclic bridged cycloalkyl and polycyclic bridged cycloalkyl (such as tricyclic bridged cycloalkyl, tetracyclic bridged cycloalkyl, etc.), preferably bicyclic bridged cycloalkyl or tricyclic bridged cycloalkyl .
  • Non-limiting examples include:
  • Cycloalkyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkane One of oxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl or more.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic heterocycle (i.e. monocyclic heterocyclyl) or polycyclic heterocyclic ring system (i.e. polycyclic heterocyclyl) containing at least one (eg 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may optionally be oxidized, i.e. form nitrogen oxides; the sulfur may optionally be oxo, i.e.
  • the heterocyclic group is preferably a heterocyclic group having 3 to 12 ring atoms (i.e. a 3 to 12 membered heterocyclic group); further preferably a heterocyclic group having 3 to 8 ring atoms (i.e.
  • a 3 to 8 membered heterocyclic group ); more preferably a heterocyclyl group having 3 to 6 ring atoms (ie, a 3- to 6-membered heterocyclyl group); most preferably a heterocyclyl group having 5 or 6 ring atoms (ie, a 5- or 6-membered heterocyclyl group).
  • Non-limiting examples of the monocyclic heterocyclic group include: pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl , Thiomorpholinyl and Homopiperazinyl, etc.
  • the polycyclic heterocyclic groups include spiro heterocyclic groups, condensed heterocyclic groups and bridged heterocyclic groups.
  • spiroheterocyclyl refers to a polycyclic heterocyclic ring system that shares one atom (called a spiro atom) between the rings, which may contain one or more double bonds in the ring, and at least one (such as 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e. to form nitrogen oxides; the sulfur may be optionally oxo, i.e.
  • the condition is to contain at least one monocyclic heterocyclic group and the point of attachment is on the monocyclic heterocyclic group, which has 5 to 20 (such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (ie 5 to 20 membered spiroheterocyclyl).
  • the spiroheterocyclyl is preferably a spiroheterocyclyl having 6 to 14 ring atoms (i.e.
  • the spiroheterocyclyl includes single spiroheterocyclyl and polyspiroheterocyclyl (such as double spiroheterocyclyl, etc.), preferably single spiroheterocyclyl or double spiroheterocyclyl, more preferably 3-membered/4-membered, 3-membered Yuan/5 yuan, 3 yuan/6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan, 5 yuan/5 yuan, 5 yuan/ 6 yuan,
  • fused heterocyclyl refers to a polycyclic heterocyclic ring system which shares two adjacent atoms between the rings, which may contain one or more double bonds, and which contains at least one (for example, 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e. to form nitrogen oxides; the sulfur may be optionally oxo, i.e.
  • sulfoxides or sulfones but not Including -O-O-, -O-S- or -S-S-), which is a monocyclic heterocyclic group fused with one or more monocyclic heterocyclic groups, or a monocyclic heterocyclic group with a cycloalkyl, aryl or heteroaryl
  • the fused heterocyclic group is preferably a fused heterocyclic group having 6 to 14 ring atoms (ie, a 6 to 14 membered fused heterocyclic group), more preferably a condensed heterocyclic group having 7 to 10 ring atoms (ie, 7 to 10 membered fused heterocyclyl).
  • the fused heterocyclic group includes bicyclic and polycyclic fused heterocyclic groups (such as tricyclic fused heterocyclic groups, tetracyclic fused heterocyclic groups, etc.), preferably bicyclic fused heterocyclic groups or tricyclic fused heterocyclic groups, more preferably 3 Yuan/4 Yuan, 3 Yuan/5 Yuan, 3 Yuan/6 Yuan, 4 Yuan/4 Yuan, 4 Yuan/5 Yuan, 4 Yuan/6 Yuan, 5 Yuan/3 Yuan, 5 Yuan/4 Yuan, 5 Yuan/ 5 yuan, 5 yuan/6 yuan, 5 yuan/7 yuan, 6 yuan/3 yuan, 6 yuan/4 yuan, 6 yuan/5 yuan, 6 yuan/6 yuan, 6 yuan/7 yuan, 7 yuan/5 yuan Or a 7-membered/6-membered bicyclic condensed heterocyclic group.
  • bridged heterocyclyl refers to a polycyclic heterocyclic ring system that shares two atoms that are not directly connected between the rings, and may contain one or more double bonds in the ring, and at least one (for example, 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e. to form nitrogen oxides; the sulfur may be optionally oxo, i.e.
  • the bridged heterocyclic group is preferably a bridged heterocyclic group having 6 to 14 ring atoms (i.e. a 6 to 14 membered bridged heterocyclic group), more preferably a bridged heterocyclic group having 7 to 10 ring atoms (i.e. 7 to 10 bridged heterocyclyl).
  • bicyclic bridged heterocyclic group and polycyclic bridged heterocyclic group such as tricyclic bridged heterocyclic group, tetracyclic bridged heterocyclic group, etc.
  • bicyclic bridged heterocyclic group or tricyclic bridged heterocyclic group base preferably bicyclic bridged heterocyclic group or tricyclic bridged heterocyclic group base.
  • Non-limiting examples include:
  • the heterocyclyl group may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, the substituents are preferably selected from D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkane One of oxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl or more.
  • aryl refers to a monocyclic all-carbon aromatic ring (i.e., a monocyclic aryl) or a polycyclic aromatic ring system (i.e., a polycyclic aryl) having a conjugated ⁇ -electron system, which has 6 to 14 (e.g., 6 , 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (ie 6 to 14 membered aryl).
  • the aryl group is preferably an aryl group having 6 to 10 ring atoms (ie, a 6 to 10 membered aryl group).
  • the monocyclic aryl group such as phenyl.
  • Non-limiting examples of the polycyclic aryl group include: naphthyl, anthracenyl, phenanthrenyl and the like.
  • the polycyclic aryl also includes the condensing of phenyl with one or more of heterocyclic or cycloalkyl, or the fused of naphthyl with one or more of heterocyclic or cycloalkyl, wherein the connection point On phenyl or naphthyl, and in this case, the number of ring atoms continues to mean the number of ring atoms in a polycyclic aromatic ring system, non-limiting examples include:
  • Aryl groups may be substituted or unsubstituted, and when substituted, they may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy one or Multiple.
  • heteroaryl refers to a monocyclic heteroaryl ring (ie, monocyclic heteroaryl) or a polycyclic heteroaryl ring system (ie, polycyclic heteroaryl) having a conjugated ⁇ -electron system, which contains at least one (eg 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may optionally be oxidized, i.e. form nitrogen oxides; the sulfur may optionally be oxo, i.e.
  • the heteroaryl group is preferably a heteroaryl group having 5 to 10 ring atoms (i.e. a 5 to 10 membered heteroaryl group), more preferably a monocyclic heteroaryl group having 5 or 6 ring atoms (i.e. a 5 or 6 membered heteroaryl group).
  • ring heteroaryl or bicyclic heteroaryl having 8 to 10 ring atoms (i.e.
  • 8 to 10 membered bicyclic heteroaryl most preferably containing 1, 2 or 3 heteroaryls selected from nitrogen, oxygen and sulfur in the ring
  • Non-limiting examples of the monocyclic heteroaryl include: furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl , pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridyl, pyrimidinyl, pyridonyl, N-alkylpyridone (such as etc.), pyrazinyl, pyridazinyl, etc.
  • the polycyclic heteroaryl non-limiting examples include: indolyl, indazolyl, quinolinyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophene group, quinazoline group, benzothiazolyl group, carbazolyl group, etc.
  • the polycyclic heteroaryl also includes a monocyclic heteroaryl fused with one or more aryls, wherein the point of attachment is on the aromatic ring, and in this case the number of ring atoms continues to represent the polycyclic heteroaryl The number of ring atoms in the system.
  • the polycyclic heteroaryl also includes monocyclic heteroaryl fused with one or more of cycloalkyl or heterocyclic, wherein the point of attachment is on the monocyclic heteroaryl ring, and in this case, the ring
  • the number of atoms continues to indicate the number of ring atoms in the polycyclic heteroaryl ring system.
  • Non-limiting examples include:
  • Heteroaryl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkane One or more of oxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
  • amino-protecting group refers to an easily detachable group introduced on an amino group in order to keep the amino group unchanged when other parts of the molecule are reacted.
  • Non-limiting examples include: (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), methoxycarbonyl (Fmoc), allyl Oxycarbonyl (Alloc), Trimethylsilylethoxycarbonyl (Teoc), Methoxycarbonyl, Ethoxycarbonyl, Phthalyl (Pht), p-Toluenesulfonyl (Tos), Trifluoroacetyl (Tfa), Trityl (Trt), 2,4-dimethoxybenzyl (DMB), acetyl, benzyl, allyl, p-methoxybenzyl, etc.
  • hydroxyl protecting group refers to an easy-to-remove group introduced on the hydroxyl group, which is used to block or protect the hydroxyl group and react on other functional groups of the compound.
  • Non-limiting examples include: trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS), tert-butyl Diphenylsilyl (TBDPS), methyl, tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), methyl Acyl, acetyl, benzoyl, p-nitrobenzoyl, etc.
  • cycloalkyloxy refers to cycloalkyl-O-, wherein cycloalkyl is as defined above.
  • heterocyclyloxy refers to heterocyclyl-O-, wherein heterocyclyl is as defined above.
  • aryloxy refers to aryl-O-, wherein aryl is as defined above.
  • heteroaryloxy refers to heteroaryl-O-, wherein heteroaryl is as defined above.
  • alkylthio refers to alkyl-S-, wherein alkyl is as defined above.
  • haloalkyl refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
  • haloalkoxy refers to an alkoxy group substituted with one or more halogens, wherein alkoxy group is as defined above.
  • deuteroalkyl refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
  • hydroxyalkyl refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • hydroxyl refers to -OH.
  • mercapto refers to -SH.
  • amino refers to -NH2 .
  • cyano refers to -CN.
  • nitro refers to -NO2 .
  • carboxylate refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O- or (cycloalkyl)C(O )O-, wherein alkyl and cycloalkyl are as defined above.
  • stereoisomer refers to isomers that are identical in structure but differ in the arrangement of the atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (e.g. racemates, mixtures of diastereomers) . Substituents in compounds of the present disclosure may be present with additional asymmetric atoms.
  • Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers, and (D)- and (L)-isomer Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers, and (D)- and (L)-isomer.
  • An isomer of a certain compound in the present disclosure can be prepared by asymmetric synthesis or chiral auxiliary agents, or, when the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxyl), with appropriate optical Reactive acids or bases form diastereomeric salts, which are then resolved by conventional methods well known in the art to yield the pure isomers. Furthermore, separation of enantiomers and diastereomers is usually accomplished by chromatography.
  • the bond Indicates unassigned configuration, i.e. if chiral isomers exist in the chemical structure, the bond can be or both Two configurations. For all carbon-carbon double bonds, even if only one configuration is named, both Z and E forms are included.
  • tautomer or tautomeric form
  • tautomer refers to structural isomers that exist in equilibrium and are readily converted from one isomeric form to the other. It includes all possible tautomers, ie present as single isomers or as mixtures of said tautomers in any ratio. Non-limiting examples include: keto-enol, imine-enamine, lactam-lactam, and the like.
  • An example of a lactam-lactim equilibrium is between A and B as shown below:
  • Atropisomers may contain atropisomers.
  • the term "atropisomer" is the result of hindered or greatly slowed rotation about a single bond in a molecule (due to steric interactions with the rest of the molecule and the asymmetry of the substituents at either end of the single bond) ) resulting in conformational stereoisomers whose interconversion is slow enough to allow separation and isolation under predetermined conditions.
  • certain compounds of the present disclosure may be present as a mixture of atropisomers (e.g., an equal mixture, a mixture enriched in one atropisomer, etc.) or as a purified atropisomer exist. Non-limiting examples include: wait.
  • isotopic derivatives refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass.
  • isotopes that may be incorporated into compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, etc., such as 2 H (deuterium, D), respectively, 3 H (tritium, T), 11 C, 13 C, 14 C, 15 N , 17 O, 18 O, 32 p, 33 p, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 125 I, 129 I, and 131 I, etc., preferably deuterium.
  • deuterated drugs Compared with non-deuterated drugs, deuterated drugs have the advantages of reducing toxic and side effects, increasing drug stability, enhancing curative effect, and prolonging the biological half-life of drugs. All permutations of isotopic composition of the disclosed compounds, whether radioactive or not, are included within the scope of the present disclosure.
  • Each available hydrogen atom attached to a carbon atom may be independently replaced by a deuterium atom, wherein the replacement of deuterium may be partial or complete, and partial deuterium replacement means that at least one hydrogen is replaced by at least one deuterium.
  • deuterium D When a position is specifically designated as deuterium D, the position is understood to have an abundance of deuterium (ie at least 15% deuterium incorporation) that is at least 1000 times greater than the natural abundance of deuterium (which is 0.015%).
  • Exemplary compounds having a natural abundance greater than deuterium can be at least 1000 times more abundant deuterium (i.e. at least 15% deuterium incorporation), at least 2000 times more abundant deuterium (i.e. at least 30% deuterium incorporation) , at least 3000 times the abundance of deuterium (i.e. at least 45% deuterium incorporation), at least 3340 times the abundance of deuterium (i.e. at least 50.1% deuterium incorporation), at least 3500 times the abundance of deuterium (i.e.
  • deuterium incorporation at least 52.5% deuterium incorporation
  • at least 4000-fold more abundant deuterium i.e. at least 60% deuterium incorporation
  • at least 4500-fold more abundant deuterium i.e. at least 67.5% deuterium incorporation
  • at least 5000-fold Deuterium in abundance i.e. at least 75% deuterium incorporation
  • deuterium in at least 5500 times abundance i.e. at least 82.5% deuterium incorporation
  • deuterium in at least 6000 times abundance i.e. at least 90% deuterium incorporation deuterium incorporation
  • at least 6333.3 times the abundance of deuterium i.e. at least 95% deuterium incorporation
  • at least 6466.7 times the abundance of deuterium i.e.
  • deuterium incorporation at least 97% deuterium incorporation
  • at least 6600 times the abundance of deuterium That is, at least 99% deuterium incorporation
  • at least 6633.3 times the abundance of deuterium ie, at least 99.5% deuterium incorporation
  • or higher abundance of deuterium at least 97% deuterium incorporation
  • alkyl optionally (optionally) substituted by halogen or cyano includes the case where the alkyl is substituted by halogen or cyano and the case where the alkyl is not substituted by halogen or cyano.
  • Substituted or “substituted” means that one or more hydrogen atoms in a group, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms are independently substituted by the corresponding number of substituents. Possible or impossible substitutions can be determined (by experiment or theory) by those skilled in the art without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated bond such as an alkene.
  • “Pharmaceutical composition” means a mixture containing one or more compounds described herein, or a pharmaceutically acceptable salt thereof, and other chemical components, such as pharmaceutically acceptable carriers and excipients.
  • the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
  • “Pharmaceutically acceptable salt” refers to a salt of a compound of the present disclosure, which may be selected from inorganic or organic salts. Such salts are safe and effective when used in mammals, and have proper biological activity. They can be prepared separately during the final isolation and purification of the compound, or by reacting the appropriate group with an appropriate base or acid.
  • Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include inorganic acids as well as organic acids.
  • the term "therapeutically effective amount” refers to an amount of the drug or agent sufficient to achieve, or at least partially achieve, the desired effect.
  • the determination of the therapeutically effective dose varies from person to person, depending on the age and general condition of the recipient, and also depends on the specific active substance. The appropriate therapeutically effective dose in individual cases can be determined by those skilled in the art according to routine tests.
  • the term "pharmaceutically acceptable” means those compounds, materials, compositions and/or dosage forms, which are suitable for use in contact with patient tissues without undue toxicity, irritation, allergic reaction or Other problems or complications that have a reasonable benefit/risk ratio and are valid for the intended use.
  • the preparation method of the compound represented by the general formula (I) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • L is halogen; preferably, L is Cl;
  • Ring A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 , s and t are as in general formula (I) defined.
  • the preparation method of the compound represented by the general formula (II) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • L is halogen; preferably, L is Cl;
  • n 0 or 1
  • Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 and t are as defined in the general formula (II).
  • the preparation method of the compound represented by the general formula (III) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • L is halogen; preferably, L is Cl;
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III).
  • the preparation method of the compound represented by the general formula (III-1) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • L is halogen; preferably, L is Cl;
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III-1).
  • the preparation method of the compound represented by the general formula (III-2) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • L is halogen; preferably, L is Cl;
  • W is C(CN) or N;
  • t 0, 1, 2 or 3;
  • n 0 or 1
  • Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III-2).
  • the preparation method of the compound represented by general formula (III-1-A) and general formula (III-1-B) or a pharmaceutically acceptable salt thereof of the present disclosure comprises the following steps:
  • the compound of general formula (III-1) or its pharmaceutically acceptable salt is resolved by high performance liquid phase preparative chromatography to obtain the compound of general formula (III-1-A) and general formula (III-1-B) or its pharmaceutically acceptable of salt;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , m and t are as defined in the general formula (III-1).
  • the preparation method of the compound represented by general formula (III-2-A) and general formula (III-2-B) or a pharmaceutically acceptable salt thereof of the present disclosure comprises the following steps:
  • the compound of general formula (III-2) or its pharmaceutically acceptable salt is resolved by high performance liquid phase preparative chromatography to obtain the compound of general formula (III-2-A) and general formula (III-2-B) or its pharmaceutically acceptable of salt;
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , m and t are as defined in the general formula (III-2).
  • the preparation method of the compound represented by the general formula (Ia) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • RL is halogen; preferably, RL is Br;
  • R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
  • R X selected from R is a hydrogen atom or a C 1-6 alkyl group
  • Rings A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , s and t are as defined in general formula (Ia).
  • the preparation method of the compound represented by the general formula (IIa) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • RL is halogen; preferably, RL is Br;
  • R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
  • R X selected from R is a hydrogen atom or a C 1-6 alkyl group
  • Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIa).
  • the preparation method of the compound represented by the general formula (IIIa) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • RL is halogen; preferably, RL is Br;
  • Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
  • R X selected from R is a hydrogen atom or a C 1-6 alkyl group
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIIa).
  • the preparation method of the compound represented by the general formula (III-1a) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • RL is halogen; preferably, RL is Br;
  • Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
  • R X selected from R is a hydrogen atom or a C 1-6 alkyl group
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1a).
  • the preparation method of the compound represented by the general formula (III-2a) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
  • RL is halogen; preferably, RL is Br;
  • Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
  • R X selected from R is a hydrogen atom or a C 1-6 alkyl group
  • W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2a).
  • the Suzuki coupling reaction is preferably carried out in the presence of a base (such as cesium carbonate) and a metal catalyst (such as bis(diphenylphosphinephenyl ether)palladium(II) dichloride).
  • a base such as cesium carbonate
  • a metal catalyst such as bis(diphenylphosphinephenyl ether)palladium(II) dichloride.
  • the bases that provide basic conditions include organic bases and inorganic bases
  • the organic bases include but are not limited to triethylamine, N,N-diisopropylethylamine, n-butyllithium, diisopropyl lithium amide, potassium acetate, sodium acetate, sodium ethoxide, sodium tert-butoxide and potassium tert-butoxide
  • the inorganic bases include but not limited to sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, anhydrous potassium carbonate, carbonic acid Cesium, sodium hydroxide, lithium hydroxide monohydrate, lithium hydroxide and potassium hydroxide, preferably anhydrous potassium carbonate.
  • the acids providing acidic conditions include organic acids and inorganic acids.
  • the organic acids include but are not limited to trifluoroacetic acid, formic acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, Me 3 SiCl and TMSOTf, preferably Trifluoroacetic acid;
  • said inorganic acid includes but not limited to hydrogen chloride, hydrogen chloride in 1,4-dioxane solution, hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid.
  • the above synthesis scheme is preferably carried out in a solvent, and the solvent used includes but is not limited to: ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-Hexane, Dimethyl Sulfoxide, 1,4-Dioxane, Water, N,N-Dimethylformamide, N,N-Dimethylacetamide and mixtures thereof.
  • the solvent used includes but is not limited to: ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-Hexane, Dimethyl Sulfoxide, 1,4-Dioxane
  • NMR nuclear magnetic resonance
  • MS mass spectroscopy
  • MS was determined with Agilent 1200/1290 DAD-6110/6120 Quadrupole MS liquid mass spectrometer (manufacturer: Agilent, MS model: 6110/6120 Quadrupole MS).
  • HPLC High performance liquid chromatography
  • Chiral HPLC analysis was performed using an Agilent 1260 DAD high performance liquid chromatograph.
  • the CombiFlash rapid preparation instrument uses Combiflash Rf200 (TELEDYNE ISCO).
  • the thin-layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate.
  • the specification of the silica gel plate used in thin-layer chromatography (TLC) is 0.15mm-0.2mm, and the specification of thin-layer chromatography separation and purification products is 0.4mm. ⁇ 0.5mm.
  • Silica gel column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
  • the known starting materials of the present disclosure can be adopted or synthesized according to methods known in the art, or can be purchased from ABCR GmbH & Co.KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc), Darui Chemicals and other companies.
  • the reactions can all be carried out under an argon atmosphere or a nitrogen atmosphere.
  • the argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a volume of about 1 L.
  • the hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
  • the pressurized hydrogenation reaction uses Parr 3916EKX hydrogenation instrument and Qinglan QL-500 hydrogen generator or HC2-SS hydrogenation instrument.
  • the hydrogenation reaction is usually vacuumized and filled with hydrogen, and the operation is repeated 3 times.
  • the solution refers to an aqueous solution.
  • reaction temperature is room temperature, which is 20°C to 30°C.
  • the monitoring of the reaction process in the embodiment adopts thin-layer chromatography (TLC), the developer used for reaction, the eluent system of the column chromatography that purifies compound adopts and the developer system of thin-layer chromatography comprise: A: Petroleum ether/ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and it can also be adjusted by adding a small amount of basic or acidic reagents such as triethylamine and acetic acid.
  • TLC thin-layer chromatography
  • HPLC analysis retention time 1.16 minutes, purity: 99% (chromatographic column: ACQUITY C18, 1.7 ⁇ m, 2.1*50mm; mobile phase: water (10mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%).
  • Benzyl (S)-(4-((tert-butyldimethylsilyl)oxy)-1-oxobutan-2-yl)carbamate 2a (2.2 g, 6.25 mmol, was prepared by the known method " Angewandte Chemie-International Edition, 2004, vol.43, no.29, p.3818-3822 and its Supporting Information "prepared), 2-aminoacetate ethyl ester hydrochloride (1.7g, 12.1mmol, Shanghai Bide ) was dissolved in methanol (15mL), glacial acetic acid (750mg, 12.5mmol) and sodium cyanoborohydride (600mg, 10.03mmol) were added successively, and the reaction was stirred for 14 hours.
  • reaction solution was neutralized by adding potassium carbonate and filtered, the filtrate was concentrated under reduced pressure, water was added, extracted with ethyl acetate (20mL ⁇ 3), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered to remove the dryness solvent, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 2b (0.9 g, yield: 33.9%).
  • HPLC analysis retention time 1.12 minutes, purity: 99% (chromatographic column: ACQUITY C18, 1.7 ⁇ m, 2.1*50mm; mobile phase: water (10mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%).
  • the compound N-benzyloxycarbonyl-D-homoserine 3a (20g, 78.9mmol, Shanghai Shaoyuan) was dissolved in a mixed solvent of methanol (60mL) and n-hexane (150mL), and 2.0M trimethylsilyl weight Nitrogen methane in n-hexane solution (79 mL), stirred for 6 hours, and the reaction solution was concentrated under reduced pressure to obtain the crude title compound 3b (21 g), which was directly used in the next reaction without purification.
  • reaction solution was neutralized by adding potassium carbonate and filtered, the filtrate was concentrated under reduced pressure, water was added, extracted with ethyl acetate (50mL ⁇ 3), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered to remove the dryness solvent, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 3e (2.5 g, yield: 36.4%).
  • H358 cells (ATCC, CRL-5807) were cultured with RPMI1640 medium (Hyclone, SH30809.01) (ie complete medium) containing 10% fetal bovine serum (Corning, 35-076-CV).
  • RPMI1640 medium Hyclone, SH30809.01
  • complete medium 10% fetal bovine serum
  • H358 cells were seeded in a 96-well plate at a density of 1200 cells/well using complete medium, 100 ⁇ L of cell suspension per well, and cultured overnight in a 37°C, 5% CO 2 cell incubator.
  • Add 10 ⁇ L of the compound to be tested in serial dilution prepared in complete medium to each well.
  • the final concentration of the compound is 9 concentration points of 5-fold serial dilution starting from 10 ⁇ M.
  • a blank control containing 0.5% DMSO is set, and the wells are Place the plate in a cell culture incubator at 37°C, 5% CO 2 for 120 hours.
  • the 96-well cell culture plate was taken out, and 50 ⁇ L of luminescent cell activity detection reagent ( Luminescent Cell Viability Assay) (Promega, G7573), after standing at room temperature for 10 minutes, using a multifunctional microplate microplate reader (PerkinElmer, 2105) read the luminescent signal value, and calculate the IC 50 value of the inhibitory activity of the compound with Graphpad Prism software.
  • luminescent cell activity detection reagent Luminescent Cell Viability Assay
  • the disclosed compound has inhibitory effect on H358 cell proliferation.
  • H358 cells (ATCC, CRL-5807) were cultured with RPMI1640 (Hyclone, SH30809.01) medium (ie complete medium) containing 10% fetal calf serum (Corning, 35-076-CV).
  • RPMI1640 Hyclone, SH30809.01
  • medium ie complete medium
  • fetal calf serum 10% fetal calf serum
  • H358 cells were seeded in a 96-well plate at a density of 25,000 cells/well using complete medium, 190 ⁇ L of cell suspension per well, and cultured overnight in a 37°C, 5% CO 2 cell incubator.
  • the final concentration of the compound is 9 concentration points of 6-fold serial dilution starting from 10 ⁇ M.
  • a blank control containing 0.5% DMSO is set, and the wells are Place the plate in a cell culture incubator at 37°C, 5% CO 2 and incubate for 3 hours. After 3 hours, the 96-well cell culture plate was taken out, the medium was sucked off, and 200 ⁇ L of PBS (Shanghai Yuanpei Biotechnology Co., Ltd., B320) was added to each well to wash once. The PBS was sucked off, and 50 ⁇ L of lysis buffer (Cisbio, 64KL1FDF) containing blocking agent (Cisbio, 64KB1AAC) was added to each well, and the plate was placed on a shaker at room temperature for lysis for 30 minutes.
  • lysis buffer Cisbio, 64KL1FDF
  • blocking agent Cisbio, 64KB1AAC
  • PHERAstar multifunctional microplate reader BMG Labtech, PHERAstar FS
  • Graphpad Prism software to calculate compound inhibition according to the ratio of compound concentration and pERK/total ERK IC50 values for activity.
  • the disclosed compound has inhibitory effect on ERK phosphorylation in H358 cells.
  • MIA PaCa-2 cells (ATCC, CRL-1420) were treated with DMEM/HIGH GLUCOSE (GE, SH30243) containing 10% fetal bovine serum (Corning, 35-076-CV) and 2.5% horse serum (Beyond Biotechnology, C0262). .01) medium (i.e. complete medium) for cultivation.
  • MIA PaCa-2 cells were seeded in a 96-well plate at a density of 500 cells/well using complete medium, 90 ⁇ L of cell suspension per well, and cultured overnight in a 37°C, 5% CO 2 cell incubator.
  • the final concentration of the compound is 9 concentration points of 5-fold gradient dilution starting from 10 ⁇ M.
  • a blank control containing 0.5% DMSO is set, and the wells are Plates were placed in a cell culture incubator at 37°C, 5% CO 2 for 72 hours.
  • the 96-well cell culture plate was taken out, and 50 ⁇ L of luminescent cell activity detection reagent ( Luminescent Cell Viability Assay) (Promega, G7573), after standing at room temperature for 10 minutes, the luminescent signal value was read using a multi-functional microplate microplate reader (PerkinElmer, EnVision2015).
  • the IC50 value of the inhibitory activity of the compound was calculated with Graphpad Prism software.
  • the disclosed compound has inhibitory effect on the proliferation of MIA PaCa-2 cells.

Abstract

The present disclosure relates to a nitrogen-containing tetracyclic compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a nitrogen-containing tetracyclic compound represented by general formula (I) and a preparation method therefor, a pharmaceutical composition containing said compound, and the use of said compound as a therapeutic agent, in particular the use as a KRAS G12C inhibitor and the use in preparation of drugs for treating and/or preventing tumors.

Description

含氮的四环化合物、其制备方法及其在医药上的应用Nitrogen-containing tetracyclic compound, its preparation method and its application in medicine 技术领域technical field
本公开属于医药领域，涉及一种含氮的四环化合物、其制备方法及其在医药上的应用。具体而言，本公开涉及一种通式(I)所示的含氮的四环化合物、其制备方法及含有该化合物的药物组合物以及其作为治疗剂的用途，特别是作为KRAS G12C抑制剂的用途和在制备用于治疗和/或预防肿瘤的药物中的用途。The disclosure belongs to the field of medicine, and relates to a nitrogen-containing tetracyclic compound, its preparation method and its application in medicine. Specifically, the present disclosure relates to a nitrogen-containing tetracyclic compound represented by general formula (I), its preparation method, a pharmaceutical composition containing the compound, and its use as a therapeutic agent, especially as a KRAS G12C inhibitor and its use in the preparation of medicines for treating and/or preventing tumors.
背景技术Background technique
RAS(Rat Sarcoma Viral Oncogene Homolog)家族属于小GTP酶超家族，广泛表达于各类真核生物。人体中有三种RAS基因(HRAS、KRAS和NARS)，可表达为四种高度相关的RAS小GTP酶(HRAS、KRAS4A、KARS4B和NRAS)。其作为GDP-GTP调控的二元开关发生作用。通常情况下它们有两种表现形式：非激活状态下的GDP(二磷酸鸟苷)结合形式和激活状态下的GTP(三磷酸鸟苷)结合形式。RAS蛋白通过在两种活性状态间切换，来调控包括RAF-MEK-ERK、PI3K/Akt/mTOR在内的多个下游通路，从而影响细胞的生长、增殖和分化(Nat Rev Cancer,2007,7,295-308)。RAS基因在胰腺癌、结直肠癌、非小细胞肺癌等多种肿瘤中突变率较高，激活的突变RAS蛋白会促进异常信号转导，从而导致癌症发生和发展，以及对靶向药产生耐药性。其中KRAS突变是人类致癌基因中突变率最高的基因，占所有肿瘤的20～30％。The RAS (Rat Sarcoma Viral Oncogene Homolog) family belongs to the small GTPase superfamily and is widely expressed in various eukaryotes. There are three RAS genes in humans (HRAS, KRAS, and NARS), which can be expressed as four highly related RAS small GTPases (HRAS, KRAS4A, KARS4B, and NRAS). It functions as a binary switch for GDP-GTP regulation. Normally, they have two forms: the GDP (guanosine diphosphate)-bound form in the inactive state and the GTP (guanosine triphosphate)-bound form in the activated state. RAS protein regulates multiple downstream pathways including RAF-MEK-ERK, PI3K/Akt/mTOR by switching between two active states, thereby affecting cell growth, proliferation and differentiation (Nat Rev Cancer, 2007, 7, 295 -308). The RAS gene has a high mutation rate in various tumors such as pancreatic cancer, colorectal cancer, and non-small cell lung cancer. The activated mutant RAS protein will promote abnormal signal transduction, leading to the occurrence and development of cancer, as well as resistance to targeted drugs. Medicinal properties. Among them, KRAS mutation is the gene with the highest mutation rate among human oncogenes, accounting for 20-30% of all tumors.
对于KRAS蛋白的突变形式和信号通路研究，近年来分子生物学已取得重大进展，然而开发相关的靶向药物却依然挑战重重。在化学药开发方面，由于KRAS和GTP的亲和力非常高，达到60pM，而且细胞内GTP浓度在mM水平，因此这类直接竞争的分子对化合物亲和力要求极高，目前为止还没有成功的案例。在生物药开发方面，抗体药穿透细胞膜靶向KRAS蛋白，药物递送效率比较低下。所以不少研究者曾试图另辟蹊径，希望抑制KRAS下游信号通路中RAF、MEK和ERK等激酶的活性，达到抑制KRAS通路的目的。这类化合物有一定疗效，但是由于下游抑制剂不能完全阻断KRAS信号，而且靶点相关毒副作用很大，导致这些化合物在KRAS突变肿瘤上药效欠佳。因此，开发新作用机理的KRAS抑制剂有非常大的临床应用价值。For the study of mutant forms and signaling pathways of KRAS protein, molecular biology has made significant progress in recent years, but the development of related targeted drugs is still challenging. In the development of chemical drugs, since the affinity between KRAS and GTP is very high, reaching 60pM, and the concentration of GTP in the cell is at the mM level, this type of direct competition molecule requires a very high affinity for the compound, and so far there has been no successful case. In terms of biopharmaceutical development, antibody drugs penetrate the cell membrane and target KRAS protein, and the drug delivery efficiency is relatively low. Therefore, many researchers have tried to find another way, hoping to inhibit the activity of kinases such as RAF, MEK and ERK in the KRAS downstream signaling pathway, so as to achieve the purpose of inhibiting the KRAS pathway. This type of compound has a certain effect, but because the downstream inhibitors cannot completely block KRAS signaling, and the target-related toxic side effects are very large, these compounds are not effective on KRAS mutant tumors. Therefore, the development of KRAS inhibitors with new mechanisms of action has great clinical application value.
KRAS突变以点突变为主，包括12、13和61位氨基酸的突变。其中12位的甘氨酸突变成半胱氨酸(G12C)最为常见，该突变在肺癌、尤其是非小细胞肺癌中比例较大(14％)，此外还在一些结直肠癌(4％)、胰腺癌(2％)患者体内表达。在美国癌症人群中，该基因突变发生率甚至大于ALK、RET、TRK基因突变总和。KRAS mutations are mainly point mutations, including 12, 13 and 61 amino acid mutations. Among them, the mutation of glycine to cysteine (G12C) at position 12 is the most common, and this mutation has a large proportion (14%) in lung cancer, especially non-small cell lung cancer, and also in some colorectal cancer (4%), pancreatic cancer Expressed in cancer (2%) patients. In the cancer population in the United States, the incidence of mutations in this gene is even greater than the sum of mutations in ALK, RET, and TRK genes.
面对KRAS蛋白成药性的难点，加州大学旧金山分校Kevan M.Shokat教授率 先验证了某些特殊的化合物可通过共价键绑定KRAS G12C突变蛋白。通过进一步研究发现，这些共价化合物可与KRAS突变蛋白12位的半胱氨酸结合，并占据II号分子开关区域(switch-II regions)一个疏水别构调节口袋，被绑定的KRAS G12C突变体会被不可逆地锁定在失活状态，从而阻断依赖该蛋白的信号通路和癌细胞生存能力(Nature 2013,503,548-551)。KRAS G12C小分子抑制剂ARS-1620在多种KRAS G12C突变肿瘤模型上都能有效抑制肿瘤生长，甚至使肿瘤完全消退。由于KRAS G12C是肿瘤细胞中的突变蛋白，而野生型KRAS并没有这个突变位点，因此提供了一个完美的肿瘤选择性靶标(Cell,2018,572,578-589)。Facing the difficulty of druggability of KRAS protein, Professor Kevan M.Shokat of University of California, San Francisco took the lead in verifying that some special compounds can bind KRAS G12C mutant protein through covalent bonds. Through further research, it was found that these covalent compounds can bind to the cysteine at position 12 of the KRAS mutant protein and occupy a hydrophobic allosteric regulatory pocket in the switch-II regions, and the bound KRAS G12C mutation The receptors are irreversibly locked in an inactive state, thereby blocking signaling pathways and cancer cell viability that depend on the protein (Nature 2013, 503, 548-551). The KRAS G12C small molecule inhibitor ARS-1620 can effectively inhibit tumor growth in a variety of KRAS G12C mutant tumor models, and even completely regress the tumor. Since KRAS G12C is a mutant protein in tumor cells, and wild-type KRAS does not have this mutation site, it provides a perfect tumor-selective target (Cell, 2018, 572, 578-589).
KRAS G12C吸引了国内外众多知名的新药研发企业参与其中。虽然进展最快的安进的小分子KRAS G12C抑制剂Sotorasib(AMG510)已于2021年5月28日被FDA批准上市，用于至少接受过一次***治疗且携带KRAS G12C突变的非小细胞肺癌患者，但礼来的新一代KRAS G12C抑制剂LY3537982更加备受关注。礼来在2021年4月美国癌症研究协会(AACR)年会上报告了LY3537982的临床前数据，数据显示，LY3537982较Sotorasib的细胞活性抑制高出了10余倍，已于2021年7月进入临床一期。可见，临床上仍需高选择性、安全和有效的KRAS G12C抑制剂。KRAS G12C has attracted many well-known new drug research and development companies at home and abroad to participate. Although Amgen’s fastest-growing small-molecule KRAS G12C inhibitor Sotorasib (AMG510) was approved by the FDA on May 28, 2021, it is used for patients with non-small cell lung cancer who have received at least one systemic therapy and carry a KRAS G12C mutation , but Eli Lilly's new generation KRAS G12C inhibitor LY3537982 has attracted more attention. Eli Lilly reported the preclinical data of LY3537982 at the annual meeting of the American Association for Cancer Research (AACR) in April 2021. The data showed that LY3537982 inhibited cell activity more than 10 times higher than Sotorasib, and entered the clinic in July 2021 Phase one. It can be seen that highly selective, safe and effective KRAS G12C inhibitors are still needed clinically.
现已公开KRAS G12C抑制剂的专利申请包括WO2014152588A1、WO2015054572A1、WO2016164675A1、WO2017087528A1、WO2017201161A1、WO2018119183A2、WO2018206539A1、WO2018217651A1、WO2019099524A1、WO2019215203A1、WO2020081282A1、WO2020178282A1、WO2021118877A1等。Patent applications for KRAS G12C inhibitors have been published, including WO2014152588A1, WO2015054572A1, WO2016164675A1, WO2017087528A1, WO2017201161A1, WO2018119183A2, WO2018206539A1, WO2018217 651A1, WO2019099524A1, WO2019215203A1, WO2020081282A1, WO2020178282A1, WO2021118877A1, etc.
发明内容Contents of the invention
本公开的目的在于提供一种通式(I)所示的化合物或其可药用的盐：The purpose of this disclosure is to provide a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof:
Figure PCTCN2022128914-appb-000001
Figure PCTCN2022128914-appb-000001
其中：in:
X选自CR aR b、NR s和氧原子； X is selected from CR a R b , NR s and an oxygen atom;
Y选自(CR cR d) r、NR t-CR eR f、CR eR f-NR t、O-CR eR f和CR eR f-O； Y is selected from ( CRcRd ) r , NRt - CReRf , CReRf - NRt , O - CReRf and CReRf - O ;
Z 1和Z 2相同或不同，且各自独立地为CR u或氮原子； Z 1 and Z 2 are the same or different, and are each independently CR u or a nitrogen atom;
环A为芳基或杂芳基；Ring A is aryl or heteroaryl;
R a、R b、R c、R d、R e和R f相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、羟烷基、烷氧基、卤代烷氧基、烯基、炔基、羟基和氰基； R a , R b , R c , R d , R e and R f are the same or different, and each independently selected from hydrogen atom, halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, hydroxyl and cyano;
R s和R t相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、羟烷基、烯基和炔基； R s and R t are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkenyl group and an alkynyl group;
R 1选自氰基、
Figure PCTCN2022128914-appb-000002
R 1 is selected from cyano,
Figure PCTCN2022128914-appb-000002
各个R 2相同或不同，且各自独立地选自氢原子、卤素、氰基、烷基、烷氧基、羟基和氨基，其中所述的烷基和烷氧基各自独立地任选被选自卤素、氰基、氨基和羟基中的一个或多个取代基所取代； Each R is the same or different, and is independently selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkoxy group, a hydroxyl group, and an amino group, wherein each of the alkyl and alkoxy groups is independently selected from One or more substituents in halogen, cyano, amino and hydroxyl;
R 3、R 4、R 5和R u相同或不同，且各自独立地选自氢原子、卤素、氰基、烷基、烯基、炔基、-NR 7aR 7b、-C(O)R 8、-OR 8、-S(O) pR 8、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、烷基、卤代烷基、氰基、-NR 7cR 7d、-OR 8a、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； R 3 , R 4 , R 5 and R u are the same or different, and each independently selected from hydrogen atom, halogen, cyano, alkyl, alkenyl, alkynyl, -NR 7a R 7b , -C(O)R 8 , -OR 8 , -S(O) p R 8 , cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl Each group is independently selected from one or more of halogen, alkyl, haloalkyl, cyano, -NR 7c R 7d , -OR 8a , cycloalkyl, heterocyclyl, aryl and heteroaryl Substituents are substituted;
各个R 6相同或不同，且各自独立地选自氢原子、卤素、氰基、烷基、烯基、炔基、-NR 9aR 9b、-C(O)NR 9aR 9b、-C(O)R 10、-C(O)OR 10、-OC(O)R 10、-OR 10、-S(O) pR 10、-S(O) pNR 9aR 9b、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、烷基、卤代烷基、氰基、-NR 9cR 9d、-OR 10a、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Each R 6 is the same or different, and each independently selected from hydrogen atom, halogen, cyano, alkyl, alkenyl, alkynyl, -NR 9a R 9b , -C(O)NR 9a R 9b , -C(O )R 10 , -C(O)OR 10 , -OC(O)R 10 , -OR 10 , -S(O) p R 10 , -S(O) p NR 9a R 9b , cycloalkyl, heterocycle radical, aryl and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently selected from halogen, alkyl, haloalkyl, cyano, - NR 9c R 9d , -OR 10a , cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
R 11、R 12、R 13和R 14相同或不同，且各自独立地选自氢原子、卤素、烷基、-NR 15aR 15b、-OR 16、氰基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、氧代基、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、-NR 15cR 15d、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； R 11 , R 12 , R 13 and R 14 are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, -NR 15a R 15b , -OR 16 , cyano, cycloalkyl, heterocyclyl, Aryl and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently selected from halogen, oxo, alkyl, haloalkyl, alkoxy One or more substituents in radical, haloalkoxy, cyano, -NR 15c R 15d , hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R 8、R 8a、R 10、R 10a和R 16相同或不同，且各自独立地选自氢原子、烷基、羟烷基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、烷基、烯基、炔基、氧代基、烷氧基、卤代烷基、卤代烷氧基、氰基、-NR 17aR 17b、羟基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； R 8 , R 8a , R 10 , R 10a and R 16 are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein The alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, oxo, alkoxy, haloalkyl, One or more substituents in haloalkoxy, cyano, -NR 17a R 17b , hydroxyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R 7a、R 7b、R 7c、R 7d、R 9a、R 9b、R 9c、R 9d、R 15a、R 15b、R 15c、R 15d、R 17a和R 17b相同或不同，且各自独立地选自氢原子、烷基、羟烷基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、氧代基、羟基、氰基、烷基、烷氧基、卤代烷基和卤代烷氧基中的一 个或多个取代基所取代； R 7a , R 7b , R 7c , R 7d , R 9a , R 9b , R 9c , R 9d , R 15a , R 15b , R 15c , R 15d , R 17a and R 17b are the same or different, and each independently selected From a hydrogen atom, an alkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are independently optionally substituted by one or more substituents selected from halogen, oxo, hydroxy, cyano, alkyl, alkoxy, haloalkyl and haloalkoxy;
或者R 7a和R 7b与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 7a and R 7b together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
或者R 7c和R 7d与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 7c and R 7d together with the attached nitrogen atom form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
或者R 9a和R 9b与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 9a and R 9b form a heterocyclic group together with the connected nitrogen atom, wherein the heterocyclic group is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
或者R 9c和R 9d与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 9c and R 9d form a heterocyclic group together with the connected nitrogen atom, wherein the heterocyclic group is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
或者R 15a和R 15b与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 15a and R 15b together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
或者R 15c和R 15d与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 15c and R 15d together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
或者R 17a和R 17b与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 17a and R 17b together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
r为1或2；r is 1 or 2;
s为0、1、2、3、4、5或6；s is 0, 1, 2, 3, 4, 5 or 6;
t为0、1、2、3、4或5；且t is 0, 1, 2, 3, 4 or 5; and
p为0、1或2。p is 0, 1 or 2.
在本公开一些实施方案中，所述的通式(I)所示的化合物或其可药用的盐，其中X为氧原子。In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein X is an oxygen atom.
在本公开一些实施方案中，所述的通式(I)所示的化合物或其可药用的盐，其中Y为(CR cR d) r，其中R c和R d相同或不同，且各自独立地选自氢原子、卤素、C 1-6烷基和C 1-6卤代烷基，r为1或2；优选地，Y为CH 2或CH 2-CH 2。 In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is (CR c R d ) r , wherein R c and R d are the same or different, and Each is independently selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl, r is 1 or 2; preferably, Y is CH 2 or CH 2 -CH 2 .
在本公开一些实施方案中，所述的通式(I)所示的化合物或其可药用的盐，其中各个R 2相同或不同，且各自独立地选自氢原子、卤素、氰基、C 1-6烷基、C 1-6烷氧基、羟基和氨基，其中所述的C 1-6烷基任选被选自卤素和氰基中的一个或多个取代基所取代；优选地，R 2为氢原子。 In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein each R 2 is the same or different, and each independently selected from a hydrogen atom, a halogen, a cyano group, C 1-6 alkyl, C 1-6 alkoxy, hydroxyl and amino, wherein said C 1-6 alkyl is optionally substituted by one or more substituents selected from halogen and cyano; preferably Ground, R 2 is a hydrogen atom.
在本公开一些实施方案中，所述的通式(I)所示的化合物或其可药用的盐，其 中s为0、1或2；优选地，s为0。In some embodiments of the present disclosure, the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, wherein s is 0, 1 or 2; preferably, s is 0.
在本公开一些实施方案中，所述的通式(I)所示的化合物或其可药用的盐，其为通式(II)所示的化合物或其可药用的盐：In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof:
Figure PCTCN2022128914-appb-000003
Figure PCTCN2022128914-appb-000003
其中：in:
m为0或1；m is 0 or 1;
环A、Z 1、Z 2、R 1、R 3、R 4、R 5、R 6和t如通式(I)中所定义。 Ring A, Z 1 , Z 2 , R 1 , R 3 , R 4 , R 5 , R 6 and t are as defined in the general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)所示的化合物或其可药用的盐，其中环A为6至10元芳基或5至10元杂芳基；优选地，环A为5至10元杂芳基；更优选地，环A为环内含有1、2或3个选自氮、氧和硫的杂原子的8至10元双环杂芳基；更优选地，环A为苯并噻吩基。In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof, wherein ring A is 6 to 10 membered aryl or 5 to 10 membered hetero Aryl; preferably, ring A is a 5 to 10 membered heteroaryl; more preferably, ring A is an 8 to 10 membered bicyclic heteroaryl group containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulfur in the ring Aryl; more preferably, ring A is benzothienyl.
在本公开一些实施方案中，所述的通式(I)、通式(II)所示的化合物或其可药用的盐，其中
Figure PCTCN2022128914-appb-000004
为
Figure PCTCN2022128914-appb-000005
W为CR 6或N，t为0、1、2、3或4，R 6如通式(I)中所定义；优选地，
Figure PCTCN2022128914-appb-000006
为
Figure PCTCN2022128914-appb-000007
W为C(CN)或N，t为0、1、2或3，R 6如通式(I)中所定义。 In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof, wherein
Figure PCTCN2022128914-appb-000004
for
Figure PCTCN2022128914-appb-000005
W is CR 6 or N, t is 0, 1, 2, 3 or 4, R 6 is as defined in general formula (I); preferably,
Figure PCTCN2022128914-appb-000006
for
Figure PCTCN2022128914-appb-000007
W is C(CN) or N, t is 0, 1, 2 or 3, R 6 is as defined in general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)所示的化合物或其可药用的盐，其中R 1为
Figure PCTCN2022128914-appb-000008
其中R 11、R 12、R 13和R 14如通式(I)中所定义；优选地，R 1为
Figure PCTCN2022128914-appb-000009
其中R 11、R 12和R 13如通式(I)中所定义。 In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof, wherein R 1 is
Figure PCTCN2022128914-appb-000008
wherein R 11 , R 12 , R 13 and R 14 are as defined in general formula (I); preferably, R 1 is
Figure PCTCN2022128914-appb-000009
wherein R 11 , R 12 and R 13 are as defined in the general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)所示的化合物或其可药用 的盐，其为通式(III)所示的化合物或其可药用的盐：In some embodiments of the present disclosure, the compound represented by the general formula (I), the general formula (II) or a pharmaceutically acceptable salt thereof is a compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof the salt:
Figure PCTCN2022128914-appb-000010
Figure PCTCN2022128914-appb-000010
其中：in:
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(I)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)所示的化合物或其可药用的盐，其为通式(III-1)所示的化合物或其可药用的盐：In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II), general formula (III) or a pharmaceutically acceptable salt thereof is represented by general formula (III-1). The indicated compound or its pharmaceutically acceptable salt:
Figure PCTCN2022128914-appb-000011
Figure PCTCN2022128914-appb-000011
其中：in:
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(I)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)所示的化合物或其可药用的盐，其为通式(III-2)所示的化合物或其可药用的盐：In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II), general formula (III) or a pharmaceutically acceptable salt thereof is represented by general formula (III-2). The indicated compound or its pharmaceutically acceptable salt:
Figure PCTCN2022128914-appb-000012
Figure PCTCN2022128914-appb-000012
其中：in:
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(I)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)所示的化合物或其可药用的盐，其为通式(III-1-A)所示的化合物或其可药用的盐：In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II), general formula (III), general formula (III-1) or a pharmaceutically acceptable salt thereof is Compounds represented by general formula (III-1-A) or pharmaceutically acceptable salts thereof:
Figure PCTCN2022128914-appb-000013
Figure PCTCN2022128914-appb-000013
其中：in:
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(I)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)所示的化合物或其可药用的盐，其为通式(III-1-B)所示的化合物或其可药用的盐：In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II), general formula (III), general formula (III-1) or a pharmaceutically acceptable salt thereof is Compounds represented by general formula (III-1-B) or pharmaceutically acceptable salts thereof:
Figure PCTCN2022128914-appb-000014
Figure PCTCN2022128914-appb-000014
其中：in:
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(I)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-2)所示的化合物或其可药用的盐，其为通式(III-2-A)所示的化合物或其可药用的盐：In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II), general formula (III), general formula (III-2) or a pharmaceutically acceptable salt thereof is A compound represented by general formula (III-2-A) or a pharmaceutically acceptable salt thereof:
Figure PCTCN2022128914-appb-000015
Figure PCTCN2022128914-appb-000015
其中：in:
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(I)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-2)所示的化合物或其可药用的盐，其为通式(III-2-B)所示的化合物或其可药用的盐：In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II), general formula (III), general formula (III-2) or a pharmaceutically acceptable salt thereof is Compounds represented by general formula (III-2-B) or pharmaceutically acceptable salts thereof:
Figure PCTCN2022128914-appb-000016
Figure PCTCN2022128914-appb-000016
其中：in:
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(I)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (I).
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中Z 1和Z 2相同或不同，且各自独立地为CR u或氮原子，其中R u选自氢原子、卤素、氰基、C 1-6烷基、C 2-6烯基和C 2-6炔基；优选地，Z 1和Z 2均为氮原子。 In some embodiments of the present disclosure, the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III- 1-A), general formula (III-1-B), general formula (III-2-A), the compound shown in general formula (III-2-B) or its pharmaceutically acceptable salt, wherein Z and Z 2 are the same or different, and each independently is CR u or a nitrogen atom, wherein R u is selected from hydrogen atom, halogen, cyano, C 1-6 alkyl, C 2-6 alkenyl and C 2-6 alkynyl ; Preferably, both Z 1 and Z 2 are nitrogen atoms.
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中R 3、R 4和R 5相同或不同，且各自独立地选自氢原子、卤素、C 1-6烷基和C 1-6卤代烷基；优选地，R 3、R 4和R 5相同或不同，且各自独立地为氢原子或卤素。 In some embodiments of the present disclosure, the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III- 1-A), a compound represented by general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein R 3 , R 4 and R 5 are the same or different, and are each independently selected from a hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; preferably, R 3 , R 4 and R 5 are the same or different, and are each independently a hydrogen atom or a halogen.
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中R 3为氢原子或卤素；优选地，R 3为氢原子。 In some embodiments of the present disclosure, the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III- 1-A), the general formula (III-1-B), the general formula (III-2-A), the compound represented by the general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein R 3 is A hydrogen atom or a halogen; preferably, R 3 is a hydrogen atom.
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中R 4为氢原子或卤素；优选地，R 4为卤素；更优选地，R 4为F。 In some embodiments of the present disclosure, the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III- 1-A), a compound represented by general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen atom or halogen; preferably, R4 is halogen; more preferably, R4 is F.
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中R 5为氢原子或卤素；优选地，R 5为卤素；更优选地，R 5为Cl。 In some embodiments of the present disclosure, the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III- 1-A), the general formula (III-1-B), the general formula (III-2-A), the compound represented by the general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen atom or halogen; preferably, R 5 is halogen; more preferably, R 5 is Cl.
在本公开一些实施方案中，所述的通式(I)、通式(II)所示的化合物或其可药用的盐，其中各个R 6相同或不同，且各自独立地选自氢原子、卤素、氰基、-NH 2、 C 1-6烷基和C 1-6卤代烷基；优选地，各个R 6相同或不同，且各自独立地选自氢原子、卤素、氰基和-NH 2。 In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof, wherein each R 6 is the same or different, and each independently selected from a hydrogen atom , halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl; preferably, each R 6 is the same or different, and each independently selected from a hydrogen atom, halogen, cyano and -NH 2 .
在本公开一些实施方案中，所述的通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中各个R 6相同或不同，且各自独立地选自氢原子、卤素、氰基、-NH 2、C 1-6烷基和C 1-6卤代烷基；优选地，各个R 6相同或不同，且各自独立地为氢原子或卤素；更优选地，各个R 6相同或不同，且各自独立地为氢原子或氟；最优选地，R 6为氟。 In some embodiments of the present disclosure, the general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1- B), compounds represented by general formula (III-2-A), general formula (III-2-B) or pharmaceutically acceptable salts thereof, wherein each R is the same or different, and each independently selected from a hydrogen atom , halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl; preferably, each R 6 is the same or different, and each independently is a hydrogen atom or halogen; more preferably, each R 6 are the same or different, and are each independently a hydrogen atom or fluorine; most preferably, R 6 is fluorine.
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中R 11选自氢原子、卤素和C 1-6烷基；优选地，R 11为氢原子。 In some embodiments of the present disclosure, the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III- 1-A), a compound represented by general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein R 11 is selected from from a hydrogen atom, halogen and C 1-6 alkyl; preferably, R 11 is a hydrogen atom.
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中R 12选自氢原子、卤素和C 1-6烷基；优选地，R 12为氢原子。 In some embodiments of the present disclosure, the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III- 1-A), a compound represented by general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein R 12 is selected from from a hydrogen atom, halogen and C 1-6 alkyl; preferably, R 12 is a hydrogen atom.
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中R 13选自氢原子、卤素和C 1-6烷基；优选地，R 13为氢原子。 In some embodiments of the present disclosure, the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III- 1-A), a compound represented by general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein R 13 is selected from from a hydrogen atom, halogen and C 1-6 alkyl; preferably, R 13 is a hydrogen atom.
在本公开一些实施方案中，所述的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中R 14选自氢原子、卤素和C 1-6烷基；优选地，R 14为氢原子。 In some embodiments of the present disclosure, the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III- 1-A), a compound represented by general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein R 14 is selected from from a hydrogen atom, halogen and C 1-6 alkyl; preferably, R 14 is a hydrogen atom.
在本公开一些实施方案中，所述的通式(I)、通式(II)所示的化合物或其可药用的盐，其中t为0、1、2或3；优选地，t为3。In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof, wherein t is 0, 1, 2 or 3; preferably, t is 3.
在本公开一些实施方案中，所述的通式(I)、通式(II)所示的化合物或其可药用的盐，其中t为0，或各个R 6相同或不同，且各自独立地选自卤素、氰基、-NH 2、C 1-6烷基和C 1-6卤代烷基，且t为1、2或3。 In some embodiments of the present disclosure, the compound represented by general formula (I), general formula (II) or a pharmaceutically acceptable salt thereof, wherein t is 0, or each R 6 is the same or different, and each independently is selected from halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl, and t is 1, 2 or 3.
在本公开一些实施方案中，所述的通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中t为0或1；优选地，t为1。In some embodiments of the present disclosure, the general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1- B), a compound represented by general formula (III-2-A), general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein t is 0 or 1; preferably, t is 1.
在本公开一些实施方案中，所述的通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中t为0，或R 6为卤素，且t为1；优选地，R 6为氟，且t为1。 In some embodiments of the present disclosure, the general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1- B), a compound represented by general formula (III-2-A), general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein t is 0, or R is halogen, and t is 1; Preferably, R 6 is fluorine and t is 1.
在本公开一些实施方案中，所述的通式(I)所示的化合物或其可药用的盐，其 中X为氧原子；Y为CH 2或CH 2-CH 2；Z 1和Z 2均为氮原子；环A为5至10元杂芳基；R 1为
Figure PCTCN2022128914-appb-000017
R 3、R 4和R 5相同或不同，且各自独立地选自氢原子、卤素、C 1-6烷基和C 1-6卤代烷基；s为0；t为0，或各个R 6相同或不同，且各自独立地选自卤素、氰基、-NH 2、C 1-6烷基和C 1-6卤代烷基，且t为1、2或3；R 11选自氢原子、卤素和C 1-6烷基；R 12选自氢原子、卤素和C 1-6烷基；R 13选自氢原子、卤素和C 1-6烷基；且R 14选自氢原子、卤素和C 1-6烷基。 In some embodiments of the present disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, wherein X is an oxygen atom; Y is CH 2 or CH 2 -CH 2 ; Z 1 and Z 2 Both are nitrogen atoms; ring A is 5 to 10 membered heteroaryl; R 1 is
Figure PCTCN2022128914-appb-000017
R 3 , R 4 and R 5 are the same or different, and are independently selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; s is 0; t is 0, or each R 6 is the same or different, and each independently selected from halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl, and t is 1, 2 or 3; R 11 is selected from hydrogen atom, halogen and C 1-6 alkyl; R 12 is selected from hydrogen atom, halogen and C 1-6 alkyl; R 13 is selected from hydrogen atom, halogen and C 1-6 alkyl; and R 14 is selected from hydrogen atom, halogen and C 1-6 alkyl.
在本公开一些实施方案中，所述的通式(II)所示的化合物或其可药用的盐，其中环A为环内含有1、2或3个选自氮、氧和硫的杂原子的8至10元双环杂芳基；m为0或1；Z 1和Z 2均为氮原子；R 1为
Figure PCTCN2022128914-appb-000018
R 3、R 4和R 5相同或不同，且各自独立地选自氢原子、卤素、C 1-6烷基和C 1-6卤代烷基；t为0，或各个R 6相同或不同，且各自独立地选自卤素、氰基、-NH 2、C 1-6烷基和C 1-6卤代烷基，且t为1、2或3；R 11选自氢原子、卤素和C 1-6烷基；R 12选自氢原子、卤素和C 1-6烷基；且R 13选自氢原子、卤素和C 1-6烷基。 In some embodiments of the present disclosure, the compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, wherein ring A contains 1, 2 or 3 hetero Atoms of 8 to 10 membered bicyclic heteroaryl; m is 0 or 1; Z 1 and Z 2 are nitrogen atoms; R 1 is
Figure PCTCN2022128914-appb-000018
R 3 , R 4 and R 5 are the same or different, and are each independently selected from a hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl; t is 0, or each R 6 is the same or different, and each independently selected from halogen, cyano, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl, and t is 1, 2 or 3; R 11 is selected from hydrogen atom, halogen and C 1-6 Alkyl; R 12 is selected from hydrogen atom, halogen and C 1-6 alkyl; and R 13 is selected from hydrogen atom, halogen and C 1-6 alkyl.
在本公开一些实施方案中，所述的通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)所示的化合物或其可药用的盐，其中W为C(CN)或N；m为0或1；Z 1和Z 2均为氮原子；R 3、R 4和R 5相同或不同，且各自独立地为氢原子或卤素；R 11为氢原子；R 12为氢原子；R 13为氢原子；R 6为卤素，且t为1。 In some embodiments of the present disclosure, the general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1- B), a compound represented by general formula (III-2-A), general formula (III-2-B) or a pharmaceutically acceptable salt thereof, wherein W is C(CN) or N; m is 0 or 1; Both Z 1 and Z 2 are nitrogen atoms; R 3 , R 4 and R 5 are the same or different, and each independently is a hydrogen atom or a halogen; R 11 is a hydrogen atom; R 12 is a hydrogen atom; R 13 is a hydrogen atom; R 6 is halogen and t is 1.
表A 本公开的典型化合物包括但不限于：Table A Typical compounds of the present disclosure include, but are not limited to:
Figure PCTCN2022128914-appb-000019
Figure PCTCN2022128914-appb-000019
Figure PCTCN2022128914-appb-000020
Figure PCTCN2022128914-appb-000020
Figure PCTCN2022128914-appb-000021
Figure PCTCN2022128914-appb-000021
本公开的另一方面涉及通式(Ia)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (Ia) or salts thereof:
Figure PCTCN2022128914-appb-000022
Figure PCTCN2022128914-appb-000022
其中：in:
环A、X、Y、Z 1、Z 2、R 2、R 3、R 4、R 5、R 6、s和t如通式(I)中所定义。 Rings A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , s and t are as defined in general formula (I).
本公开的另一方面涉及通式(IIa)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (IIa) or salts thereof:
Figure PCTCN2022128914-appb-000023
Figure PCTCN2022128914-appb-000023
其中：in:
环A、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(II)中所定义。 Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (II).
本公开的另一方面涉及通式(IIIa)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (IIIa) or salts thereof:
Figure PCTCN2022128914-appb-000024
Figure PCTCN2022128914-appb-000024
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III).
本公开的另一方面涉及通式(III-1a)所示的化合物或其盐：Another aspect of the present disclosure relates to a compound represented by general formula (III-1a) or a salt thereof:
Figure PCTCN2022128914-appb-000025
Figure PCTCN2022128914-appb-000025
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-1)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1).
本公开的另一方面涉及通式(III-2a)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (III-2a) or salts thereof:
Figure PCTCN2022128914-appb-000026
Figure PCTCN2022128914-appb-000026
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-2)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2).
本公开的另一方面涉及通式(III-1-Aa)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (III-1-Aa) or salts thereof:
Figure PCTCN2022128914-appb-000027
Figure PCTCN2022128914-appb-000027
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-1-A)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1-A).
本公开的另一方面涉及通式(III-1-Ba)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (III-1-Ba) or salts thereof:
Figure PCTCN2022128914-appb-000028
Figure PCTCN2022128914-appb-000028
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-1-B)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1-B).
本公开的另一方面涉及通式(III-2-Aa)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (III-2-Aa) or salts thereof:
Figure PCTCN2022128914-appb-000029
Figure PCTCN2022128914-appb-000029
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-2-A)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2-A).
本公开的另一方面涉及通式(III-2-Ba)所示的化合物或其盐：Another aspect of the present disclosure relates to a compound or a salt thereof represented by general formula (III-2-Ba):
Figure PCTCN2022128914-appb-000030
Figure PCTCN2022128914-appb-000030
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-2-B)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2-B).
本公开的通式(Ia)、通式(IIa)、通式(IIIa)、通式(III-1a)、通式(III-2a)、通式(III-1-Aa)、通式(III-1-Ba)、通式(III-2-Aa)、通式(III-2-Ba)所示的化合物或其盐，其中所述的盐优选二2,2,2-三氟乙酸盐。General formula (Ia), general formula (IIa), general formula (IIIa), general formula (III-1a), general formula (III-2a), general formula (III-1-Aa), general formula ( III-1-Ba), general formula (III-2-Aa), compound or salt thereof represented by general formula (III-2-Ba), wherein said salt is preferably di-2,2,2-trifluoroethane salt.
表B 本公开的典型中间体化合物包括但不限于：Table B Typical intermediate compounds of the present disclosure include, but are not limited to:
Figure PCTCN2022128914-appb-000031
Figure PCTCN2022128914-appb-000031
Figure PCTCN2022128914-appb-000032
Figure PCTCN2022128914-appb-000032
Figure PCTCN2022128914-appb-000033
Figure PCTCN2022128914-appb-000033
本公开的另一方面涉及通式(Iaa)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (Iaa) or salts thereof:
Figure PCTCN2022128914-appb-000034
Figure PCTCN2022128914-appb-000034
其中：in:
R W2为氨基保护基；优选地，R W2为叔丁氧羰基； R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
环A、X、Y、Z 1、Z 2、R 2、R 3、R 4、R 5、R 6、s和t如通式(Ia)中所定义。 Rings A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , s and t are as defined in general formula (Ia).
本公开的另一方面涉及通式(IIaa)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds or salts thereof represented by general formula (IIaa):
Figure PCTCN2022128914-appb-000035
Figure PCTCN2022128914-appb-000035
其中：in:
R W2为氨基保护基；优选地，R W2为叔丁氧羰基； R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
环A、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(IIa)中所定义。 Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIa).
本公开的另一方面涉及通式(IIIaa)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds or salts thereof represented by general formula (IIIaa):
Figure PCTCN2022128914-appb-000036
Figure PCTCN2022128914-appb-000036
其中：in:
R W1和R W2相同或不同，且各自独立地为氨基保护基；优选地，R W1和R W2均为叔丁氧羰基； R W1 and R W2 are the same or different, and each independently is an amino protecting group; preferably, both R W1 and R W2 are tert-butoxycarbonyl;
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(IIIa)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIIa).
本公开的另一方面涉及通式(III-1aa)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (III-1aa) or salts thereof:
Figure PCTCN2022128914-appb-000037
Figure PCTCN2022128914-appb-000037
其中：in:
R W1和R W2相同或不同，且各自独立地为氨基保护基；优选地，R W1和R W2均为叔丁氧羰基； R W1 and R W2 are the same or different, and each independently is an amino protecting group; preferably, both R W1 and R W2 are tert-butoxycarbonyl;
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-1a)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1a).
本公开的另一方面涉及通式(III-2aa)所示的化合物或其盐：Another aspect of the present disclosure relates to compounds represented by general formula (III-2aa) or salts thereof:
Figure PCTCN2022128914-appb-000038
Figure PCTCN2022128914-appb-000038
其中：in:
R W1和R W2相同或不同，且各自独立地为氨基保护基；优选地，R W1和R W2均为叔丁氧羰基； R W1 and R W2 are the same or different, and each independently is an amino protecting group; preferably, both R W1 and R W2 are tert-butoxycarbonyl;
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-2a)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2a).
表C 本公开的典型中间体化合物包括但不限于：Table C Typical intermediate compounds of the present disclosure include, but are not limited to:
Figure PCTCN2022128914-appb-000039
Figure PCTCN2022128914-appb-000039
Figure PCTCN2022128914-appb-000040
Figure PCTCN2022128914-appb-000040
本公开的另一方面涉及一种制备通式(I)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000041
Figure PCTCN2022128914-appb-000041
通式(Ia)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(X)化合物或其盐发生反应得到通式(I)化合物或其可药用的盐；General formula (Ia) compound or its salt (preferably two 2,2,2-trifluoroacetic acid salt) and general formula (X) compound or its salt react to obtain general formula (I) compound or its pharmaceutically acceptable salt ;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
R 1为
Figure PCTCN2022128914-appb-000042
 R1 is
Figure PCTCN2022128914-appb-000042
环A、X、Y、Z 1、Z 2、R 2、R 3、R 4、R 5、R 6、R 11、R 12、R 13、R 14、s和t如通式(I)中所定义。 Ring A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 , s and t are as in general formula (I) defined.
本公开的另一方面涉及一种制备通式(II)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000043
Figure PCTCN2022128914-appb-000043
通式(IIa)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(X)化合物或其盐发生反应得到通式(II)化合物或其可药用的盐；The compound of general formula (IIa) or its salt (preferably two 2,2,2-trifluoroacetic acid salt) and the compound of general formula (X) or its salt react to obtain the compound of general formula (II) or its pharmaceutically acceptable salt ;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
R 1为
Figure PCTCN2022128914-appb-000044
 R1 is
Figure PCTCN2022128914-appb-000044
m为0或1；m is 0 or 1;
环A、Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12、R 13、R 14和t如通式(II)中所定义。 Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 and t are as defined in the general formula (II).
本公开的另一方面涉及一种制备通式(III)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000045
Figure PCTCN2022128914-appb-000045
通式(IIIa)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(XI)化合物或其盐发生反应得到通式(III)化合物或其可药用的盐；The compound of general formula (IIIa) or its salt (preferably two 2,2,2-trifluoroacetate) and the compound of general formula (XI) or its salt react to obtain the compound of general formula (III) or its pharmaceutically acceptable salt ;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(III)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III).
本公开的另一方面涉及一种制备通式(III-1)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-1) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000046
Figure PCTCN2022128914-appb-000046
通式(III-1a)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(XI)化合物或其盐发生反应得到通式(III-1)化合物或其可药用的盐；General formula (III-1a) compound or its salt (preferably two 2,2,2-trifluoroacetate) and general formula (XI) compound or its salt react to obtain general formula (III-1) compound or its medicinal salts;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(III-1)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III-1).
本公开的另一方面涉及一种制备通式(III-2)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-2) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000047
Figure PCTCN2022128914-appb-000047
通式(III-2a)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(XI)化合物或其盐发生反应得到通式(III-2)化合物或其可药用的盐；General formula (III-2a) compound or its salt (preferably two 2,2,2-trifluoroacetic acid salt) and general formula (XI) compound or its salt react to obtain general formula (III-2) compound or its medicinal salts;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(III-2)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III-2).
本公开的另一方面涉及一种制备通式(III-1-A)和通式(III-1-B)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-1-A) and general formula (III-1-B) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000048
Figure PCTCN2022128914-appb-000048
通式(III-1)化合物或其可药用的盐经拆分得到通式(III-1-A)和通式(III-1-B)化合物或其可药用的盐；The compound of general formula (III-1) or its pharmaceutically acceptable salt is obtained by resolution of general formula (III-1-A) and general formula (III-1-B) compound or its pharmaceutically acceptable salt;
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12、R 13、m和t如通式(III-1)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , m and t are as defined in the general formula (III-1).
本公开的另一方面涉及一种制备通式(III-2-A)和通式(III-2-B)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-2-A) and general formula (III-2-B) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000049
Figure PCTCN2022128914-appb-000049
通式(III-2)化合物或其可药用的盐经拆分得到通式(III-2-A)和通式(III-2-B)化 合物或其可药用的盐；General formula (III-2) compound or its pharmaceutically acceptable salt obtains general formula (III-2-A) and general formula (III-2-B) compound or its pharmaceutically acceptable salt through resolution;
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12、R 13、m和t如通式(III-2)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , m and t are as defined in the general formula (III-2).
本公开的另一方面涉及一种制备通式(Ia)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (Ia) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000050
Figure PCTCN2022128914-appb-000050
通式(Iaa)化合物或其盐脱去R W2得到通式(Ia)化合物或其可药用的盐； General formula (Iaa) compound or its salt remove R W2 and obtain general formula (Ia) compound or its pharmaceutically acceptable salt;
其中：in:
R W2为氨基保护基；优选地，R W2为叔丁氧羰基； R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
环A、X、Y、Z 1、Z 2、R 2、R 3、R 4、R 5、R 6、s和t如通式(Ia)中所定义。 Rings A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , s and t are as defined in general formula (Ia).
本公开的另一方面涉及一种制备通式(IIa)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IIa) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000051
Figure PCTCN2022128914-appb-000051
通式(IIaa)化合物或其盐脱去R W2得到通式(IIa)化合物或其可药用的盐； General formula (IIaa) compound or its salt removes R W2 and obtains general formula (IIa) compound or its pharmaceutically acceptable salt;
其中：in:
R W2为氨基保护基；优选地，R W2为叔丁氧羰基； R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
环A、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(IIa)中所定义。 Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIa).
本公开的另一方面涉及一种制备通式(IIIa)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (IIIa) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000052
Figure PCTCN2022128914-appb-000052
通式(IIIaa)化合物或其盐脱去R W1和R W2得到通式(IIIa)化合物或其可药用的盐； The compound of general formula (IIIaa) or its salt is removed from R W1 and R W2 to obtain the compound of general formula (IIIa) or its pharmaceutically acceptable salt;
其中：in:
R W1和R W2均为氨基保护基；优选地，R W1和R W2均为叔丁氧羰基； Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(IIIa)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIIa).
本公开的另一方面涉及一种制备通式(III-1a)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-1a) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000053
Figure PCTCN2022128914-appb-000053
通式(III-1aa)化合物或其盐脱去R W1和R W2得到通式(III-1a)化合物或其可药用的盐； The compound of general formula (III-1aa) or its salt is removed from R W1 and R W2 to obtain the compound of general formula (III-1a) or its pharmaceutically acceptable salt;
其中：in:
R W1和R W2均为氨基保护基；优选地，R W1和R W2均为叔丁氧羰基； Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-1a)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1a).
本公开的另一方面涉及一种制备通式(III-2a)所示的化合物或其可药用的盐的方法，其包括：Another aspect of the present disclosure relates to a method for preparing a compound represented by general formula (III-2a) or a pharmaceutically acceptable salt thereof, comprising:
Figure PCTCN2022128914-appb-000054
Figure PCTCN2022128914-appb-000054
通式(III-2aa)化合物或其盐脱去R W1和R W2得到通式(III-2a)化合物或其可药用的盐； The compound of general formula (III-2aa) or its salt is removed from R W1 and R W2 to obtain the compound of general formula (III-2a) or its pharmaceutically acceptable salt;
其中：in:
R W1和R W2均为氨基保护基；优选地，R W1和R W2均为叔丁氧羰基； Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-2a)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2a).
本公开的另一方面涉及一种药物组合物，所述药物组合物含有本公开通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐，以及一种或多种药学上可接受的载体、稀释剂或赋形剂。Another aspect of the present disclosure relates to a pharmaceutical composition, which contains the general formula (I), general formula (II), general formula (III), general formula (III-1), general formula ( III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and Table A A compound or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
本公开进一步涉及通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐或包含其的药物组合物在制备用于抑制KRAS G12C的药物中的用途。The present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or its pharmaceutically acceptable salt or the pharmaceutical composition comprising it in preparation Use in a medicament for inhibiting KRAS G12C.
本公开进一步涉及通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐或包含其的药物组合物在制备用于治疗和/或预防由KRAS G12C介导的疾病或病症的药物中的用途。The present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or its pharmaceutically acceptable salt or the pharmaceutical composition comprising it in preparation Use in a medicament for treating and/or preventing a disease or condition mediated by KRAS G12C.
本公开进一步涉及通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐或包含其的药物组合物在制备用于治疗和/或预防肿瘤的药物中的用途。The present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or its pharmaceutically acceptable salt or the pharmaceutical composition comprising it in preparation Use in medicines for treating and/or preventing tumors.
本公开还涉及一种抑制KRAS G12C的方法，其包括给予所需患者治疗有效量的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐，或包含其的药物组合物。The present disclosure also relates to a method for inhibiting KRAS G12C, which comprises administering a therapeutically effective dose of general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it.
本公开还涉及一种治疗和/或预防由KRAS G12C介导的疾病或病症的方法，其包括给予所需患者治疗有效量的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐，或包含其的药物组合物。The present disclosure also relates to a method for treating and/or preventing a disease or condition mediated by KRAS G12C, which comprises administering a therapeutically effective amount of the general formula (I), general formula (II), general formula (III) to the patient in need , general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula ( III-2-B) and a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it.
本公开还涉及一种治疗和/或预防肿瘤的方法，其包括给予所需患者治疗和/或预防有效量的通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐，或包含其的药物组合物。The present disclosure also relates to a method for treating and/or preventing tumors, which comprises administering an effective dose of general formula (I), general formula (II), general formula (III), general formula ( III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2- B) and a compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it.
本公开进一步涉及一种通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐，或包含其的药物组合物，其用作药物。The present disclosure further relates to a general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), Compounds shown in general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and Table A or pharmaceutically acceptable salts thereof, or pharmaceutical combinations comprising them substances, which are used as medicines.
本公开进一步涉及通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐，或包含其的药物组合物，其用作KRAS G12C抑制剂。The present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it, It acts as a KRAS G12C inhibitor.
本公开进一步涉及通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐，或包含其的药物组合物，其用于治疗和/或预防由KRAS G12C介导的疾病或病症。The present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it, It is used for the treatment and/or prevention of diseases or conditions mediated by KRAS G12C.
本公开进一步涉及通式(I)、通式(II)、通式(III)、通式(III-1)、通式(III-2)、通式(III-1-A)、通式(III-1-B)、通式(III-2-A)、通式(III-2-B)以及表A所示的化合物或其可药用的盐，或包含其的药物组合物，其用于治疗和/或预防肿瘤。The present disclosure further relates to general formula (I), general formula (II), general formula (III), general formula (III-1), general formula (III-2), general formula (III-1-A), general formula (III-1-B), general formula (III-2-A), general formula (III-2-B) and the compound shown in Table A or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising it, It is used in the treatment and/or prevention of tumors.
本公开中如上所述的由KRAS G12C介导的疾病或病症优选为肿瘤。The disease or condition mediated by KRAS G12C as described above in the present disclosure is preferably a tumor.
本公开中如上所述的肿瘤为癌症；所述的癌症优选选自肺癌(如非小细胞肺癌和小细胞肺癌)、胰腺癌、***、食管癌、子宫内膜癌、卵巢癌、胆管癌、结直肠癌(如结肠癌和直肠癌)、肝癌、乳腺癌、***癌、甲状腺癌、胃癌、尿路上皮癌、睾丸癌、白血病、皮肤癌、鳞状细胞癌、基底细胞癌、膀胱癌、头颈癌、肾癌、鼻咽癌、骨癌、淋巴瘤、黑色素瘤、肉瘤、外周神经上皮瘤、胶质瘤(如星形细胞瘤和成胶质细胞瘤)、脑瘤和骨髓瘤；更优选选自肺癌(如非小细胞肺癌)、胰腺癌、***、食管癌、子宫内膜癌、卵巢癌、胆管癌和结直肠癌。The tumor as described above in the present disclosure is cancer; said cancer is preferably selected from lung cancer (such as non-small cell lung cancer and small cell lung cancer), pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer , colorectal cancer (such as colon and rectal cancer), liver cancer, breast cancer, prostate cancer, thyroid cancer, stomach cancer, urothelial cancer, testicular cancer, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, bladder cancer , head and neck cancer, renal cancer, nasopharyngeal cancer, bone cancer, lymphoma, melanoma, sarcoma, peripheral neuroepithelial tumor, glioma (such as astrocytoma and glioblastoma), brain tumor and myeloma; More preferably selected from lung cancer (such as non-small cell lung cancer), pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer and colorectal cancer.
可将活性化合物制成适合于通过任何适当途径给药的形式，活性化合物优选是以单位剂量的方式，或者是以患者可以以单剂自我给药的方式。本公开化合物或组合物的单位剂量的表达方式可以是片剂、胶囊、扁囊剂、瓶装药水、药粉、颗粒剂、锭剂、栓剂、再生药粉或液体制剂。The active compound may be presented in a form suitable for administration by any suitable route, preferably in unit dosage form, or in such a form that the patient can self-administer a single dose. A unit dosage form of a compound or composition of the present disclosure may be presented as a tablet, capsule, cachet, bottle, powder, granule, lozenge, suppository, reconstituted powder or liquid.
作为一般性指导，合适的单位剂量可以是0.1～1000mg。As a general guide, a suitable unit dose may be 0.1 to 1000 mg.
本公开的药物组合物除活性化合物外，可含有一种或多种辅料，所述辅料选自以下成分：填充剂(稀释剂)、粘合剂、润湿剂、崩解剂或赋形剂等。根据给药方法的不同，组合物可含有0.1至99重量％的活性化合物。In addition to the active compound, the pharmaceutical composition of the present disclosure may contain one or more auxiliary materials selected from the following components: fillers (diluents), binders, wetting agents, disintegrants or excipients wait. Depending on the method of administration, the compositions may contain from 0.1 to 99% by weight of active compound.
含活性成分的药物组合物可以是适用于口服的形式，例如片剂、糖锭剂、锭剂、水或油混悬液、可分散粉末或颗粒、乳液、硬或软胶囊，或糖浆剂或酏剂。可按照本领域任何已知制备药用组合物的方法制备口服组合物，此类组合物可含有一种或多种选自以下的成分：甜味剂、矫味剂、着色剂和防腐剂，以提供悦目和可口的药用制剂。片剂含有活性成分和用于混合的适宜制备片剂的无毒的可药用的赋形剂。这些赋形剂可以是惰性赋形剂、造粒剂、崩解剂、粘合剂和润滑剂。这些片剂可以不包衣或可通过掩盖药物的味道或在胃肠道中延迟崩解和吸收，因而在较长时间内提供缓释作用的已知技术将其包衣。The pharmaceutical composition containing the active ingredient may be in a form suitable for oral administration, such as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixir. Oral compositions can be prepared according to any method known in the art for the preparation of pharmaceutical compositions, and such compositions can contain one or more ingredients selected from the group consisting of sweeteners, flavoring agents, coloring agents and preservatives, To provide pleasing and palatable medicinal preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients suitable for the manufacture of tablets. These excipients may be inert excipients, granulating agents, disintegrants, binders and lubricants. These tablets may be uncoated or may be coated by known techniques to mask the taste of the drug or to delay disintegration and absorption in the gastrointestinal tract, thus providing sustained release over an extended period of time.
也可用其中活性成分与惰性固体稀释剂或其中活性成分与水溶性载体或油溶媒混合的软明胶胶囊提供口服制剂。Oral formulations can also be provided in soft gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, or where the active ingredient is mixed with a water-soluble carrier or an oil vehicle.
水混悬液含有活性物质和用于混合的适宜制备水混悬液的赋形剂。此类赋形剂是悬浮剂、分散剂或湿润剂。水混悬液也可以含有一种或多种防腐剂、一种或多种着色剂、一种或多种矫味剂和一种或多种甜味剂。Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending, dispersing or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.
油混悬液可通过使活性成分悬浮于植物油或矿物油配制而成。油悬浮液可含有增稠剂。可加入上述的甜味剂和矫味剂，以提供可口的制剂。可通过加入抗氧化剂保存这些组合物。Oily suspensions can be formulated by suspending the active ingredient in a vegetable or mineral oil. The oily suspensions may contain a thickening agent. Sweetening and flavoring agents as mentioned above may be added to provide a palatable preparation. These compositions can be preserved by adding antioxidants.
本公开的药物组合物也可以是水包油乳剂的形式。油相可以是植物油、矿物油或其混合物。适宜的乳化剂可以是天然产生的磷脂，乳剂也可以含有甜味剂、矫味剂、防腐剂和抗氧剂。此类制剂也可含有缓和剂、防腐剂、着色剂和抗氧剂。The pharmaceutical compositions of the present disclosure may also be in the form of oil-in-water emulsions. The oily phase may be vegetable oil, mineral oil or mixtures thereof. Suitable emulsifiers may be naturally occurring phospholipids, and the emulsions may also contain sweetening agents, flavoring agents, preservatives and antioxidants. Such formulations may also contain a demulcent, a preservative, coloring agents and antioxidants.
本公开的药物组合物可以是无菌注射水溶液形式。可以使用的可接受的溶媒或溶剂有水、林格氏液和等渗氯化钠溶液。无菌注射制剂可以是其中活性成分溶于油相的无菌注射水包油微乳，可通过局部大量注射将注射液或微乳注入患者的血流中。或者，最好按可保持本公开化合物恒定循环浓度的方式给予溶液和微乳。为保持这种恒定浓度，可使用连续静脉内递药装置。这种装置的实例是Deltec CADD-PLUS.TM.5400型静脉注射泵。The pharmaceutical compositions of the present disclosure may be in the form of sterile injectable aqueous solutions. Among the acceptable vehicles or solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. The sterile injectable preparation can be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oily phase, and the injection or microemulsion can be injected into the patient's bloodstream by local bulk injection. Alternatively, solutions and microemulsions are preferably administered in a manner that maintains a constant circulating concentration of the disclosed compounds. To maintain this constant concentration, a continuous intravenous delivery device can be used. An example of such a device is the Deltec CADD-PLUS.TM. Model 5400 IV pump.
本公开的药物组合物可以是用于肌内和皮下给药的无菌注射水或油混悬液的形式。可按已知技术，用适宜的分散剂或湿润剂和悬浮剂配制该混悬液。无菌注射制剂也可以是在肠胃外可接受的无毒稀释剂或溶剂中制备的无菌注射溶液或混悬液。此外，可方便地用无菌固定油作为溶剂或悬浮介质。为此目的，可使用任何调和固定油。此外，脂肪酸也可以制备注射剂。The pharmaceutical compositions of the present disclosure may be in the form of sterile injectable aqueous or oily suspensions for intramuscular and subcutaneous administration. This suspension may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension prepared in a parenterally acceptable non-toxic diluent or solvent. In addition, sterile fixed oils are conveniently employed as a solvent or suspending medium. For this purpose, any blended and fixed oil may be used. In addition, fatty acids are also used in the preparation of injectables.
可按用于直肠给药的栓剂形式给予本公开化合物。可通过将药物与在普通温度下为固体但在直肠中为液体，因而在直肠中会溶化而释放药物的适宜的无刺激性赋形剂混合来制备这些药物组合物。The disclosed compounds may be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid in the rectum and will therefore melt in the rectum to release the drug.
如本领域技术人员所熟知的，药物的给药剂量依赖于多种因素，包括但并非限定于以下因素：所用具体化合物的活性、患者的年龄、患者的体重、患者的健康状况、患者的行为、患者的饮食、给药时间、给药方式、***的速率、药物的组合、疾病的严重性等；另外，最佳的治疗方式如治疗的模式、化合物的日用量或可药用的盐的种类可以根据传统的治疗方案来验证。As is well known to those skilled in the art, the dosage of the drug to be administered depends on many factors, including but not limited to the following factors: the activity of the specific compound used, the age of the patient, the weight of the patient, the state of health of the patient, the behavior of the patient , patient's diet, administration time, administration method, rate of excretion, combination of drugs, severity of disease, etc.; in addition, the optimal treatment mode such as the mode of treatment, the daily dosage of the compound or the content of the pharmaceutically acceptable salt Kinds can be validated against traditional treatment regimens.
术语说明Glossary
除非有相反陈述，在说明书和权利要求书中使用的术语具有下述含义。Unless stated to the contrary, the terms used in the specification and claims have the following meanings.
术语“烷基”指饱和的直链或带有支链的脂肪族烃基，其具有1至20个(例如1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个)碳原子(即C 1-20烷基)。所述烷基优选具有1至12个碳原子的烷基(即C 1-12烷基)，更优选具有1至6个碳原子的烷基(即C 1-6烷基)。非限制性的实例包括：甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊 基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基、正庚基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基戊基、2,4-二甲基戊基、2,2-二甲基戊基、3,3-二甲基戊基、2-乙基戊基、3-乙基戊基、正辛基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基己基、3,3-二甲基己基、4,4-二甲基己基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、正壬基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2,2-二乙基戊基、正癸基、3,3-二乙基己基、2,2-二乙基己基，及其各种支链异构体等。烷基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点被取代，取代基优选选自D原子、卤素、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。 The term "alkyl" refers to a saturated linear or branched aliphatic hydrocarbon group having 1 to 20 (for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (ie C 1-20 alkyl). The alkyl group is preferably an alkyl group having 1 to 12 carbon atoms (ie, a C 1-12 alkyl group), more preferably an alkyl group having 1 to 6 carbon atoms (ie, a C 1-6 alkyl group). Non-limiting examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl , 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl- 2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1 ,3-Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl , 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-di Methylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl , 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4 -Ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3 -Ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched isomers thereof. Alkyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, ring One or more of alkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
术语“烯基”指分子中含有至少一个碳碳双键的烷基，其中烷基的定义如上所述，其具有2至12个(例如2、3、4、5、6、7、8、9、10、11或12个)碳原子(即C 2-12烯基)。所述烯基优选具有2至6个碳原子的烯基(即C 2-6烯基)。非限制性的实例包括：乙烯基、丙烯基、异丙烯基、丁烯基等。烯基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点被取代，取代基优选选自D原子、烷氧基、卤素、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。 The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein the definition of the alkyl group is as described above, and it has 2 to 12 (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (ie C 2-12 alkenyl). The alkenyl group is preferably an alkenyl group having 2 to 6 carbon atoms (ie, a C 2-6 alkenyl group). Non-limiting examples include: vinyl, propenyl, isopropenyl, butenyl, and the like. Alkenyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, the substituents being preferably selected from D atoms, alkoxy, halogen, haloalkyl, haloalkoxy, ring One or more of alkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
术语“炔基”指分子中含有至少一个碳碳三键的烷基，其中烷基的定义如上所述，其具有2至12个(例如2、3、4、5、6、7、8、9、10、11或12个)碳原子(即C 2-12炔基)。所述炔基优选具有2至6个碳原子的炔基(即C 2-6炔基)。非限制性的实例包括：乙炔基、丙炔基、丁炔基、戊炔基、己炔基等。炔基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点被取代，取代基优选选自D原子、烷氧基、卤素、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。 The term "alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond in the molecule, wherein the definition of the alkyl group is as described above, and it has 2 to 12 (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (ie C 2-12 alkynyl). The alkynyl group is preferably an alkynyl group having 2 to 6 carbon atoms (ie, a C 2-6 alkynyl group). Non-limiting examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Alkynyl groups may be substituted or unsubstituted, and when substituted, they may be substituted at any available point of attachment, the substituents being preferably selected from the group consisting of D atom, alkoxy, halogen, haloalkyl, haloalkoxy, ring One or more of alkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
术语“烷氧基”指-O-(烷基)，其中烷基的定义如上所述。非限制性的实例包括：甲氧基、乙氧基、丙氧基和丁氧基等。烷氧基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点被取代，取代基优选选自D原子、卤素、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples include: methoxy, ethoxy, propoxy, and butoxy, and the like. Alkoxy may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, One or more of cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
术语“环烷基”指饱和或部分不饱和的单环全碳环(即单环环烷基)或多环***(即多环环烷基)，其具有3至20个(例如3、4、5、6、7、8、9、10、11、 12、13、14、15、16、17、18、19或20个)环原子(即3至20元环烷基)。所述环烷基优选具有3至12个环原子的环烷基(即3至12元环烷基)，更优选具有3至8个环原子的环烷基(即3至8元环烷基)，最优选具有3至6个环原子的环烷基(即3至6元环烷基)。The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic full carbocycle (ie monocyclic cycloalkyl) or polycyclic ring system (ie polycyclic cycloalkyl) having 3 to 20 (eg 3, 4 , 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (ie 3 to 20 membered cycloalkyl). The cycloalkyl group is preferably a cycloalkyl group having 3 to 12 ring atoms (i.e. a 3 to 12 membered cycloalkyl group), more preferably a cycloalkyl group having 3 to 8 ring atoms (i.e. a 3 to 8 membered cycloalkyl group). ), most preferably a cycloalkyl group having 3 to 6 ring atoms (ie a 3 to 6 membered cycloalkyl group).
所述的单环环烷基，非限制性的实例包括：环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基和环辛基等。Said monocyclic cycloalkyl, non-limiting examples include: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl , cycloheptatrienyl and cyclooctyl, etc.
所述的多环环烷基包括：螺环烷基、稠环烷基和桥环烷基。The polycyclic cycloalkyl includes: spirocycloalkyl, condensed cycloalkyl and bridged cycloalkyl.
术语“螺环烷基”指环之间共用一个碳原子(称螺原子)的多环***，其环内可以含有一个或多个双键，或其环内可以含有一个或多个选自氮、氧和硫的杂原子(所述的氮可任选被氧化，即形成氮氧化物；所述的硫可任选被氧代，即形成亚砜或砜，但不包括-O-O-、-O-S-或-S-S-)，条件是至少含有一个全碳环且连接点在该全碳环上，其具有5至20个(例如5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个)环原子(即5至20元螺环烷基)。所述螺环烷基优选具有6至14个环原子的螺环烷基(即6至14元螺环烷基)，更优选具有7至10个环原子的螺环烷基(即7至10元螺环烷基)。所述螺环烷基包括单螺环烷基和多螺环烷基(如双螺环烷基等)，优选单螺环烷基或双螺环烷基，更优选3元/4元、3元/5元、3元/6元、4元/4元、4元/5元、4元/6元、5元/3元、5元/4元、5元/5元、5元/6元、5元/7元、6元/3元、6元/4元、6元/5元、6元/6元、6元/7元、7元/5元或7元/6元单螺环烷基。非限制性的实例包括：The term "spirocycloalkyl" refers to a polycyclic ring system that shares one carbon atom (called a spiro atom) between the rings, which may contain one or more double bonds in the ring, or may contain one or more rings selected from nitrogen, Oxygen and sulfur heteroatoms (the nitrogen may be optionally oxidized, i.e. form nitrogen oxides; the sulfur may be optionally oxo, i.e. form sulfoxides or sulfones, but excluding -O-O-, -O-S - or -S-S-), provided that it contains at least one full carbon ring and the point of attachment is on the full carbon ring, it has 5 to 20 (such as 5, 6, 7, 8, 9, 10, 11, 12, 13 , 14, 15, 16, 17, 18, 19 or 20) ring atoms (ie 5 to 20 membered spirocycloalkyl). The spirocycloalkyl is preferably a spirocycloalkyl having 6 to 14 ring atoms (i.e. a 6 to 14 membered spirocycloalkyl), more preferably a spirocycloalkyl having 7 to 10 ring atoms (i.e. 7 to 10 member spirocycloalkyl). The spirocycloalkyl group includes single spirocycloalkyl and polyspirocycloalkyl (such as double spirocycloalkyl, etc.), preferably single spirocycloalkyl or double spirocycloalkyl, more preferably 3-membered/4-membered, 3-membered Yuan/5 yuan, 3 yuan/6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan, 5 yuan/5 yuan, 5 yuan/ 6 yuan, 5 yuan/7 yuan, 6 yuan/3 yuan, 6 yuan/4 yuan, 6 yuan/5 yuan, 6 yuan/6 yuan, 6 yuan/7 yuan, 7 yuan/5 yuan or 7 yuan/6 yuan Single spirocycloalkyl. Non-limiting examples include:
Figure PCTCN2022128914-appb-000055
其连接点可在任意位置；还包括：
Figure PCTCN2022128914-appb-000056
等。
Figure PCTCN2022128914-appb-000055
Its connection point can be anywhere; also includes:
Figure PCTCN2022128914-appb-000056
wait.
术语“稠环烷基”指环之间共享毗邻的两个碳原子的多环***，其为单环环烷基与一个或多个单环环烷基稠合，或者单环环烷基与杂环基、芳基或杂芳基中的一个或多个稠合，其中连接点在单环环烷基上，其环内可以含有一个或多个双键，且具有5至20个(例如5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个)环原子(即5至20元稠环烷基)。所述稠环烷基优选具有6至14个环原子的稠环烷基(即6至14元稠环烷基)，更优选具有7至10个环原子的稠环烷基(即7至10元稠环烷基)。所述稠环烷基包括双环稠环烷基和多环稠环烷基(如三环稠环烷基、四环稠环烷基等)，优选双环稠环烷基或三环稠环烷基，更优选3元/4元、3元/5元、3元/6元、4元/4元、4元/5元、4元/6元、5元 /3元、5元/4元、5元/5元、5元/6元、5元/7元、6元/3元、6元/4元、6元/5元、6元/6元、6元/7元、7元/5元或7元/6元双环稠环烷基。非限制性的实例包括：The term "fused cycloalkyl" refers to a polycyclic ring system in which two adjacent carbon atoms are shared between the rings, which is a monocyclic cycloalkyl fused to one or more monocyclic cycloalkyls, or a monocyclic cycloalkyl to a heterocyclic One or more of cyclic groups, aryl groups or heteroaryl groups are condensed, wherein the point of attachment is on the monocyclic cycloalkyl group, which can contain one or more double bonds in the ring, and have 5 to 20 (for example, 5 , 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (ie 5 to 20 membered fused cycloalkyl). The condensed cycloalkyl group is preferably a fused cycloalkyl group having 6 to 14 ring atoms (i.e. a 6 to 14 membered fused cycloalkyl group), more preferably a fused cycloalkyl group having 7 to 10 ring atoms (i.e. 7 to 10 fused cycloalkyl). The fused cycloalkyl includes bicyclic fused cycloalkyl and polycyclic fused cycloalkyl (such as tricyclic fused cycloalkyl, tetracyclic fused cycloalkyl, etc.), preferably bicyclic fused cycloalkyl or tricyclic fused cycloalkyl , more preferably 3 yuan/4 yuan, 3 yuan/5 yuan, 3 yuan/6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan , 5 yuan/5 yuan, 5 yuan/6 yuan, 5 yuan/7 yuan, 6 yuan/3 yuan, 6 yuan/4 yuan, 6 yuan/5 yuan, 6 yuan/6 yuan, 6 yuan/7 yuan, 7 yuan Member/5-member or 7-member/6-membered bicyclic fused cycloalkyl group. Non-limiting examples include:
Figure PCTCN2022128914-appb-000057
，其连接点可在任意位置；还包括：
Figure PCTCN2022128914-appb-000057
, whose connection point can be anywhere; also includes:
Figure PCTCN2022128914-appb-000058
等。
Figure PCTCN2022128914-appb-000058
wait.
术语“桥环烷基”指环之间共用两个不直接连接的碳原子的全碳多环***，其环内可以含有一个或多个双键，且具有5至20个(例如5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个)碳原子(即5至20元桥环烷基)。所述桥环烷基优选具有6至14个碳原子的桥环烷基(即6至14元桥环烷基)，更优选具有7至10个碳原子的桥环烷基(即7至10元桥环烷基)。所述桥环烷基包括双环桥环烷基和多环桥环烷基(如三环桥环烷基、四环桥环烷基等)，优选双环桥环烷基或三环桥环烷基。非限制性的实例包括：The term "bridged cycloalkyl" refers to an all-carbon polycyclic ring system which shares two carbon atoms not directly connected between the rings, which may contain one or more double bonds in the ring, and has 5 to 20 (for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms (ie, 5 to 20 membered bridged cycloalkyl). The bridged cycloalkyl group is preferably a bridged cycloalkyl group having 6 to 14 carbon atoms (i.e. a 6 to 14 membered bridged cycloalkyl group), more preferably a bridged cycloalkyl group having 7 to 10 carbon atoms (i.e. 7 to 10 bridged cycloalkyl). The bridged cycloalkyl includes bicyclic bridged cycloalkyl and polycyclic bridged cycloalkyl (such as tricyclic bridged cycloalkyl, tetracyclic bridged cycloalkyl, etc.), preferably bicyclic bridged cycloalkyl or tricyclic bridged cycloalkyl . Non-limiting examples include:
Figure PCTCN2022128914-appb-000059
其连接点可在任意位置。
Figure PCTCN2022128914-appb-000059
Its connection point can be anywhere.
环烷基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点被取代，取代基优选选自D原子、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氧代基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。Cycloalkyl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkane One of oxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl or more.
术语“杂环基”指饱和或部分不饱和的单环杂环(即单环杂环基)或多环杂环***(即多环杂环基)，其环内至少含有一个(例如1、2、3或4个)选自氮、氧和硫的杂原子(所述的氮可任选被氧化，即形成氮氧化物；所述的硫可任选被氧代，即形成亚砜或砜，但不包括-O-O-、-O-S-或-S-S-)，且具有3至20个(例如3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个)环原子(即3至20元杂环基)。所述杂环基优选具有3至12个环原子的杂环基(即3至12元杂环基)；进一步优选具有3至8个环原子的杂环基(即3至8元杂环基)；更优选具有3至6个环原子的杂环基(即3至6元杂环基)；最优选具有5或6个环原子的杂环基(即5或6元杂环基)。The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic heterocycle (i.e. monocyclic heterocyclyl) or polycyclic heterocyclic ring system (i.e. polycyclic heterocyclyl) containing at least one (eg 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may optionally be oxidized, i.e. form nitrogen oxides; the sulfur may optionally be oxo, i.e. form sulfoxides or sulfone, but not including -O-O-, -O-S- or -S-S-), with 3 to 20 (eg 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (ie 3 to 20 membered heterocyclyl). The heterocyclic group is preferably a heterocyclic group having 3 to 12 ring atoms (i.e. a 3 to 12 membered heterocyclic group); further preferably a heterocyclic group having 3 to 8 ring atoms (i.e. a 3 to 8 membered heterocyclic group) ); more preferably a heterocyclyl group having 3 to 6 ring atoms (ie, a 3- to 6-membered heterocyclyl group); most preferably a heterocyclyl group having 5 or 6 ring atoms (ie, a 5- or 6-membered heterocyclyl group).
所述的单环杂环基，非限制性的实例包括：吡咯烷基、四氢吡喃基、1,2,3,6-四氢吡啶基、哌啶基、哌嗪基、吗啉基、硫代吗啉基和高哌嗪基等。Non-limiting examples of the monocyclic heterocyclic group include: pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl , Thiomorpholinyl and Homopiperazinyl, etc.
所述的多环杂环基包括螺杂环基、稠杂环基和桥杂环基。The polycyclic heterocyclic groups include spiro heterocyclic groups, condensed heterocyclic groups and bridged heterocyclic groups.
术语“螺杂环基”指环之间共用一个原子(称螺原子)的多环杂环***，其环内可以含有一个或多个双键，且其环内至少含有一个(例如1、2、3或4个)选自氮、氧和硫的杂原子(所述的氮可任选被氧化，即形成氮氧化物；所述的硫可任选被氧代，即形成亚砜或砜，但不包括-O-O-、-O-S-或-S-S-)，条件是至少含有一个单环杂环基且连接点在该单环杂环基上，其具有5至20个(例如5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个)环原子(即5至20元螺杂环基)。所述螺杂环基优选具有6至14个环原子的螺杂环基(即6至14元螺杂环基)，更优选具有7至10个环原子的螺杂环基(即7至10元螺杂环基)。所述螺杂环基包括单螺杂环基和多螺杂环基(如双螺杂环基等)，优选单螺杂环基或双螺杂环基，更优选3元/4元、3元/5元、3元/6元、4元/4元、4元/5元、4元/6元、5元/3元、5元/4元、5元/5元、5元/6元、5元/7元、6元/3元、6元/4元、6元/5元、6元/6元、6元/7元、7元/5元或7元/6元单螺杂环基。非限制性的实例包括：The term "spiroheterocyclyl" refers to a polycyclic heterocyclic ring system that shares one atom (called a spiro atom) between the rings, which may contain one or more double bonds in the ring, and at least one (such as 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e. to form nitrogen oxides; the sulfur may be optionally oxo, i.e. to form sulfoxides or sulfones, But not including -O-O-, -O-S- or -S-S-), the condition is to contain at least one monocyclic heterocyclic group and the point of attachment is on the monocyclic heterocyclic group, which has 5 to 20 (such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (ie 5 to 20 membered spiroheterocyclyl). The spiroheterocyclyl is preferably a spiroheterocyclyl having 6 to 14 ring atoms (i.e. 6 to 14 membered spiroheterocyclyl), more preferably a spiroheterocyclyl having 7 to 10 ring atoms (i.e. 7 to 10 membered spiroheterocyclyl). The spiroheterocyclyl includes single spiroheterocyclyl and polyspiroheterocyclyl (such as double spiroheterocyclyl, etc.), preferably single spiroheterocyclyl or double spiroheterocyclyl, more preferably 3-membered/4-membered, 3-membered Yuan/5 yuan, 3 yuan/6 yuan, 4 yuan/4 yuan, 4 yuan/5 yuan, 4 yuan/6 yuan, 5 yuan/3 yuan, 5 yuan/4 yuan, 5 yuan/5 yuan, 5 yuan/ 6 yuan, 5 yuan/7 yuan, 6 yuan/3 yuan, 6 yuan/4 yuan, 6 yuan/5 yuan, 6 yuan/6 yuan, 6 yuan/7 yuan, 7 yuan/5 yuan or 7 yuan/6 yuan Monospiroheterocyclyl. Non-limiting examples include:
Figure PCTCN2022128914-appb-000060
等。
Figure PCTCN2022128914-appb-000060
wait.
术语“稠杂环基”指环之间共享毗邻的两个原子的多环杂环***，其环内可以含有一个或多个双键，且其环内至少含有一个(例如1、2、3或4个)选自氮、氧和硫的杂原子(所述的氮可任选被氧化，即形成氮氧化物；所述的硫可任选被氧代，即形成亚砜或砜，但不包括-O-O-、-O-S-或-S-S-)，其为单环杂环基与一个或多个单环杂环基稠合，或者单环杂环基与环烷基、芳基或杂芳基中的一个或多个稠合，其中连接点在单环杂环基上，且具有5至20个(例如5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个)环原子(即5至20元稠杂环基)。所述稠杂环基优选具有6至14个环原子的稠杂环基(即6至14元稠杂环基)，更优选具有7至10个环原子的稠杂环基(即7至10元稠杂环基)。所述稠杂环基包括双环和多环稠杂环基(如三环稠杂环基、四环稠杂环基等)，优选双环稠杂环基或三环稠杂环基，更优选3元/4元、3元/5元、3元/6元、4元/4元、4元/5元、4元/6元、5元/3元、5元/4元、5元/5元、5元/6元、5元/7元、6元/3元、6元/4元、6元/5元、6元/6元、6元/7元、7元/5元或7元/6元双环稠杂环基。非限制性的实例包括：The term "fused heterocyclyl" refers to a polycyclic heterocyclic ring system which shares two adjacent atoms between the rings, which may contain one or more double bonds, and which contains at least one (for example, 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e. to form nitrogen oxides; the sulfur may be optionally oxo, i.e. to form sulfoxides or sulfones, but not Including -O-O-, -O-S- or -S-S-), which is a monocyclic heterocyclic group fused with one or more monocyclic heterocyclic groups, or a monocyclic heterocyclic group with a cycloalkyl, aryl or heteroaryl One or more of the fused groups, wherein the point of attachment is on the monocyclic heterocyclic group, and there are 5 to 20 (for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 , 16, 17, 18, 19 or 20) ring atoms (ie 5 to 20 membered fused heterocyclyl). The fused heterocyclic group is preferably a fused heterocyclic group having 6 to 14 ring atoms (ie, a 6 to 14 membered fused heterocyclic group), more preferably a condensed heterocyclic group having 7 to 10 ring atoms (ie, 7 to 10 membered fused heterocyclyl). The fused heterocyclic group includes bicyclic and polycyclic fused heterocyclic groups (such as tricyclic fused heterocyclic groups, tetracyclic fused heterocyclic groups, etc.), preferably bicyclic fused heterocyclic groups or tricyclic fused heterocyclic groups, more preferably 3 Yuan/4 Yuan, 3 Yuan/5 Yuan, 3 Yuan/6 Yuan, 4 Yuan/4 Yuan, 4 Yuan/5 Yuan, 4 Yuan/6 Yuan, 5 Yuan/3 Yuan, 5 Yuan/4 Yuan, 5 Yuan/ 5 yuan, 5 yuan/6 yuan, 5 yuan/7 yuan, 6 yuan/3 yuan, 6 yuan/4 yuan, 6 yuan/5 yuan, 6 yuan/6 yuan, 6 yuan/7 yuan, 7 yuan/5 yuan Or a 7-membered/6-membered bicyclic condensed heterocyclic group. Non-limiting examples include:
Figure PCTCN2022128914-appb-000061
等。
Figure PCTCN2022128914-appb-000061
wait.
术语“桥杂环基”指环之间共用两个不直接连接的原子的多环杂环***，其环内可以含有一个或多个双键，并且其环内至少含有一个(例如1、2、3或4个)选自氮、氧和硫的杂原子(所述的氮可任选被氧化，即形成氮氧化物；所述的硫可任选被氧代，即形成亚砜或砜，但不包括-O-O-、-O-S-或-S-S-)，其具有5至20个(例如5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20个)环原子(即5至20元桥杂环基)。所述桥杂环基优选具有6至14个环原子的桥杂环基(即6至14元桥杂环基)，更优选具有7至10个环原子的桥杂环基(即7至10元桥杂环基)。根据组成环的数目可以分为双环桥杂环基和多环桥杂环基(如三环桥杂环基、四环桥杂环基等)，优选双环桥杂环基或三环桥杂环基。非限制性的实例包括：The term "bridged heterocyclyl" refers to a polycyclic heterocyclic ring system that shares two atoms that are not directly connected between the rings, and may contain one or more double bonds in the ring, and at least one (for example, 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may be optionally oxidized, i.e. to form nitrogen oxides; the sulfur may be optionally oxo, i.e. to form sulfoxides or sulfones, but not including -O-O-, -O-S- or -S-S-), which have 5 to 20 (eg 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (ie 5 to 20 membered bridged heterocyclyl). The bridged heterocyclic group is preferably a bridged heterocyclic group having 6 to 14 ring atoms (i.e. a 6 to 14 membered bridged heterocyclic group), more preferably a bridged heterocyclic group having 7 to 10 ring atoms (i.e. 7 to 10 bridged heterocyclyl). According to the number of rings, it can be divided into bicyclic bridged heterocyclic group and polycyclic bridged heterocyclic group (such as tricyclic bridged heterocyclic group, tetracyclic bridged heterocyclic group, etc.), preferably bicyclic bridged heterocyclic group or tricyclic bridged heterocyclic group base. Non-limiting examples include:
Figure PCTCN2022128914-appb-000062
等。
Figure PCTCN2022128914-appb-000062
wait.
杂环基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点被取代，取代基优选选自D原子、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氧代基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。The heterocyclyl group may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, the substituents are preferably selected from D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkane One of oxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, oxo, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl or more.
术语“芳基”指具有共轭的π电子体系的单环全碳芳环(即单环芳基)或多环芳环***(即多环芳基)，其具有6至14个(例如6、7、8、9、10、11、12、13或14个)环原子(即6至14元芳基)。所述芳基优选具有6至10个环原子的芳基(即6至10元芳基)。所述的单环芳基，例如苯基。所述的多环芳基，非限制性的实例包括：萘基、蒽基、菲基等。所述多环芳基还包括苯基与杂环基或环 烷基中的一个或多个稠合，或萘基与杂环基或环烷基中的一个或多个稠合，其中连接点在苯基或萘基上，并且在这种情况下，环原子个数继续表示多环芳环***中的环原子个数，非限制性的实例包括：The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., a monocyclic aryl) or a polycyclic aromatic ring system (i.e., a polycyclic aryl) having a conjugated π-electron system, which has 6 to 14 (e.g., 6 , 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (ie 6 to 14 membered aryl). The aryl group is preferably an aryl group having 6 to 10 ring atoms (ie, a 6 to 10 membered aryl group). The monocyclic aryl group, such as phenyl. Non-limiting examples of the polycyclic aryl group include: naphthyl, anthracenyl, phenanthrenyl and the like. The polycyclic aryl also includes the condensing of phenyl with one or more of heterocyclic or cycloalkyl, or the fused of naphthyl with one or more of heterocyclic or cycloalkyl, wherein the connection point On phenyl or naphthyl, and in this case, the number of ring atoms continues to mean the number of ring atoms in a polycyclic aromatic ring system, non-limiting examples include:
Figure PCTCN2022128914-appb-000063
等。
Figure PCTCN2022128914-appb-000063
wait.
芳基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点被取代，取代基优选选自D原子、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氧代基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。Aryl groups may be substituted or unsubstituted, and when substituted, they may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy one or Multiple.
术语“杂芳基”指具有共轭的π电子体系的单环杂芳环(即单环杂芳基)或多环杂芳环***(即多环杂芳基)，其环内至少含有一个(例如1、2、3或4个)选自氮、氧和硫的杂原子(所述的氮可任选被氧化，即形成氮氧化物；所述的硫可任选被氧代，即形成亚砜或砜，但不包括-O-O-、-O-S-或-S-S-)，其具有5至14个(例如5、6、7、8、9、10、11、12、13或14个)环原子(即5至14元杂芳基)。所述杂芳基优选具有5至10个环原子的杂芳基(即5至10元杂芳基)，更优选具有5或6个环原子的单环杂芳基(即5或6元单环杂芳基)或具有8至10个环原子的双环杂芳基(即8至10元双环杂芳基)，最优选环内含有1、2或3个选自氮、氧和硫的杂原子的5或6元单环杂芳基或环内含有1、2或3个选自氮、氧和硫的杂原子的8至10元双环杂芳基。The term "heteroaryl" refers to a monocyclic heteroaryl ring (ie, monocyclic heteroaryl) or a polycyclic heteroaryl ring system (ie, polycyclic heteroaryl) having a conjugated π-electron system, which contains at least one (eg 1, 2, 3 or 4) heteroatoms selected from nitrogen, oxygen and sulfur (the nitrogen may optionally be oxidized, i.e. form nitrogen oxides; the sulfur may optionally be oxo, i.e. forming sulfoxides or sulfones, but excluding -O-O-, -O-S- or -S-S-), which have 5 to 14 (eg 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ) ring atoms (ie 5 to 14 membered heteroaryl). The heteroaryl group is preferably a heteroaryl group having 5 to 10 ring atoms (i.e. a 5 to 10 membered heteroaryl group), more preferably a monocyclic heteroaryl group having 5 or 6 ring atoms (i.e. a 5 or 6 membered heteroaryl group). ring heteroaryl) or bicyclic heteroaryl having 8 to 10 ring atoms (i.e. 8 to 10 membered bicyclic heteroaryl), most preferably containing 1, 2 or 3 heteroaryls selected from nitrogen, oxygen and sulfur in the ring A 5- or 6-membered monocyclic heteroaryl group or an 8- to 10-membered bicyclic heteroaryl group containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulfur in the ring.
所述的单环杂芳基，非限制性的实例包括：呋喃基、噻吩基、噻唑基、异噻唑基、噁唑基、异噁唑基、噁二唑基、噻二唑基、咪唑基、吡唑基、***基、四唑基、呋咱基、吡咯基、N-烷基吡咯基、吡啶基、嘧啶基、吡啶酮基、N-烷基吡啶酮(如
Figure PCTCN2022128914-appb-000064
等)、吡嗪基、哒嗪基等。 Non-limiting examples of the monocyclic heteroaryl include: furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl , pyrazolyl, triazolyl, tetrazolyl, furazanyl, pyrrolyl, N-alkylpyrrolyl, pyridyl, pyrimidinyl, pyridonyl, N-alkylpyridone (such as
Figure PCTCN2022128914-appb-000064
etc.), pyrazinyl, pyridazinyl, etc.
所述的多环杂芳基，非限制性的实例包括：吲哚基、吲唑基、喹啉基、异喹啉基、喹喔啉基、酞嗪基、苯并咪唑基、苯并噻吩基、喹唑啉基、苯并噻唑基、咔唑基等。所述多环杂芳基还包括单环杂芳基与一个或多个芳基稠合，其中连接点在芳香环上，并且在这种情况下，环原子个数继续表示多环杂芳环***中的环原子个数。所述多环杂芳基还包括单环杂芳基与环烷基或杂环基中的一个或多个稠合，其中连接点在单环杂芳环上，并且在这种情况下，环原子个数继续表示多环杂芳环***中的环原子个数。非限制性的实例包括：The polycyclic heteroaryl, non-limiting examples include: indolyl, indazolyl, quinolinyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophene group, quinazoline group, benzothiazolyl group, carbazolyl group, etc. The polycyclic heteroaryl also includes a monocyclic heteroaryl fused with one or more aryls, wherein the point of attachment is on the aromatic ring, and in this case the number of ring atoms continues to represent the polycyclic heteroaryl The number of ring atoms in the system. The polycyclic heteroaryl also includes monocyclic heteroaryl fused with one or more of cycloalkyl or heterocyclic, wherein the point of attachment is on the monocyclic heteroaryl ring, and in this case, the ring The number of atoms continues to indicate the number of ring atoms in the polycyclic heteroaryl ring system. Non-limiting examples include:
Figure PCTCN2022128914-appb-000065
Figure PCTCN2022128914-appb-000065
Figure PCTCN2022128914-appb-000066
Figure PCTCN2022128914-appb-000067
等。
Figure PCTCN2022128914-appb-000066
Figure PCTCN2022128914-appb-000067
wait.
杂芳基可以是取代的或非取代的，当被取代时，其可以在任何可使用的连接点被取代，取代基优选选自D原子、卤素、烷基、烷氧基、卤代烷基、卤代烷氧基、环烷基氧基、杂环基氧基、羟基、羟烷基、氰基、氨基、硝基、环烷基、杂环基、芳基和杂芳基中的一个或多个。Heteroaryl may be substituted or unsubstituted, and when substituted, it may be substituted at any available point of attachment, substituents are preferably selected from D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkane One or more of oxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
术语“氨基保护基”是指为了使分子其它部位进行反应时氨基保持不变，在氨基上引入的易于脱去的基团。非限制性的实例包括：(三甲基硅)乙氧基甲基、四氢吡喃基、叔丁氧羰基(Boc)、苄氧羰基(Cbz)、笏甲氧羰基(Fmoc)、烯丙氧羰基(Alloc)、三甲基硅乙氧羰基(Teoc)、甲氧羰基、乙氧羰基、邻苯二甲酰基(Pht)、对甲苯磺酰基(Tos)、三氟乙酰基(Tfa)、三苯甲基(Trt)、2,4-二甲氧基苄基(DMB)、乙酰基、苄基、烯丙基、对甲氧苄基等。The term "amino-protecting group" refers to an easily detachable group introduced on an amino group in order to keep the amino group unchanged when other parts of the molecule are reacted. Non-limiting examples include: (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), methoxycarbonyl (Fmoc), allyl Oxycarbonyl (Alloc), Trimethylsilylethoxycarbonyl (Teoc), Methoxycarbonyl, Ethoxycarbonyl, Phthalyl (Pht), p-Toluenesulfonyl (Tos), Trifluoroacetyl (Tfa), Trityl (Trt), 2,4-dimethoxybenzyl (DMB), acetyl, benzyl, allyl, p-methoxybenzyl, etc.
术语“羟基保护基”是指在羟基上引入的易于脱去的基团，用于阻断或保护羟基而在化合物的其它官能团上进行反应。非限制性的实例包括：三甲基硅基(TMS)、三乙基硅基(TES)、三异丙基硅基(TIPS)、叔丁基二甲基硅基(TBS)、叔丁基二苯基硅基(TBDPS)、甲基、叔丁基、烯丙基、苄基、甲氧基甲基(MOM)、乙氧基乙基、2-四氢吡喃基(THP)、甲酰基、乙酰基、苯甲酰基、对硝基苯甲酰基等。The term "hydroxyl protecting group" refers to an easy-to-remove group introduced on the hydroxyl group, which is used to block or protect the hydroxyl group and react on other functional groups of the compound. Non-limiting examples include: trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), tert-butyldimethylsilyl (TBS), tert-butyl Diphenylsilyl (TBDPS), methyl, tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-tetrahydropyranyl (THP), methyl Acyl, acetyl, benzoyl, p-nitrobenzoyl, etc.
术语“环烷基氧基”指环烷基-O-，其中环烷基如上所定义。The term "cycloalkyloxy" refers to cycloalkyl-O-, wherein cycloalkyl is as defined above.
术语“杂环基氧基”指杂环基-O-，其中杂环基如上所定义。The term "heterocyclyloxy" refers to heterocyclyl-O-, wherein heterocyclyl is as defined above.
术语“芳基氧基”指芳基-O-，其中芳基如上所定义。The term "aryloxy" refers to aryl-O-, wherein aryl is as defined above.
术语“杂芳基氧基”指杂芳基-O-，其中杂芳基如上所定义。The term "heteroaryloxy" refers to heteroaryl-O-, wherein heteroaryl is as defined above.
术语“烷硫基”指烷基-S-，其中烷基如上所定义。The term "alkylthio" refers to alkyl-S-, wherein alkyl is as defined above.
术语“卤代烷基”指烷基被一个或多个卤素取代，其中烷基如上所定义。The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
术语“卤代烷氧基”指烷氧基被一个或多个卤素取代，其中烷氧基如上所定义。The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy group is as defined above.
术语“氘代烷基”指烷基被一个或多个氘原子取代，其中烷基如上所定义。The term "deuteroalkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
术语“羟烷基”指烷基被一个或多个羟基取代，其中烷基如上所定义。The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
术语“卤素”指氟、氯、溴或碘。The term "halogen" refers to fluorine, chlorine, bromine or iodine.
术语“羟基”指-OH。The term "hydroxyl" refers to -OH.
术语“巯基”指-SH。The term "mercapto" refers to -SH.
术语“氨基”指-NH 2。 The term "amino" refers to -NH2 .
术语“氰基”指-CN。The term "cyano" refers to -CN.
术语“硝基”指-NO 2。 The term "nitro" refers to -NO2 .
术语“氧代”或“氧代基”指“＝O”。The term "oxo" or "oxo" refers to "=O".
术语“羰基”指C＝O。The term "carbonyl" refers to C=O.
术语“羧基”指-C(O)OH。The term "carboxy" refers to -C(O)OH.
术语“羧酸酯基”指-C(O)O(烷基)、-C(O)O(环烷基)、(烷基)C(O)O-或(环烷基)C(O)O-，其中烷基和环烷基如上所定义。The term "carboxylate" refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O- or (cycloalkyl)C(O )O-, wherein alkyl and cycloalkyl are as defined above.
本公开化合物可以存在特定的立体异构体形式。术语“立体异构体”是指结构相同但原子在空间中的排列不同的异构体。其包括顺式和反式(或Z和E)异构体、(-)-和(+)-异构体、(R)-和(S)-对映异构体、非对映异构体、(D)-和(L)-异构体、互变异构体、阻转异构体、构象异构体及其混合物(如外消旋体、非对映异构体的混合物)。本公开化合物中的取代基可以存在另外的不对称原子。所有这些立体异构体以及它们的混合物，均包括在本公开的范围内。可以通过手性合成、手性试剂或者其他常规技术制备光学活性的(-)-和(+)-异构体、(R)-和(S)-对映异构体以及(D)-和(L)-异构体。本公开某化合物的一种异构体，可以通过不对称合成或者手性助剂来制备，或者，当分子中含有碱性官能团(如氨基)或酸性官能团(如羧基)时，与适当的光学活性的酸或碱形成非对映异构体的盐，然后通过本领域所公知的常规方法进行非对映异构体拆分，得到纯的异构体。此外，对映异构体和非对映异构体的分离通常是通过色谱法完成。Compounds of the present disclosure may exist in particular stereoisomeric forms. The term "stereoisomer" refers to isomers that are identical in structure but differ in the arrangement of the atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (e.g. racemates, mixtures of diastereomers) . Substituents in compounds of the present disclosure may be present with additional asymmetric atoms. All such stereoisomers, as well as mixtures thereof, are included within the scope of the present disclosure. Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers, and (D)- and (L)-isomer. An isomer of a certain compound in the present disclosure can be prepared by asymmetric synthesis or chiral auxiliary agents, or, when the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxyl), with appropriate optical Reactive acids or bases form diastereomeric salts, which are then resolved by conventional methods well known in the art to yield the pure isomers. Furthermore, separation of enantiomers and diastereomers is usually accomplished by chromatography.
本公开所述化合物的化学结构中，键
Figure PCTCN2022128914-appb-000068
表示未指定构型，即如果化学结构中存在手性异构体，键
Figure PCTCN2022128914-appb-000069
可以为
Figure PCTCN2022128914-appb-000070
或者同时包含
Figure PCTCN2022128914-appb-000071
两种构型。对于所有的碳-碳双键，即使仅命名了一个构型，Z型和E型均包括在内。 In the chemical structures of the compounds described in this disclosure, the bond
Figure PCTCN2022128914-appb-000068
Indicates unassigned configuration, i.e. if chiral isomers exist in the chemical structure, the bond
Figure PCTCN2022128914-appb-000069
can be
Figure PCTCN2022128914-appb-000070
or both
Figure PCTCN2022128914-appb-000071
Two configurations. For all carbon-carbon double bonds, even if only one configuration is named, both Z and E forms are included.
本公开的化合物可以以不同的互变异构体形式存在，并且所有这样的形式包含在本公开的范围内。术语“互变异构体”或“互变异构体形式”是指平衡存在并且容易从一种异构形式转化为另一种异构形式的结构异构体。其包括所有可能的互变异构体，即以单一异构体的形式或以所述互变异构体的任意比例的混合物的形式存在。非限制性的实例包括：酮-烯醇、亚胺-烯胺、内酰胺-内酰亚胺等。内酰胺-内酰亚胺平衡实例是在如下所示的A和B之间：The compounds of the present disclosure may exist in different tautomeric forms and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers that exist in equilibrium and are readily converted from one isomeric form to the other. It includes all possible tautomers, ie present as single isomers or as mixtures of said tautomers in any ratio. Non-limiting examples include: keto-enol, imine-enamine, lactam-lactam, and the like. An example of a lactam-lactim equilibrium is between A and B as shown below:
Figure PCTCN2022128914-appb-000072
Figure PCTCN2022128914-appb-000072
如当提及吡唑基时，应理解为包括如下两种结构中的任何一种或两种互变异 构体的混合物：For example, when referring to pyrazolyl, it should be understood as including any one of the following two structures or a mixture of two tautomers:
Figure PCTCN2022128914-appb-000073
Figure PCTCN2022128914-appb-000073
所有的互变异构形式在本公开的范围内，且化合物的命名不排除任何互变异构体。All tautomeric forms are within the scope of the present disclosure, and the naming of compounds does not exclude any tautomers.
本公开的化合物可包含阻转异构体。术语“阻转异构体”是由于围绕分子中单键的旋转受阻或大大减慢(这是由于与分子的其它部分的空间相互作用和在单键的两端处取代基是不对称的结果)而产生的构象立体异构体，其互变是足够慢的，以允许在预定条件下分开和分离。例如，某些本公开化合物可以以阻转异构体的混合物的形式(如等比例混合物、富集一种阻转异构体的混合物等)或经纯化的一种阻转异构体的形式存在。非限制性的实例包括：
Figure PCTCN2022128914-appb-000074
Figure PCTCN2022128914-appb-000075
等。 Compounds of the present disclosure may contain atropisomers. The term "atropisomer" is the result of hindered or greatly slowed rotation about a single bond in a molecule (due to steric interactions with the rest of the molecule and the asymmetry of the substituents at either end of the single bond) ) resulting in conformational stereoisomers whose interconversion is slow enough to allow separation and isolation under predetermined conditions. For example, certain compounds of the present disclosure may be present as a mixture of atropisomers (e.g., an equal mixture, a mixture enriched in one atropisomer, etc.) or as a purified atropisomer exist. Non-limiting examples include:
Figure PCTCN2022128914-appb-000074
Figure PCTCN2022128914-appb-000075
wait.
本公开的化合物包括其化合物的所有合适的同位素衍生物。术语“同位素衍生物”是指至少一个原子被具有相同原子序数但原子质量不同的原子替代的化合物。可引入到本公开化合物中的同位素的实例包括氢、碳、氮、氧、磷、硫、氟、氯、溴和碘等的稳定和放射性的同位素，例如分别为 2H(氘，D)、 3H(氚，T)、 11C、 13C、 14C、 15N、 17O、 18O、 32p、 33p、 33S、 34S、 35S、 36S、 18F、 36Cl、 82Br、 123I、 124I、 125I、 129I和 131I等，优选氘。 Compounds of the present disclosure include all suitable isotopic derivatives of their compounds. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that may be incorporated into compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, etc., such as 2 H (deuterium, D), respectively, 3 H (tritium, T), 11 C, 13 C, 14 C, 15 N , 17 O, 18 O, 32 p, 33 p, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 125 I, 129 I, and 131 I, etc., preferably deuterium.
相比于未氘代药物，氘代药物有降低毒副作用、增加药物稳定性、增强疗效、延长药物生物半衰期等优势。本公开的化合物的所有同位素组成的变换，无论放射性与否，都包括在本公开的范围之内。与碳原子连接的各个可用的氢原子可独立地被氘原子替换，其中氘的替换可以是部分或完全的，部分氘的替换是指至少一个氢被至少一个氘替换。Compared with non-deuterated drugs, deuterated drugs have the advantages of reducing toxic and side effects, increasing drug stability, enhancing curative effect, and prolonging the biological half-life of drugs. All permutations of isotopic composition of the disclosed compounds, whether radioactive or not, are included within the scope of the present disclosure. Each available hydrogen atom attached to a carbon atom may be independently replaced by a deuterium atom, wherein the replacement of deuterium may be partial or complete, and partial deuterium replacement means that at least one hydrogen is replaced by at least one deuterium.
当一个位置被特别地指定为氘D时，该位置应理解为具有大于氘的天然丰度(其为0.015％)至少1000倍的丰度的氘(即至少15％的氘掺入)。示例中化合物的具有大于氘的天然丰度可以是至少1000倍的丰度的氘(即至少15％的氘掺入)、 至少2000倍的丰度的氘(即至少30％的氘掺入)、至少3000倍的丰度的氘(即至少45％的氘掺入)、至少3340倍的丰度的氘(即至少50.1％的氘掺入)、至少3500倍的丰度的氘(即至少52.5％的氘掺入)、至少4000倍的丰度的氘(即至少60％的氘掺入)、至少4500倍的丰度的氘(即至少67.5％的氘掺入)、至少5000倍的丰度的氘(即至少75％的氘掺入)、至少5500倍的丰度的氘(即至少82.5％的氘掺入)、至少6000倍的丰度的氘(即至少90％的氘掺入)、至少6333.3倍的丰度的氘(即至少95％的氘掺入)、至少6466.7倍的丰度的氘(即至少97％的氘掺入)、至少6600倍的丰度的氘(即至少99％的氘掺入)、至少6633.3倍的丰度的氘(即至少99.5％的氘掺入)或更高丰度的氘。When a position is specifically designated as deuterium D, the position is understood to have an abundance of deuterium (ie at least 15% deuterium incorporation) that is at least 1000 times greater than the natural abundance of deuterium (which is 0.015%). Exemplary compounds having a natural abundance greater than deuterium can be at least 1000 times more abundant deuterium (i.e. at least 15% deuterium incorporation), at least 2000 times more abundant deuterium (i.e. at least 30% deuterium incorporation) , at least 3000 times the abundance of deuterium (i.e. at least 45% deuterium incorporation), at least 3340 times the abundance of deuterium (i.e. at least 50.1% deuterium incorporation), at least 3500 times the abundance of deuterium (i.e. at least 52.5% deuterium incorporation), at least 4000-fold more abundant deuterium (i.e. at least 60% deuterium incorporation), at least 4500-fold more abundant deuterium (i.e. at least 67.5% deuterium incorporation), at least 5000-fold Deuterium in abundance (i.e. at least 75% deuterium incorporation), deuterium in at least 5500 times abundance (i.e. at least 82.5% deuterium incorporation), deuterium in at least 6000 times abundance (i.e. at least 90% deuterium incorporation deuterium incorporation), at least 6333.3 times the abundance of deuterium (i.e. at least 95% deuterium incorporation), at least 6466.7 times the abundance of deuterium (i.e. at least 97% deuterium incorporation), at least 6600 times the abundance of deuterium ( That is, at least 99% deuterium incorporation), at least 6633.3 times the abundance of deuterium (ie, at least 99.5% deuterium incorporation), or higher abundance of deuterium.
“任选地”或“任选”是指随后所描述的事件或环境可以但不必然发生，其包括该事件或环境发生或不发生两种情形。例如“任选地(任选)被卤素或者氰基取代的烷基”包括烷基被卤素或者氰基取代的情形和烷基不被卤素和氰基取代的情形。"Optionally" or "optionally" means that the subsequently described event or circumstance may but not necessarily occur, and it includes two situations in which the event or circumstance occurs or does not occur. For example, "alkyl optionally (optionally) substituted by halogen or cyano" includes the case where the alkyl is substituted by halogen or cyano and the case where the alkyl is not substituted by halogen or cyano.
“取代”或“取代的”指基团中的一个或多个氢原子，优选1～6个，更优选1～3个氢原子彼此独立地被相应数目的取代基取代。本领域技术人员能够在不付出过多努力的情况下(通过实验或理论)确定可能或不可能的取代。例如，具有游离氢的氨基或羟基与具有不饱和键的碳原子(如烯)结合时可能是不稳定的。"Substituted" or "substituted" means that one or more hydrogen atoms in a group, preferably 1 to 6, more preferably 1 to 3 hydrogen atoms are independently substituted by the corresponding number of substituents. Possible or impossible substitutions can be determined (by experiment or theory) by those skilled in the art without undue effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated bond such as an alkene.
“药物组合物”表示含有一种或多种本文所述化合物或其可药用的盐与其他化学组分的混合物，以及其他组分例如药学上可接受的载体和赋形剂。药物组合物的目的是促进对生物体的给药，利于活性成分的吸收进而发挥生物活性。"Pharmaceutical composition" means a mixture containing one or more compounds described herein, or a pharmaceutically acceptable salt thereof, and other chemical components, such as pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredient and thus exert biological activity.
“可药用的盐”是指本公开化合物的盐，可选自无机盐或有机盐。这类盐用于哺乳动物体内时具有安全性和有效性，且具有应有的生物活性。可以在化合物的最终分离和纯化过程中，或通过使合适的基团与合适的碱或酸反应来单独制备。通常用于形成药学上可接受的盐的碱包括无机碱，例如氢氧化钠和氢氧化钾，以及有机碱，例如氨。通常用于形成药学上可接受的盐的酸包括无机酸以及有机酸。"Pharmaceutically acceptable salt" refers to a salt of a compound of the present disclosure, which may be selected from inorganic or organic salts. Such salts are safe and effective when used in mammals, and have proper biological activity. They can be prepared separately during the final isolation and purification of the compound, or by reacting the appropriate group with an appropriate base or acid. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include inorganic acids as well as organic acids.
针对药物或药理学活性剂而言，术语“治疗有效量”是指足以达到或至少部分达到预期效果的药物或药剂的用量。治疗有效量的确定因人而异，取决于受体的年龄和一般情况，也取决于具体的活性物质，个案中合适的治疗有效量可以由本领域技术人员根据常规试验确定。With respect to a drug or pharmacologically active agent, the term "therapeutically effective amount" refers to an amount of the drug or agent sufficient to achieve, or at least partially achieve, the desired effect. The determination of the therapeutically effective dose varies from person to person, depending on the age and general condition of the recipient, and also depends on the specific active substance. The appropriate therapeutically effective dose in individual cases can be determined by those skilled in the art according to routine tests.
本文所用的术语“药学上可接受的”是指这些化合物、材料、组合物和/或剂型，在合理的医学判断范围内，适用于与患者组织接触而没有过度毒性、刺激性、过敏反应或其他问题或并发症，具有合理的获益/风险比，并且对预期的用途是有效。As used herein, the term "pharmaceutically acceptable" means those compounds, materials, compositions and/or dosage forms, which are suitable for use in contact with patient tissues without undue toxicity, irritation, allergic reaction or Other problems or complications that have a reasonable benefit/risk ratio and are valid for the intended use.
本文所使用的，单数形式的“一个”、“一种”和“该”包括复数引用，反之亦然，除非上下文另外明确指出。As used herein, the singular forms "a", "an" and "the" include plural references and vice versa unless the context clearly dictates otherwise.
当将术语“约”应用于诸如pH、浓度、温度等的参数时，表明该参数可以变 化±10％，并且有时更优选地在±5％之内。如本领域技术人员将理解的，当参数不是关键时，通常仅出于说明目的给出数字，而不是限制。When the term "about" is applied to a parameter such as pH, concentration, temperature, etc., it means that the parameter may vary by ± 10%, and sometimes more preferably within ± 5%. As will be understood by those skilled in the art, when a parameter is not critical, the numbers are generally given for illustrative purposes only, and not for limitation.
本公开化合物的合成方法Synthetic Methods of the Disclosed Compounds
为了完成本公开的目的，本公开采用如下技术方案：In order to accomplish the purpose of this disclosure, this disclosure adopts the following technical solutions:
方案一Option One
本公开通式(I)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (I) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000076
Figure PCTCN2022128914-appb-000076
通式(Ia)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(X)化合物或其盐在碱性条件下发生反应得到通式(I)化合物或其可药用的盐；The compound of general formula (Ia) or its salt (preferably two 2,2,2-trifluoroacetates) and the compound of general formula (X) or its salt react under alkaline conditions to obtain the compound of general formula (I) or its salt pharmaceutically acceptable salts;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
R 1为
Figure PCTCN2022128914-appb-000077
 R1 is
Figure PCTCN2022128914-appb-000077
环A、X、Y、Z 1、Z 2、R 2、R 3、R 4、R 5、R 6、R 11、R 12、R 13、R 14、s和t如通式(I)中所定义。 Ring A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 , s and t are as in general formula (I) defined.
方案二Option II
本公开通式(II)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (II) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000078
Figure PCTCN2022128914-appb-000078
通式(IIa)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(X)化合物或其盐在碱性条件下发生反应得到通式(II)化合物或其可药用的盐；The compound of general formula (IIa) or its salt (preferably two 2,2,2-trifluoroacetic acid salt) and the compound of general formula (X) or its salt react under basic conditions to obtain the compound of general formula (II) or its salt pharmaceutically acceptable salts;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
R 1为
Figure PCTCN2022128914-appb-000079
 R1 is
Figure PCTCN2022128914-appb-000079
m为0或1；m is 0 or 1;
环A、Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12、R 13、R 14和t如通式(II)中所定义。 Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 and t are as defined in the general formula (II).
方案三third solution
本公开通式(III)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (III) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000080
Figure PCTCN2022128914-appb-000080
通式(IIIa)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(XI)化合物或其盐在碱性条件下发生反应得到通式(III)化合物或其可药用的盐；The compound of general formula (IIIa) or its salt (preferably two 2,2,2-trifluoroacetic acid salt) and the compound of general formula (XI) or its salt react under basic conditions to obtain the compound of general formula (III) or its salt pharmaceutically acceptable salts;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(III)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III).
方案四Option four
本公开通式(III-1)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (III-1) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000081
Figure PCTCN2022128914-appb-000081
通式(III-1a)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(XI)化合物或其盐在碱性条件下发生反应得到通式(III-1)化合物或其可药用的盐；General formula (III-1a) compound or its salt (preferably two 2,2,2-trifluoroacetic acid salt) and general formula (XI) compound or its salt react under alkaline conditions to obtain general formula (III-1 ) compound or a pharmaceutically acceptable salt thereof;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(III-1)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III-1).
方案五Option five
本公开通式(III-2)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (III-2) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000082
Figure PCTCN2022128914-appb-000082
通式(III-2a)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(XI)化合物或其盐在碱性条件下发生反应得到通式(III-2)化合物或其可药用的盐；General formula (III-2a) compound or its salt (preferably two 2,2,2-trifluoroacetic acid salt) and general formula (XI) compound or its salt react under alkaline conditions to obtain general formula (III-2 ) compound or a pharmaceutically acceptable salt thereof;
其中：in:
L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
W为C(CN)或N；W is C(CN) or N;
t为0、1、2或3；t is 0, 1, 2 or 3;
m为0或1；m is 0 or 1;
Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如通式(III-2)中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in the general formula (III-2).
方案六Option six
本公开通式(III-1-A)和通式(III-1-B)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by general formula (III-1-A) and general formula (III-1-B) or a pharmaceutically acceptable salt thereof of the present disclosure comprises the following steps:
Figure PCTCN2022128914-appb-000083
Figure PCTCN2022128914-appb-000083
通式(III-1)化合物或其可药用的盐经高效液相制备色谱法拆分得到通式(III-1-A)和通式(III-1-B)化合物或其可药用的盐；The compound of general formula (III-1) or its pharmaceutically acceptable salt is resolved by high performance liquid phase preparative chromatography to obtain the compound of general formula (III-1-A) and general formula (III-1-B) or its pharmaceutically acceptable of salt;
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12、R 13、m和t如通式(III-1)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , m and t are as defined in the general formula (III-1).
方案七Option seven
本公开通式(III-2-A)和通式(III-2-B)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by general formula (III-2-A) and general formula (III-2-B) or a pharmaceutically acceptable salt thereof of the present disclosure comprises the following steps:
Figure PCTCN2022128914-appb-000084
Figure PCTCN2022128914-appb-000084
通式(III-2)化合物或其可药用的盐经高效液相制备色谱法拆分得到通式(III-2-A)和通式(III-2-B)化合物或其可药用的盐；The compound of general formula (III-2) or its pharmaceutically acceptable salt is resolved by high performance liquid phase preparative chromatography to obtain the compound of general formula (III-2-A) and general formula (III-2-B) or its pharmaceutically acceptable of salt;
其中：in:
W、Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12、R 13、m和t如通式(III-2)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , m and t are as defined in the general formula (III-2).
方案八Option eight
本公开通式(Ia)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (Ia) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000085
Figure PCTCN2022128914-appb-000085
(a)通式(Iaaa)化合物或其盐和通式(Iaab)化合物或其盐发生Suzuki偶联反应得到通式(Iaa)化合物或其可药用的盐；(a) Suzuki coupling reaction occurs between the compound of general formula (Iaaa) or its salt and the compound of general formula (Iaab) or its salt to obtain the compound of general formula (Iaa) or its pharmaceutically acceptable salt;
(b)通式(Iaa)化合物或其盐在酸性条件下脱去R W2得到通式(Ia)化合物或其可药用的盐； (b) the compound of general formula (Iaa) or its salt is sloughed under acidic conditions R W2 obtains the compound of general formula (Ia) or its pharmaceutically acceptable salt;
其中：in:
R L为卤素；优选地，R L为Br； RL is halogen; preferably, RL is Br;
R W2为氨基保护基；优选地，R W2为叔丁氧羰基； R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
R X选自
Figure PCTCN2022128914-appb-000086
R为氢原子或C 1-6烷基； R X selected from
Figure PCTCN2022128914-appb-000086
R is a hydrogen atom or a C 1-6 alkyl group;
环A、X、Y、Z 1、Z 2、R 2、R 3、R 4、R 5、R 6、s和t如通式(Ia)中所定义。 Rings A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , s and t are as defined in general formula (Ia).
方案九Option nine
本公开通式(IIa)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (IIa) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000087
Figure PCTCN2022128914-appb-000087
(a)通式(IIaaa)化合物或其盐和通式(Iaab)化合物或其盐发生Suzuki偶联反应得到通式(IIaa)化合物或其可药用的盐；(a) Suzuki coupling reaction occurs between the compound of general formula (IIaaa) or its salt and the compound of general formula (Iaab) or its salt to obtain the compound of general formula (IIaa) or its pharmaceutically acceptable salt;
(b)通式(IIaa)化合物或其盐在酸性条件下脱去R W2得到通式(IIa)化合物或其可药用的盐； (b) the compound of general formula (IIaa) or its salt is removed under acidic conditions R W2 to obtain the compound of general formula (IIa) or its pharmaceutically acceptable salt;
其中：in:
R L为卤素；优选地，R L为Br； RL is halogen; preferably, RL is Br;
R W2为氨基保护基；优选地，R W2为叔丁氧羰基； R W2 is an amino protecting group; preferably, R W2 is tert-butoxycarbonyl;
R X选自
Figure PCTCN2022128914-appb-000088
R为氢原子或C 1-6烷基； R X selected from
Figure PCTCN2022128914-appb-000088
R is a hydrogen atom or a C 1-6 alkyl group;
环A、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(IIa)中所定义。 Ring A, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIa).
方案十Plan ten
本公开通式(IIIa)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (IIIa) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000089
Figure PCTCN2022128914-appb-000089
(a)通式(IIIaaa)化合物或其盐和通式(IIIaab)化合物或其盐发生Suzuki偶联反应得到通式(IIIaa)化合物或其可药用的盐；(a) Suzuki coupling reaction occurs between the compound of general formula (IIIaaa) or its salt and the compound of general formula (IIIaab) or its salt to obtain the compound of general formula (IIIaa) or its pharmaceutically acceptable salt;
(b)通式(IIIaa)化合物或其盐在酸性条件下脱去R W1和R W2得到通式(IIIa)化合物或其可药用的盐； (b) the compound of general formula (IIIaa) or its salt is removed under acidic conditions R W1 and R W2 to obtain the compound of general formula (IIIa) or its pharmaceutically acceptable salt;
其中：in:
R L为卤素；优选地，R L为Br； RL is halogen; preferably, RL is Br;
R W1和R W2均为氨基保护基；优选地，R W1和R W2均为叔丁氧羰基； Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
R X选自
Figure PCTCN2022128914-appb-000090
R为氢原子或C 1-6烷基； R X selected from
Figure PCTCN2022128914-appb-000090
R is a hydrogen atom or a C 1-6 alkyl group;
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(IIIa)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in general formula (IIIa).
方案十一Plan Eleven
本公开通式(III-1a)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (III-1a) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000091
Figure PCTCN2022128914-appb-000091
(a)通式(III-1aaa)化合物或其盐和通式(IIIaab)化合物或其盐发生Suzuki偶联反应得到通式(III-1aa)化合物或其可药用的盐；(a) Suzuki coupling reaction occurs between the compound of general formula (III-1aaa) or its salt and the compound of general formula (IIIaab) or its salt to obtain the compound of general formula (III-1aa) or its pharmaceutically acceptable salt;
(b)通式(III-1aa)化合物或其盐在酸性条件下脱去R W1和R W2得到通式(III-1a)化合物或其可药用的盐； (b) the compound of general formula (III-1aa) or its salt is removed under acidic conditions R W1 and R W2 to obtain the compound of general formula (III-1a) or its pharmaceutically acceptable salt;
其中：in:
R L为卤素；优选地，R L为Br； RL is halogen; preferably, RL is Br;
R W1和R W2均为氨基保护基；优选地，R W1和R W2均为叔丁氧羰基； Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
R X选自
Figure PCTCN2022128914-appb-000092
R为氢原子或C 1-6烷基； R X selected from
Figure PCTCN2022128914-appb-000092
R is a hydrogen atom or a C 1-6 alkyl group;
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-1a)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-1a).
方案十二Plan twelve
本公开通式(III-2a)所示的化合物或其可药用的盐的制备方法，其包括以下步骤：The preparation method of the compound represented by the general formula (III-2a) of the present disclosure or a pharmaceutically acceptable salt thereof comprises the following steps:
Figure PCTCN2022128914-appb-000093
Figure PCTCN2022128914-appb-000093
(a)通式(III-2aaa)化合物或其盐和通式(IIIaab)化合物或其盐发生Suzuki偶联反应得到通式(III-2aa)化合物或其可药用的盐；(a) Suzuki coupling reaction occurs between the compound of general formula (III-2aaa) or its salt and the compound of general formula (IIIaab) or its salt to obtain the compound of general formula (III-2aa) or its pharmaceutically acceptable salt;
(b)通式(III-2aa)化合物或其盐在酸性条件下脱去R W1和R W2得到通式(III-2a)化合物或其可药用的盐； (b) the compound of general formula (III-2aa) or its salt is removed under acidic conditions R W1 and R W2 to obtain the compound of general formula (III-2a) or its pharmaceutically acceptable salt;
其中：in:
R L为卤素；优选地，R L为Br； RL is halogen; preferably, RL is Br;
R W1和R W2均为氨基保护基；优选地，R W1和R W2均为叔丁氧羰基； Both R W1 and R W2 are amino protecting groups; preferably, R W1 and R W2 are both tert-butoxycarbonyl;
R X选自
Figure PCTCN2022128914-appb-000094
R为氢原子或C 1-6烷基； R X selected from
Figure PCTCN2022128914-appb-000094
R is a hydrogen atom or a C 1-6 alkyl group;
W、Z 1、Z 2、R 3、R 4、R 5、R 6、m和t如通式(III-2a)中所定义。 W, Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , m and t are as defined in the general formula (III-2a).
上述合成方案中，Suzuki偶联反应优选在碱(例如碳酸铯)和金属催化剂(例如双(二苯基膦苯基醚)二氯化钯(II))的存在下进行。In the above synthesis scheme, the Suzuki coupling reaction is preferably carried out in the presence of a base (such as cesium carbonate) and a metal catalyst (such as bis(diphenylphosphinephenyl ether)palladium(II) dichloride).
上述合成方案中，提供碱性条件的碱包括有机碱和无机碱，所述的有机碱包括但不限于三乙胺、N,N-二异丙基乙胺、正丁基锂、二异丙基氨基锂、醋酸钾、乙酸钠、乙醇钠、叔丁醇钠和叔丁醇钾；所述的无机碱包括但不限于氢化钠、磷酸钾、碳酸钠、碳酸钾、无水碳酸钾、碳酸铯、氢氧化钠、氢氧化锂一水合物、氢氧化锂和氢氧化钾，优选无水碳酸钾。In the above synthesis scheme, the bases that provide basic conditions include organic bases and inorganic bases, and the organic bases include but are not limited to triethylamine, N,N-diisopropylethylamine, n-butyllithium, diisopropyl lithium amide, potassium acetate, sodium acetate, sodium ethoxide, sodium tert-butoxide and potassium tert-butoxide; the inorganic bases include but not limited to sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, anhydrous potassium carbonate, carbonic acid Cesium, sodium hydroxide, lithium hydroxide monohydrate, lithium hydroxide and potassium hydroxide, preferably anhydrous potassium carbonate.
上述合成方案中，提供酸性条件的酸包括有机酸和无机酸，所述的有机酸包括但不限于三氟乙酸、甲酸、乙酸、甲磺酸、对甲苯磺酸、Me 3SiCl和TMSOTf，优选三氟乙酸；所述的无机酸包括但不限于氯化氢、氯化氢的1,4-二氧六环溶液、盐酸、硫酸、硝酸和磷酸。 In the above synthesis scheme, the acids providing acidic conditions include organic acids and inorganic acids. The organic acids include but are not limited to trifluoroacetic acid, formic acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, Me 3 SiCl and TMSOTf, preferably Trifluoroacetic acid; said inorganic acid includes but not limited to hydrogen chloride, hydrogen chloride in 1,4-dioxane solution, hydrochloric acid, sulfuric acid, nitric acid and phosphoric acid.
上述合成方案优选在溶剂中进行，所用溶剂包括但不限于：乙二醇二甲醚、醋酸、甲醇、乙醇、乙腈、正丁醇、甲苯、四氢呋喃、二氯甲烷、石油醚、乙酸乙酯、正己烷、二甲基亚砜、1,4-二氧六环、水、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺及其混合物。The above synthesis scheme is preferably carried out in a solvent, and the solvent used includes but is not limited to: ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-Hexane, Dimethyl Sulfoxide, 1,4-Dioxane, Water, N,N-Dimethylformamide, N,N-Dimethylacetamide and mixtures thereof.
具体实施方式Detailed ways
以下结合实施例用于进一步描述本公开，但这些实施例并非限制着本公开的范围。The following examples are used to further describe the present disclosure, but these examples do not limit the scope of the present disclosure.
实施例Example
化合物的结构是通过核磁共振(NMR)或/和质谱(MS)来确定的。NMR位移(δ)以10 -6(ppm)的单位给出。NMR的测定是用Bruker AVANCE-400核磁仪或Bruker AVANCE NEO 500M，测定溶剂为氘代二甲基亚砜(DMSO-d 6)、氘代氯仿(CDCl 3)、氘代甲醇(CD 3OD)，内标为四甲基硅烷(TMS)。 Compound structures were determined by nuclear magnetic resonance (NMR) or/and mass spectroscopy (MS). NMR shifts (δ) are given in units of 10 -6 (ppm). The determination of NMR is to use Bruker AVANCE-400 nuclear magnetic apparatus or Bruker AVANCE NEO 500M, and the determination solvent is deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD) , the internal standard is tetramethylsilane (TMS).
MS的测定用Agilent 1200/1290 DAD-6110/6120 Quadrupole MS液质联用仪(生产商：Agilent，MS型号：6110/6120 Quadrupole MS)。MS was determined with Agilent 1200/1290 DAD-6110/6120 Quadrupole MS liquid mass spectrometer (manufacturer: Agilent, MS model: 6110/6120 Quadrupole MS).
waters ACQuity UPLC-QD/SQD(生产商：waters，MS型号：waters ACQuity Qda Detector/waters SQ Detector)waters ACQuity UPLC-QD/SQD (manufacturer: waters, MS model: waters ACQuity Qda Detector/waters SQ Detector)
THERMO Ultimate 3000-Q Exactive(生产商：THERMO，MS型号：THERMO Q Exactive)THERMO Ultimate 3000-Q Exactive (manufacturer: THERMO, MS model: THERMO Q Exactive)
高效液相色谱法(HPLC)分析使用Agilent HPLC 1200DAD、Agilent HPLC 1200VWD和Waters HPLC e2695-2489高效液相色谱仪。High performance liquid chromatography (HPLC) was analyzed using Agilent HPLC 1200DAD, Agilent HPLC 1200VWD and Waters HPLC e2695-2489 high performance liquid chromatography.
手性HPLC分析测定使用Agilent 1260 DAD高效液相色谱仪。Chiral HPLC analysis was performed using an Agilent 1260 DAD high performance liquid chromatograph.
高效液相制备使用Waters 2545-2767、Waters 2767-SQ Detecor2、Shimadzu LC-20AP和Gilson GX-281制备型色谱仪。Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP and Gilson GX-281 preparative chromatographs were used for HPLC preparation.
手性制备使用Shimadzu LC-20AP制备型色谱仪。A Shimadzu LC-20AP preparative chromatograph was used for chiral preparation.
CombiFlash快速制备仪使用Combiflash Rf200(TELEDYNE ISCO)。The CombiFlash rapid preparation instrument uses Combiflash Rf200 (TELEDYNE ISCO).
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板，薄层色谱法(TLC)使用的硅胶板采用的规格是0.15mm～0.2mm，薄层层析分离纯化产品采用的规格是0.4mm～0.5mm。The thin-layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The specification of the silica gel plate used in thin-layer chromatography (TLC) is 0.15mm-0.2mm, and the specification of thin-layer chromatography separation and purification products is 0.4mm. ~0.5mm.
硅胶柱色谱法一般使用烟台黄海硅胶200～300目硅胶为载体。Silica gel column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
激酶平均抑制率及IC 50值的测定用NovoStar酶标仪(德国BMG公司)。 Kinase average inhibition rate and IC 50 value were measured with NovoStar microplate reader (BMG Company, Germany).
本公开的已知的起始原料可以采用或按照本领域已知的方法来合成，或可购买自ABCR GmbH & Co.KG，Acros Organics，Aldrich Chemical Company，韶远化学科技(Accela ChemBio Inc)、达瑞化学品等公司。The known starting materials of the present disclosure can be adopted or synthesized according to methods known in the art, or can be purchased from ABCR GmbH & Co.KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc), Darui Chemicals and other companies.
实施例中无特殊说明，反应均能够在氩气氛或氮气氛下进行。Unless otherwise specified in the examples, the reactions can all be carried out under an argon atmosphere or a nitrogen atmosphere.
氩气氛或氮气氛是指反应瓶连接一个约1L容积的氩气或氮气气球。The argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a volume of about 1 L.
氢气氛是指反应瓶连接一个约1L容积的氢气气球。The hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
加压氢化反应使用Parr 3916EKX型氢化仪和清蓝QL-500型氢气发生器或HC2-SS型氢化仪。The pressurized hydrogenation reaction uses Parr 3916EKX hydrogenation instrument and Qinglan QL-500 hydrogen generator or HC2-SS hydrogenation instrument.
氢化反应通常抽真空，充入氢气，反复操作3次。The hydrogenation reaction is usually vacuumized and filled with hydrogen, and the operation is repeated 3 times.
微波反应使用CEM Discover-S 908860型微波反应器。For the microwave reaction, a CEM Discover-S 908860 microwave reactor was used.
实施例中无特殊说明，溶液是指水溶液。Unless otherwise specified in the examples, the solution refers to an aqueous solution.
实施例中无特殊说明，反应的温度为室温，为20℃～30℃。Unless otherwise specified in the examples, the reaction temperature is room temperature, which is 20°C to 30°C.
实施例中的反应进程的监测采用薄层色谱法(TLC)，反应所使用的展开剂，纯化化合物采用的柱层析的洗脱剂的体系和薄层色谱法的展开剂体系包括：A：石油醚/乙酸乙酯体系，溶剂的体积比根据化合物的极性不同而进行调节，也可以加入少量的三乙胺和醋酸等碱性或酸性试剂进行调节。The monitoring of the reaction process in the embodiment adopts thin-layer chromatography (TLC), the developer used for reaction, the eluent system of the column chromatography that purifies compound adopts and the developer system of thin-layer chromatography comprise: A: Petroleum ether/ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and it can also be adjusted by adding a small amount of basic or acidic reagents such as triethylamine and acetic acid.
实施例1Example 1
4-((5aR,9S)-4-丙烯酰基-8-氯-10-氟-4,5,5a,6-四氢-3H-7-氧杂-1,2,2a1,4-四氮杂二苯并[cd,h]薁-9-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈1-p14-((5aR,9S)-4-acryloyl-8-chloro-10-fluoro-4,5,5a,6-tetrahydro-3H-7-oxa-1,2,2a1,4-tetraaze Heterodibenzo[cd,h]azulene-9-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 1-p1
4-((5aR,9R)-4-丙烯酰基-8-氯-10-氟-4,5,5a,6-四氢-3H-7-氧杂-1,2,2a1,4-四氮杂二苯并[cd,h]薁-9-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈1-p24-((5aR,9R)-4-acryloyl-8-chloro-10-fluoro-4,5,5a,6-tetrahydro-3H-7-oxa-1,2,2a1,4-tetraaze Heterodibenzo[cd,h]azulene-9-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 1-p2
Figure PCTCN2022128914-appb-000095
Figure PCTCN2022128914-appb-000095
Figure PCTCN2022128914-appb-000096
Figure PCTCN2022128914-appb-000096
第一步first step
4-溴-3-氯-2,5-二氟苯甲酰肼1b4-Bromo-3-chloro-2,5-difluorobenzohydrazide 1b
将化合物4-溴-3-氯-2,5-二氟苯甲酸甲酯1a(1.0g，3.50mmol)溶于乙醇(30mL)，加入水合肼一水合物(410mg，6.96mmol，85％纯度)，搅拌反应14小时。反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物1b(800mg，产率：79.9％)。The compound 4-bromo-3-chloro-2,5-difluorobenzoic acid methyl ester 1a (1.0g, 3.50mmol) was dissolved in ethanol (30mL), and hydrazine hydrate monohydrate (410mg, 6.96mmol, 85% purity ), stirred and reacted for 14 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 1b (800 mg, yield: 79.9%).
MS m/z(ESI):284.9[M+1]。MS m/z (ESI): 284.9 [M+1].
第二步second step
(R)-3-(((叔丁基二甲基硅基)氧基)甲基)-5-氧代哌嗪-1-甲酸叔丁酯1d(R)-3-(((tert-Butyldimethylsilyl)oxy)methyl)-5-oxopiperazine-1-carboxylic acid tert-butyl ester 1d
将化合物(R)-3-(羟甲基)-5-氧代哌嗪-1-羧酸叔丁酯1c(5.3g，23mmol，采用公知的方法“Organic Letters,2004,vol.6,no.22,p.4069–4072及其Supporting Information”制备而得)溶于N,N-二甲基甲酰胺(30mL)，依次加入咪唑(3.4g，49.94mmol)，叔丁基二甲基氯硅烷(2.3g，27.92mmol)，搅拌反应14小时。反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物1d(6.0g，产率：75.6％)。The compound (R)-3-(hydroxymethyl)-5-oxopiperazine-1-carboxylate tert-butyl ester 1c (5.3g, 23mmol, was prepared by a known method "Organic Letters, 2004, vol.6, no .22, p.4069–4072 and its Supporting Information”) were dissolved in N,N-dimethylformamide (30mL), followed by adding imidazole (3.4g, 49.94mmol), tert-butyldimethyl chloride Silane (2.3 g, 27.92 mmol), stirred for 14 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 1d (6.0 g, yield: 75.6%).
MS m/z(ESI):345.2[M+1]。MS m/z (ESI): 345.2 [M+1].
第三步third step
(R)-3-(((叔丁基二甲基硅基)氧基)甲基)-5-硫代哌嗪-1-甲酸叔丁酯1e(R)-3-(((tert-Butyldimethylsilyl)oxy)methyl)-5-thiopiperazine-1-carboxylic acid tert-butyl ester 1e
将化合物1d(2.0g，5.80mmol)溶于四氢呋喃(30mL)，加入劳森试剂(1.8g,4.4503mmol)。80℃反应2小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物1e(1.0g，产率：47.7％)。Compound 1d (2.0 g, 5.80 mmol) was dissolved in tetrahydrofuran (30 mL), and Lawson's reagent (1.8 g, 4.4503 mmol) was added. After reacting at 80°C for 2 hours, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 1e (1.0 g, yield: 47.7%).
MS m/z(ESI):361.2[M+1]。MS m/z (ESI): 361.2 [M+1].
第四步the fourth step
(R)-3-(4-溴-3-氯-2,5-二氟苯基)-5-(((叔丁基二甲基硅基)氧基)甲基)-5,6-二氢-[1,2,4]***并[4,3-a]吡嗪-7(8H)-甲酸叔丁酯1f(R)-3-(4-bromo-3-chloro-2,5-difluorophenyl)-5-(((tert-butyldimethylsilyl)oxy)methyl)-5,6- Dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-tert-butyl carboxylate 1f
将化合物1e(500mg，1.38mmol)，化合物1b(375mg，1.31mmol)溶于二甲苯(4mL)，微波加热至120℃反应2小时。反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物1f(250mg，产率：30.3％)。Compound 1e (500mg, 1.38mmol) and compound 1b (375mg, 1.31mmol) were dissolved in xylene (4mL) and heated to 120°C for 2 hours in microwave. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 1f (250 mg, yield: 30.3%).
MS m/z(ESI):593.2[M+1]。MS m/z (ESI): 593.2 [M+1].
第五步the fifth step
(R)-9-溴-8-氯-10-氟-5a,6-二氢-3H-7-氧杂-1,2,2a1,4-四氮杂二苯并[cd,h]薁-4(5H)-甲酸叔丁酯1g(R)-9-Bromo-8-chloro-10-fluoro-5a,6-dihydro-3H-7-oxa-1,2,2a1,4-tetraazadibenzo[cd,h]azulene -4(5H)-tert-butyl formate 1g
将化合物1f(100mg，168.36μmol)溶于四氢呋喃(2mL)，加入1M四丁基氟化铵的四氢呋喃溶液(841.80μL)，搅拌反应2小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物1g(70mg，产率：90.4％).Dissolve compound 1f (100mg, 168.36μmol) in tetrahydrofuran (2mL), add 1M tetrabutylammonium fluoride solution in tetrahydrofuran (841.80μL), stir and react for 2 hours, the reaction solution is concentrated under reduced pressure, and the residue is subjected to silica gel column chromatography Purification with eluent system A gave the title compound 1g (70 mg, yield: 90.4%).
MS m/z(ESI):459.2[M+1]。MS m/z (ESI): 459.2 [M+1].
第六步step six
(5aR)-9-(2-((叔丁氧基羰基)氨基)-3-氰基-7-氟苯并[b]噻吩-4-基)-8-氯-10-氟-5a,6-二氢-3H-7-氧杂-1,2,2a 1,4-四氮杂二苯并[cd,h]薁-4(5H)-甲酸叔丁酯1h (5aR)-9-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-8-chloro-10-fluoro-5a, 6-Dihydro-3H-7-oxa-1,2,2a 1 ,4-tetraazadibenzo[cd,h]azulene-4(5H)-carboxylic acid tert-butyl ester 1h
将化合物1g(35mg，76.13μmol)，化合物(3-氰基-4-(5,5-二甲基-1,3,2-二氧硼杂环己-2-基)-7-氟苯并[b]噻吩-2-基)氨基甲酸叔丁酯(70mg，121.2μmol，采用专利申请“WO2021118877A1”中说明书第50页的制备15公开的方法制备而得)溶于2mL的甲苯中，加入双(二苯基膦苯基醚)二氯化钯(II)(20mg，13.9μmol，上海泰坦)，碳酸铯(65mg，199.7μmol)，氮气置换，105℃搅拌反应6小时，反应液冷却至室温后过滤，滤液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物1h(45mg，产率：88％)。Compound 1g (35 mg, 76.13 μmol), compound (3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborin-2-yl)-7-fluorobenzene And [b] thiophen-2-yl) tert-butyl carbamate (70 mg, 121.2 μmol, prepared by the method disclosed in Preparation 15 on page 50 of the specification in the patent application "WO2021118877A1") was dissolved in 2 mL of toluene, and added Bis(diphenylphosphine phenyl ether) palladium(II) dichloride (20mg, 13.9μmol, Shanghai Titan), cesium carbonate (65mg, 199.7μmol), nitrogen replacement, stirring reaction at 105°C for 6 hours, the reaction solution was cooled to After filtering at room temperature, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 1h (45 mg, yield: 88%).
MS m/z(ESI):671.2[M+1]。MS m/z (ESI): 671.2 [M+1].
第七步step seven
2-氨基-4-((5aR)-8-氯-10-氟-4,5,5a,6-四氢-3H-7-氧杂-1,2,2a 1,4-四氮杂二苯并[cd,h]薁-9-基)-7-氟苯并[b]噻吩-3-甲腈二2,2,2-三氟乙酸盐1i 2-Amino-4-((5aR)-8-chloro-10-fluoro-4,5,5a,6-tetrahydro-3H-7-oxa-1,2,2a 1 ,4-tetraazabis Benzo[cd,h]azulene-9-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile di-2,2,2-trifluoroacetate 1i
将化合物1h(45mg，67.05μmol)溶于1mL二氯甲烷中，0℃下加入1mL三氟乙酸，搅拌反应2小时，反应液减压浓缩得到粗品标题化合物1i(40mg)，产品不经纯化直接用于下步反应。Compound 1h (45 mg, 67.05 μmol) was dissolved in 1 mL of dichloromethane, 1 mL of trifluoroacetic acid was added at 0°C, and the reaction was stirred for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the crude title compound 1i (40 mg), which was directly obtained without purification. for the next reaction.
MS m/z(ESI):471.1[M+1]。MS m/z (ESI): 471.1 [M+1].
第八步eighth step
4-((5aR)-4-丙烯酰基-8-氯-10-氟-4,5,5a,6-四氢-3H-7-氧杂-1,2,2a 1,4-四氮杂二苯并[cd,h]薁-9-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈1 4-((5aR)-4-acryloyl-8-chloro-10-fluoro-4,5,5a,6-tetrahydro-3H-7-oxa-1,2,2a 1 ,4-tetraaza Dibenzo[cd,h]azulene-9-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 1
4-((5aR,9S)-4-丙烯酰基-8-氯-10-氟-4,5,5a,6-四氢-3H-7-氧杂-1,2,2a 1,4-四氮杂二苯并[cd,h]薁-9-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈1-p1 4-((5aR,9S)-4-acryloyl-8-chloro-10-fluoro-4,5,5a,6-tetrahydro-3H-7-oxa-1,2,2a 1 ,4-tetra Azadibenzo[cd,h]azulene-9-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 1-p1
4-((5aR,9R)-4-丙烯酰基-8-氯-10-氟-4,5,5a,6-四氢-3H-7-氧杂-1,2,2a 1,4-四氮杂二苯并[cd,h]薁-9-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈1-p2 4-((5aR,9R)-4-acryloyl-8-chloro-10-fluoro-4,5,5a,6-tetrahydro-3H-7-oxa-1,2,2a 1 ,4-tetra Azadibenzo[cd,h]azulene-9-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 1-p2
将化合物1i(40mg，57.2μmol)悬浮于2mL乙酸乙酯，1mL四氢呋喃和2mL水中，加入无水碳酸钾(52mg，0.37mmol)，冰浴下加入丙烯酰氯(5mg，55.24μmol)，反应5分钟后用乙酸乙酯(5mL×2)萃取，合并有机相，减压浓缩，得到粗品标题化合物1(30mg)，用高效液相制备色谱法纯化(Waters-2545，色谱柱：SharpSil-T C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)纯化得到标题化合物(2mg，2mg，产率：6.6％，6.6％)。单一构型化合物(较短保留时间)(2mg，产率：6.6％)Compound 1i (40mg, 57.2μmol) was suspended in 2mL of ethyl acetate, 1mL of tetrahydrofuran and 2mL of water, anhydrous potassium carbonate (52mg, 0.37mmol) was added, and acryloyl chloride (5mg, 55.24μmol) was added under ice-cooling, and reacted for 5 minutes After extraction with ethyl acetate (5mL × 2), the organic phases were combined and concentrated under reduced pressure to obtain the crude product title compound 1 (30mg), which was purified by preparative high performance liquid chromatography (Waters-2545, chromatographic column: SharpSil-T C18, 30*150mm, 5μm; Mobile phase: aqueous phase (10mmol/L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 30%-45%, flow rate: 30mL/min) Purify and obtain the title compound (2mg, 2mg, yield : 6.6%, 6.6%). Single configuration compound (shorter retention time) (2 mg, yield: 6.6%)
MS m/z(ESI):525.2[M+1]。MS m/z (ESI): 525.2 [M+1].
HPLC分析：保留时间1.16分钟，纯度：99％(色谱柱:ACQUITY
Figure PCTCN2022128914-appb-000097
C18,1.7μm,2.1*50mm；流动相：水(10mM碳酸氢铵)，乙腈，梯度配比：乙腈10％-95％)。 HPLC analysis: retention time 1.16 minutes, purity: 99% (chromatographic column: ACQUITY
Figure PCTCN2022128914-appb-000097
C18, 1.7μm, 2.1*50mm; mobile phase: water (10mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%).
1H NMR(500MHz,CD3OD):δ8.19(d,1H),7.19(dd,1H),7.04(dd,1H),6.94(s,1H),6.38(dd,1H),5.91(d,1H),4.97-4.94(M,2H),4.24(dd,1H),3.36(s,2H),2.21(t,1H),2.05(q,1H)。 1 H NMR (500MHz, CD3OD): δ8.19(d,1H),7.19(dd,1H),7.04(dd,1H),6.94(s,1H),6.38(dd,1H),5.91(d, 1H), 4.97-4.94(M, 2H), 4.24(dd, 1H), 3.36(s, 2H), 2.21(t, 1H), 2.05(q, 1H).
单一构型化合物(较长保留时间)(2mg，产率：6.6％)Single configuration compound (longer retention time) (2 mg, yield: 6.6%)
MS m/z(ESI):525.2[M+1]。MS m/z (ESI): 525.2 [M+1].
LCMS分析:保留时间1.18分钟，纯度：99％(色谱柱:ACQUITY
Figure PCTCN2022128914-appb-000098
C18,1.7μm,2.1*50mm；流动相：水(10mM碳酸氢铵)，乙腈，梯度配比：乙腈10％-95％)。 LCMS analysis: retention time 1.18 minutes, purity: 99% (chromatographic column: ACQUITY
Figure PCTCN2022128914-appb-000098
C18, 1.7μm, 2.1*50mm; mobile phase: water (10mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%).
1H NMR(500MHz,CD3OD):δ8.21(d,1H),7.19(dd,1H),7.03(t,1H),6.93(d,1H),6.38(dd,1H),5.91(d,1H),4.99-4.93(m,2H),4.23(dd,1H),3.35(s,2H),2.21(t,1H),2.05(q,1H)。 1 H NMR (500MHz, CD3OD): δ8.21(d,1H),7.19(dd,1H),7.03(t,1H),6.93(d,1H),6.38(dd,1H),5.91(d, 1H), 4.99-4.93(m, 2H), 4.23(dd, 1H), 3.35(s, 2H), 2.21(t, 1H), 2.05(q, 1H).
实施例2Example 2
4-((3aS,8S)-2-丙烯酰基-7-氯-9-氟-1,2,3,3a,4,5-六氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-8-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈2-p1 4-((3aS,8S)-2-acryloyl-7-chloro-9-fluoro-1,2,3,3a,4,5-hexahydro-6-oxa-2,3a 1 ,11,12 -tetraazabenzo[7,8]octcyclo[1,2,3-cd]inden-8-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 2- p1
4-((3aS,8R)-2-丙烯酰基-7-氯-9-氟-1,2,3,3a,4,5-六氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-8-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈2-p2 4-((3aS,8R)-2-acryloyl-7-chloro-9-fluoro-1,2,3,3a,4,5-hexahydro-6-oxa-2,3a 1 ,11,12 -tetraazabenzo[7,8]octcyclo[1,2,3-cd]inden-8-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 2- p2
Figure PCTCN2022128914-appb-000099
Figure PCTCN2022128914-appb-000099
第一步first step
(S)-(2-((苄氧基)羰基)氨基)-4-(((叔丁基二甲基硅基)氧基)丁基)甘氨酸甲酯2b(S)-(2-((Benzyloxy)carbonyl)amino)-4-(((tert-butyldimethylsilyl)oxy)butyl)glycine methyl ester 2b
将(S)-(4-((叔丁基二甲基硅基)氧基)-1-氧代丁-2-基)氨基甲酸苄酯2a(2.2g，6.25mmol，采用公知的方法“Angewandte Chemie-International Edition,2004,vol.43,no.29,p.3818-3822及其Supporting Information”制备而得)，2-氨基乙酸乙酯盐酸盐(1.7g，12.1mmol，上海毕得)溶于甲醇(15mL)，依次加入冰醋酸(750mg，12.5mmol)，氰基硼氢化钠(600mg，10.03mmol)，搅拌反应14小时。反应液加入碳酸钾中和后过滤，滤液减压浓缩，加入水，用乙酸乙酯(20mL×3)萃取，合并 有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂，滤液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物2b(0.9g，产率：33.9％)。Benzyl (S)-(4-((tert-butyldimethylsilyl)oxy)-1-oxobutan-2-yl)carbamate 2a (2.2 g, 6.25 mmol, was prepared by the known method " Angewandte Chemie-International Edition, 2004, vol.43, no.29, p.3818-3822 and its Supporting Information "prepared), 2-aminoacetate ethyl ester hydrochloride (1.7g, 12.1mmol, Shanghai Bide ) was dissolved in methanol (15mL), glacial acetic acid (750mg, 12.5mmol) and sodium cyanoborohydride (600mg, 10.03mmol) were added successively, and the reaction was stirred for 14 hours. The reaction solution was neutralized by adding potassium carbonate and filtered, the filtrate was concentrated under reduced pressure, water was added, extracted with ethyl acetate (20mL×3), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered to remove the dryness solvent, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 2b (0.9 g, yield: 33.9%).
MS m/z(ESI):425.2[M+1]。MS m/z (ESI): 425.2 [M+1].
第二步second step
(S)-6-(2-((叔丁基二甲基硅基)氧基)乙基)哌嗪-2-酮2c(S)-6-(2-((tert-butyldimethylsilyl)oxy)ethyl)piperazin-2-one 2c
将化合物(S)-(2-((苄氧基)羰基)氨基)-4-(((叔丁基二甲基硅基)氧基)丁基)甘氨酸甲酯2b(1.8g，4.10mmol)溶于乙醇(20mL)，加入钯碳催化剂(10％)(440mg，4.13mmol)，氢气置换，搅拌反应2小时。反应液过滤，滤液减压浓缩得到粗品标题化合物2c(1g)，产品不经纯化直接用于下步反应。Compound (S)-(2-((benzyloxy)carbonyl)amino)-4-(((tert-butyldimethylsilyl)oxy)butyl)glycine methyl ester 2b (1.8g, 4.10mmol ) was dissolved in ethanol (20 mL), palladium carbon catalyst (10%) (440 mg, 4.13 mmol) was added, replaced by hydrogen, and stirred for 2 hours. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude title compound 2c (1 g), which was directly used in the next reaction without purification.
MS m/z(ESI):259.2[M+1]。MS m/z (ESI): 259.2 [M+1].
第三步third step
(S)-3-(2-((叔丁基二甲基硅基)氧基)乙基)-5-氧代哌嗪-1-甲酸叔丁酯2d(S)-3-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-5-oxopiperazine-1-carboxylic acid tert-butyl ester 2d
将化合物2c(1.0g，3.8695mmol)溶于二氯甲烷(10mL)，加入二碳酸二叔丁酯(1.01g，4.64mmol)，反应14小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物2d(1.1g，产率：79.28％)。Compound 2c (1.0g, 3.8695mmol) was dissolved in dichloromethane (10mL), di-tert-butyl dicarbonate (1.01g, 4.64mmol) was added, reacted for 14 hours, the reaction solution was concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography Purified with eluent system A to obtain the title compound 2d (1.1 g, yield: 79.28%).
MS m/z(ESI):359.2[M+1]。MS m/z (ESI): 359.2 [M+1].
第四步the fourth step
(S)-3-(2-((叔丁基二甲基硅基)氧基)乙基)-5-硫代哌嗪-1-甲酸叔丁酯2e(S)-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5-thiopiperazine-1-carboxylic acid tert-butyl ester 2e
将化合物2d(100mg，278.9μmol)溶于四氢呋喃(5mL)，加入劳森试剂(135mg，333.3μmol)。加热至80℃回流反应2小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物2e(40mg，产率：47.7％)。Compound 2d (100 mg, 278.9 μmol) was dissolved in tetrahydrofuran (5 mL), and Lawson's reagent (135 mg, 333.3 μmol) was added. Heated to 80°C and refluxed for 2 hours, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 2e (40 mg, yield: 47.7%).
MS m/z(ESI):375.2[M+1]。MS m/z (ESI): 375.2 [M+1].
第五步the fifth step
(S)-3-(4-溴-3-氯-2,5-二氟苯基)-5-(2-((叔丁基二甲基硅基)氧基)乙基)-5,6-二氢-[1,2,4]***并[4,3-a]吡嗪-7(8H)-甲酸叔丁酯2f(S)-3-(4-bromo-3-chloro-2,5-difluorophenyl)-5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-5, 6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-tert-butyl carboxylate 2f
将化合物2e(250mg，667.3μmol)，化合物1b(215mg，753.1μmol)溶于二甲苯(2mL)，微波120℃反应2小时。反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物2f(170mg，产率：41.8％)。Compound 2e (250 mg, 667.3 μmol) and compound 1b (215 mg, 753.1 μmol) were dissolved in xylene (2 mL), and reacted in microwave at 120° C. for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 2f (170 mg, yield: 41.8%).
MS m/z(ESI):607.2[M+1]。MS m/z (ESI): 607.2 [M+1].
第六步step six
(S)-8-溴-7-氯-9-氟-3,3a,4,5-四氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-2(1H)-甲酸叔丁酯2g (S)-8-bromo-7-chloro-9-fluoro-3,3a,4,5-tetrahydro-6-oxa-2,3a 1 ,11,12-tetraazabenzo[7,8 ]octcyclo[1,2,3-cd]indene-2(1H)-tert-butyl carboxylate 2g
将化合物2f(170mg，279.6μmol)溶于四氢呋喃(5mL)，加入1M四丁基氟化铵的四氢呋喃溶液(1.4mL)，搅拌反应2小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物2g(124mg，产率：93.6％)。Dissolve compound 2f (170mg, 279.6μmol) in tetrahydrofuran (5mL), add 1M tetrabutylammonium fluoride in tetrahydrofuran (1.4mL), stir and react for 2 hours, the reaction solution is concentrated under reduced pressure, and the residue is subjected to silica gel column chromatography Purification with eluent system A gave the title compound 2g (124 mg, yield: 93.6%).
MS m/z(ESI):473.2[M+1]。MS m/z (ESI): 473.2 [M+1].
第七步step seven
(3aS)-8-(2-((叔丁氧基羰基)氨基)-3-氰基-7-氟苯并[b]噻吩-4-基)-7-氯-9-氟-3,3a,4,5-四氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-2(1H)-甲酸叔 (3aS)-8-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-7-chloro-9-fluoro-3, 3a,4,5-tetrahydro-6-oxa-2,3a 1 ,11,12-tetraazabenzo[7,8]octcyclo[1,2,3-cd]indene-2(1H )-tert-formic acid
丁酯2hbutyl ester 2h
将化合物2g(140mg，295.5μmol)，化合物(3-氰基-4-(5,5-二甲基-1,3,2-二氧硼杂环己-2-基)-7-氟苯并[b]噻吩-2-基)氨基甲酸叔丁酯(60mg，148.4μmol)溶于2mL的甲苯中，加入双(二苯基膦苯基醚)二氯化钯(II)(20mg，13.9μmol)，碳酸铯(100mg，306.9μmol)，氮气置换，105℃搅拌反应6小时，反应液冷却至室温后过滤，滤液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物2h(56mg，产率：55％)。Compound 2g (140 mg, 295.5 μmol), compound (3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborin-2-yl)-7-fluorobenzene And [b] thiophen-2-yl) tert-butyl carbamate (60 mg, 148.4 μ mol) was dissolved in 2 mL of toluene, bis (diphenylphosphine phenyl ether) dichloride palladium (II) (20 mg, 13.9 μmol), cesium carbonate (100mg, 306.9μmol), nitrogen replacement, 105 ° C stirring reaction for 6 hours, the reaction solution was cooled to room temperature and then filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain The title compound 2h (56 mg, yield: 55%).
MS m/z(ESI):685.2[M+1]。MS m/z (ESI): 685.2 [M+1].
第八步eighth step
2-氨基-4-((3aS)-7-氯-9-氟-1,2,3,3a,4,5-六氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-8-基)-7-氟苯并[b]噻吩-3-甲腈二2,2,2-三氟乙酸盐2i 2-amino-4-((3aS)-7-chloro-9-fluoro-1,2,3,3a,4,5-hexahydro-6-oxa-2,3a 1 ,11,12-tetraaza Heterobenzo[7,8]octcyclo[1,2,3-cd]inden-8-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile di-2,2,2-trifluoro Acetate 2i
将化合物2h(56mg，81.7μmol)溶于1mL二氯甲烷中，0℃下加入1mL三氟乙酸，搅拌反应2小时，反应液减压浓缩得到粗品标题化合物2i(58mg)，产品不经纯化直接用于下步反应。Compound 2h (56 mg, 81.7 μmol) was dissolved in 1 mL of dichloromethane, 1 mL of trifluoroacetic acid was added at 0°C, and the reaction was stirred for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the crude title compound 2i (58 mg), which was directly obtained without purification. for the next reaction.
MS m/z(ESI):485.1[M+1]。MS m/z (ESI): 485.1 [M+1].
第九步Ninth step
4-((3aS)-2-丙烯酰基-7-氯-9-氟-1,2,3,3a,4,5-六氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-8-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈2 4-((3aS)-2-acryloyl-7-chloro-9-fluoro-1,2,3,3a,4,5-hexahydro-6-oxa-2,3a 1 ,11,12-tetra Azabenzo[7,8]octcyclo[1,2,3-cd]inden-8-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 2
4-((3aS,8S)-2-丙烯酰基-7-氯-9-氟-1,2,3,3a,4,5-六氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-8-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈2-p1 4-((3aS,8S)-2-acryloyl-7-chloro-9-fluoro-1,2,3,3a,4,5-hexahydro-6-oxa-2,3a 1 ,11,12 -tetraazabenzo[7,8]octcyclo[1,2,3-cd]inden-8-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 2- p1
4-((3aS,8R)-2-丙烯酰基-7-氯-9-氟-1,2,3,3a,4,5-六氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-8-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈2-p2 4-((3aS,8R)-2-acryloyl-7-chloro-9-fluoro-1,2,3,3a,4,5-hexahydro-6-oxa-2,3a 1 ,11,12 -tetraazabenzo[7,8]octcyclo[1,2,3-cd]inden-8-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 2- p2
将化合物2i(58mg，81.3μmol)悬浮于2mL乙酸乙酯，1mL四氢呋喃和2mL水中，加入无水碳酸钾(56mg，0.45mmol)，冰浴下加入丙烯酰氯(15mg，165.7μmol)，反应5分钟后用乙酸乙酯(5mL×2)萃取，合并有机相，减压浓缩，得到粗品标题化合物2(40mg)，用高效液相制备色谱法纯化(Waters-2545，色谱柱：SharpSil-T C18,30*150mm,5μm；流动相：水相(10mmol/L碳酸氢铵)和乙腈，梯度配比：乙腈30％-45％，流速：30mL/min)纯化得到标题化合物(2mg，0.7mg，产率：4.5％，1.9％)。Compound 2i (58 mg, 81.3 μmol) was suspended in 2 mL of ethyl acetate, 1 mL of tetrahydrofuran and 2 mL of water, anhydrous potassium carbonate (56 mg, 0.45 mmol) was added, acryloyl chloride (15 mg, 165.7 μmol) was added under ice cooling, and the reaction was carried out for 5 minutes After extraction with ethyl acetate (5mL × 2), the organic phases were combined and concentrated under reduced pressure to obtain the crude product title compound 2 (40mg), which was purified by preparative high performance liquid chromatography (Waters-2545, chromatographic column: SharpSil-T C18, 30*150mm, 5μm; Mobile phase: aqueous phase (10mmol/L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 30%-45%, flow rate: 30mL/min) Purify and obtain the title compound (2mg, 0.7mg, produce rate: 4.5%, 1.9%).
单一构型化合物(较短保留时间)(2mg，产率：4.5％)Single configuration compound (shorter retention time) (2 mg, yield: 4.5%)
MS m/z(ESI):539.2[M+1]。MS m/z (ESI): 539.2 [M+1].
HPLC分析：保留时间1.12分钟，纯度：99％(色谱柱:ACQUITY
Figure PCTCN2022128914-appb-000100
C18, 1.7μm,2.1*50mm；流动相：水(10mM碳酸氢铵)，乙腈，梯度配比：乙腈10％-95％)。 HPLC analysis: retention time 1.12 minutes, purity: 99% (chromatographic column: ACQUITY
Figure PCTCN2022128914-appb-000100
C18, 1.7μm, 2.1*50mm; mobile phase: water (10mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%).
1H NMR(500MHz,CD3OD):δ7.58(s,1H),7.19(dd,1H),7.05(dd,1H),6.92(dd,1H),6.40(d,1H),5.92(s,1H),5.54-5.42(m,1H),4.28(t,2H),3.94(d,1H),3.69-3.57(m,1H),2.34(s,1H),2.21(t,1H),2.12-2.00(m,2H)。 1 H NMR (500MHz, CD3OD): δ7.58(s,1H),7.19(dd,1H),7.05(dd,1H),6.92(dd,1H),6.40(d,1H),5.92(s, 1H),5.54-5.42(m,1H),4.28(t,2H),3.94(d,1H),3.69-3.57(m,1H),2.34(s,1H),2.21(t,1H),2.12 -2.00(m,2H).
单一构型化合物(较长保留时间)(0.7mg，产率：1.9％)Single configuration compound (longer retention time) (0.7 mg, yield: 1.9%)
MS m/z(ESI):539.2[M+1]。MS m/z (ESI): 539.2 [M+1].
LCMS分析:保留时间1.13分钟，纯度：99％(色谱柱:ACQUITY
Figure PCTCN2022128914-appb-000101
C18,1.7μm,2.1*50mm；流动相：水(10mM碳酸氢铵)，乙腈，梯度配比：乙腈10％-95％)。 LCMS analysis: retention time 1.13 minutes, purity: 99% (chromatographic column: ACQUITY
Figure PCTCN2022128914-appb-000101
C18, 1.7μm, 2.1*50mm; mobile phase: water (10mM ammonium bicarbonate), acetonitrile, gradient ratio: acetonitrile 10%-95%).
1H NMR(500MHz,CD3OD):δ7.46(d,1H),7.26(dd,1H),7.06(dd,1H),6.99-6.87(m,1H),6.39(d,1H),5.91(s,1H),5.44-5.33(m,1H),4.724.49(m,2H),4.44-4.31(m,2H),3.773.69(m,1H),2.29(dd,1H),2.112.05(m,2H)。 1 H NMR (500MHz, CD3OD): δ7.46(d,1H),7.26(dd,1H),7.06(dd,1H),6.99-6.87(m,1H),6.39(d,1H),5.91( s,1H),5.44-5.33(m,1H),4.724.49(m,2H),4.44-4.31(m,2H),3.773.69(m,1H),2.29(dd,1H),2.112. 05(m,2H).
实施例3Example 3
4-((3aR)-2-丙烯酰基-7-氯-9-氟-1,2,3,3a,4,5-六氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-8-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈3 4-((3aR)-2-acryloyl-7-chloro-9-fluoro-1,2,3,3a,4,5-hexahydro-6-oxa-2,3a 1 ,11,12-tetra Azabenzo[7,8]octcyclo[1,2,3-cd]inden-8-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 3
Figure PCTCN2022128914-appb-000102
Figure PCTCN2022128914-appb-000102
第一步first step
((苄氧基)羰基)-D-高丝氨酸甲酯3b((Benzyloxy)carbonyl)-D-homoserine methyl ester 3b
将化合物N-苄氧羰基-D-高丝氨酸3a(20g，78.9mmol，上海韶远)溶于甲醇(60mL)和正己烷(150mL)的混合溶剂中，加入2.0M的三甲基硅基重氮甲烷的正己烷溶液(79mL)，搅拌反应6小时，反应液减压浓缩得到粗品标题化合物3b(21g)，产品不经纯化直接用于下步反应。The compound N-benzyloxycarbonyl-D-homoserine 3a (20g, 78.9mmol, Shanghai Shaoyuan) was dissolved in a mixed solvent of methanol (60mL) and n-hexane (150mL), and 2.0M trimethylsilyl weight Nitrogen methane in n-hexane solution (79 mL), stirred for 6 hours, and the reaction solution was concentrated under reduced pressure to obtain the crude title compound 3b (21 g), which was directly used in the next reaction without purification.
MS m/z(ESI):568.2[M+1]。MS m/z (ESI): 568.2 [M+1].
第二步second step
N-((苄氧基)羰基)-O-(叔丁基二甲基硅基)-D-高丝氨酸甲酯3cN-((Benzyloxy)carbonyl)-O-(tert-butyldimethylsilyl)-D-homoserine methyl ester 3c
将粗品化合物3b(21g，78.5mmol)溶于N,N-二甲基甲酰胺(30mL)，依次加入咪唑(53.48g，785.5mmol)，叔丁基二甲基氯硅烷(59.2g，392.8mmol)，搅拌反应14小时，反应液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物3c(11.3g，产率：37.6％)。Crude compound 3b (21g, 78.5mmol) was dissolved in N,N-dimethylformamide (30mL), followed by adding imidazole (53.48g, 785.5mmol), tert-butyldimethylsilyl chloride (59.2g, 392.8mmol ), stirred and reacted for 14 hours, the reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 3c (11.3 g, yield: 37.6%).
第三步third step
(R)-(4-((叔丁基二甲基硅基)氧基)-1-氧代丁-2-基)氨基甲酸苄酯3dBenzyl (R)-(4-((tert-butyldimethylsilyl)oxy)-1-oxobut-2-yl)carbamate 3d
将化合物3c(6g，15.7mmol)溶于无水四氢呋喃(120mL)中，氮气保护下，-78℃加入1M二异丁基氢化铝的正己烷溶液(66mL)，维持温度反应6小时。将反应液倒入300mL 1M冰盐酸中，搅拌10分钟后，用乙酸乙酯(100mL×3)萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂，滤液减压浓缩得粗品化合物3d(5.5g)，产品不经纯化直接用于下步反应。Compound 3c (6g, 15.7mmol) was dissolved in anhydrous tetrahydrofuran (120mL), under nitrogen protection, 1M diisobutylaluminum hydride solution in n-hexane (66mL) was added at -78°C, and the temperature was maintained for 6 hours. Pour the reaction solution into 300mL 1M glacial hydrochloric acid, stir for 10 minutes, extract with ethyl acetate (100mL×3), combine the organic phases, wash with saturated sodium chloride solution, dry over anhydrous sodium sulfate, filter to remove the desiccant, The filtrate was concentrated under reduced pressure to obtain crude compound 3d (5.5 g), which was directly used in the next reaction without purification.
MS m/z(ESI):352.2[M+1]。MS m/z (ESI): 352.2 [M+1].
第四步the fourth step
(R)-(2-(((苄氧基)羰基)氨基)-4-((叔丁基二甲基硅基)氧基)丁基)甘氨酸甲酯3e(R)-(2-(((Benzyloxy)carbonyl)amino)-4-((tert-butyldimethylsilyl)oxy)butyl)glycine methyl ester 3e
将粗品化合物3d(5.50g，15.64mmol)，2-氨基乙酸乙酯盐酸盐(4.36g，31.29mmol，上海毕得)溶于甲醇(100mL)，依次加入冰醋酸(1.87g，31.29mmol)，氰基硼氢化钠(1.49g，25.03mmol)，搅拌反应14小时。反应液加入碳酸钾中和后过滤，滤液减压浓缩，加入水，用乙酸乙酯(50mL×3)萃取，合并有机相，用饱和氯化钠溶液洗涤，无水硫酸钠干燥，过滤除去干燥剂，滤液减压浓缩，残余物用硅胶柱色谱法以洗脱剂体系A纯化得到标题化合物3e(2.5g，产率：36.4％)。Crude compound 3d (5.50g, 15.64mmol), ethyl 2-aminoacetate hydrochloride (4.36g, 31.29mmol, Shanghai Bide) were dissolved in methanol (100mL), and glacial acetic acid (1.87g, 31.29mmol) was added successively , sodium cyanoborohydride (1.49g, 25.03mmol), stirred for 14 hours. The reaction solution was neutralized by adding potassium carbonate and filtered, the filtrate was concentrated under reduced pressure, water was added, extracted with ethyl acetate (50mL×3), the organic phases were combined, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered to remove the dryness solvent, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain the title compound 3e (2.5 g, yield: 36.4%).
MS m/z(ESI):425.2[M+1]。MS m/z (ESI): 425.2 [M+1].
第五步the fifth step
4-((3aR)-2-丙烯酰基-7-氯-9-氟-1,2,3,3a,4,5-六氢-6-氧杂-2,3a 1,11,12-四氮杂苯并[7,8]辛环并[1,2,3-cd]茚-8-基)-2-氨基-7-氟苯并[b]噻吩-3-甲腈3 4-((3aR)-2-acryloyl-7-chloro-9-fluoro-1,2,3,3a,4,5-hexahydro-6-oxa-2,3a 1 ,11,12-tetra Azabenzo[7,8]octcyclo[1,2,3-cd]inden-8-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile 3
采用实施例2中的合成路线，将第二步原料2b替换为化合物3e，得到标题化合物3(3mg，产率：5.3％)。Using the synthetic route in Example 2, the second-step raw material 2b was replaced by compound 3e to obtain the title compound 3 (3 mg, yield: 5.3%).
MS m/z(ESI):539.2[M+1]。MS m/z (ESI): 539.2 [M+1].
1H NMR(500MHz,CD3OD):δ7.58(s,1H),7.19(dd,1H),7.04(d,1H),6.93(dd,1H),6.40(d,1H),5.92(s,1H),5.48(s,1H),4.28-4.25(m,2H),3.90-3.83(m,1H),3.58-3.50(m,1H),2.33-2.25(m,1H),2.21(dd,1H),2.12-2.05(m,2H)。1H NMR(500MHz,CD3OD):δ7.58(s,1H),7.19(dd,1H),7.04(d,1H),6.93(dd,1H),6.40(d,1H),5.92(s,1H ),5.48(s,1H),4.28-4.25(m,2H),3.90-3.83(m,1H),3.58-3.50(m,1H),2.33-2.25(m,1H),2.21(dd,1H ),2.12-2.05(m,2H).
生物学评价biological evaluation
以下结合测试例进一步描述解释本公开，但这些实施例并非意味着限制本公 开的范围。The following further describes and explains the present disclosure in conjunction with test examples, but these embodiments are not meant to limit the scope of the present disclosure.
测试例1：H358增殖实验生物学评价Test Example 1: Biological Evaluation of H358 Proliferation Experiment
以下方法用来测定本公开化合物对H358细胞增殖的抑制活性，实验方法简述如下：The following methods are used to determine the inhibitory activity of the disclosed compounds on H358 cell proliferation, and the experimental methods are briefly described as follows:
H358细胞(ATCC，CRL-5807)用含有10％胎牛血清(Corning，35-076-CV)的RPMI1640培养基(Hyclone，SH30809.01)(即完全培养基)进行培养。实验第一天，使用完全培养基将H358细胞以1200个细胞/孔的密度种于96孔板，每孔100μL细胞悬液，放置37℃，5％CO 2细胞培养箱培养过夜。第二天，每孔加入10μL用完全培养基配制的梯度稀释的待测化合物，化合物的终浓度是从10μM开始进行5倍梯度稀释的9个浓度点，设置含有0.5％DMSO的空白对照，孔板放置37℃，5％CO 2的细胞培养箱培养120小时。第七天，取出96孔细胞培养板，每孔加入50μL发光细胞活性检测试剂(
Figure PCTCN2022128914-appb-000103
Luminescent Cell Viability Assay)(Promega，G7573)，室温放置10分钟后，使用多功能微孔板酶标仪(PerkinElmer，
Figure PCTCN2022128914-appb-000104
2105)读取发光信号值，用Graphpad Prism软件计算化合物抑制活性的IC 50值。 H358 cells (ATCC, CRL-5807) were cultured with RPMI1640 medium (Hyclone, SH30809.01) (ie complete medium) containing 10% fetal bovine serum (Corning, 35-076-CV). On the first day of the experiment, H358 cells were seeded in a 96-well plate at a density of 1200 cells/well using complete medium, 100 μL of cell suspension per well, and cultured overnight in a 37°C, 5% CO 2 cell incubator. On the second day, add 10 μL of the compound to be tested in serial dilution prepared in complete medium to each well. The final concentration of the compound is 9 concentration points of 5-fold serial dilution starting from 10 μM. A blank control containing 0.5% DMSO is set, and the wells are Place the plate in a cell culture incubator at 37°C, 5% CO 2 for 120 hours. On the seventh day, the 96-well cell culture plate was taken out, and 50 μL of luminescent cell activity detection reagent (
Figure PCTCN2022128914-appb-000103
Luminescent Cell Viability Assay) (Promega, G7573), after standing at room temperature for 10 minutes, using a multifunctional microplate microplate reader (PerkinElmer,
Figure PCTCN2022128914-appb-000104
2105) read the luminescent signal value, and calculate the IC 50 value of the inhibitory activity of the compound with Graphpad Prism software.
表1 本公开化合物对H358细胞增殖的抑制活性Table 1 The inhibitory activity of the disclosed compounds on the proliferation of H358 cells
化合物编号Compound number IC 50(nM) IC 50 (nM)
2-p1和2-p2中较短保留时间对应的化合物Compounds corresponding to shorter retention times in 2-p1 and 2-p2 14.0114.01
结论：本公开化合物对H358细胞增殖具有抑制作用。Conclusion: The disclosed compound has inhibitory effect on H358 cell proliferation.
测试例2：H358细胞ERK磷酸化抑制实验生物学评价Test Example 2: Biological Evaluation of ERK Phosphorylation Inhibition Experiment in H358 Cells
以下方法用来测定本公开化合物对H358细胞ERK磷酸化的抑制作用。实验方法简述如下：The following method was used to determine the inhibitory effect of the disclosed compounds on ERK phosphorylation in H358 cells. The experimental method is briefly described as follows:
H358细胞(ATCC，CRL-5807)用含有10％胎牛血清(Corning，35-076-CV)的RPMI1640(Hyclone，SH30809.01)培养基(即完全培养基)进行培养。实验第一天，使用完全培养基将H358细胞以25,000个/孔的密度种于96孔板，每孔190μL细胞悬液，放置37℃，5％CO 2细胞培养箱培养过夜。第二天，每孔加入10μL用完全培养基配制的梯度稀释的待测化合物，化合物的终浓度是从10μM开始进行6倍梯度稀释的9个浓度点，设置含有0.5％DMSO的空白对照，孔板放置37℃，5％CO 2的细胞培养箱孵育3个小时。3小时后，取出96孔细胞培养板，吸掉培养基，每孔加入200μL PBS(上海源培生物科技股份有限公司，B320)洗一遍。吸掉PBS，每孔加入50μL含封闭剂(Cisbio，64KB1AAC)的裂解缓冲液(Cisbio，64KL1FDF)，孔板放置振荡器上室温震荡裂解30分钟。裂解后用移液器吹打混匀，每孔各转移16μL裂解液分别至两块HTRF 96孔检测板(Cisbio，66PL96100)中，之后两块板分别加入4μL预混的磷酸-ERK1/2抗体溶液(Cisbio，64AERPEG) 或4μL预混的总-ERK1/2抗体溶液(Cisbio，64NRKPEG)。微孔板用封板膜密封，在微孔板离心机中离心1分钟，室温避光孵育过夜。第三天，使用PHERAstar多功能酶标仪(BMG Labtech，PHERAstar FS)读取337nm波长激发，665nm和620nm波长发射的荧光值，用Graphpad Prism软件根据化合物浓度和pERK/总ERK的比值计算化合物抑制活性的IC 50值。 H358 cells (ATCC, CRL-5807) were cultured with RPMI1640 (Hyclone, SH30809.01) medium (ie complete medium) containing 10% fetal calf serum (Corning, 35-076-CV). On the first day of the experiment, H358 cells were seeded in a 96-well plate at a density of 25,000 cells/well using complete medium, 190 μL of cell suspension per well, and cultured overnight in a 37°C, 5% CO 2 cell incubator. On the second day, add 10 μL of the compound to be tested in a gradient dilution prepared with complete medium to each well. The final concentration of the compound is 9 concentration points of 6-fold serial dilution starting from 10 μM. A blank control containing 0.5% DMSO is set, and the wells are Place the plate in a cell culture incubator at 37°C, 5% CO 2 and incubate for 3 hours. After 3 hours, the 96-well cell culture plate was taken out, the medium was sucked off, and 200 μL of PBS (Shanghai Yuanpei Biotechnology Co., Ltd., B320) was added to each well to wash once. The PBS was sucked off, and 50 μL of lysis buffer (Cisbio, 64KL1FDF) containing blocking agent (Cisbio, 64KB1AAC) was added to each well, and the plate was placed on a shaker at room temperature for lysis for 30 minutes. After lysis, pipette and mix well, transfer 16 μL of lysate to each well of two HTRF 96-well detection plates (Cisbio, 66PL96100), and then add 4 μL of premixed phospho-ERK1/2 antibody solution to the two plates respectively (Cisbio, 64AERPEG) or 4 μL of premixed total-ERK1/2 antibody solution (Cisbio, 64NRKPEG). The microplate was sealed with a plate sealer, centrifuged in a microplate centrifuge for 1 minute, and incubated overnight at room temperature in the dark. On the third day, use the PHERAstar multifunctional microplate reader (BMG Labtech, PHERAstar FS) to read the fluorescence values of 337nm wavelength excitation, 665nm and 620nm wavelength emission, and use Graphpad Prism software to calculate compound inhibition according to the ratio of compound concentration and pERK/total ERK IC50 values for activity.
表2 本公开化合物对H358细胞ERK磷酸化的抑制作用Table 2 The inhibitory effect of the disclosed compounds on ERK phosphorylation in H358 cells
化合物编号Compound number IC 50(nM) IC 50 (nM)
1-p1和1-p2中较短保留时间对应的化合物Compounds corresponding to shorter retention times in 1-p1 and 1-p2 14.0914.09
1-p1和1-p2中较长保留时间对应的化合物Compounds corresponding to longer retention times in 1-p1 and 1-p2 2.322.32
2-p1和2-p2中较短保留时间对应的化合物Compounds corresponding to shorter retention times in 2-p1 and 2-p2 0.250.25
2-p1和2-p2中较长保留时间对应的化合物Compounds corresponding to longer retention times in 2-p1 and 2-p2 3.433.43
结论：本公开化合物对H358细胞ERK磷酸化具有抑制作用。Conclusion: The disclosed compound has inhibitory effect on ERK phosphorylation in H358 cells.
测试例3：MIA PaCa-2细胞增殖实验生物学评价Test Example 3: Biological Evaluation of MIA PaCa-2 Cell Proliferation Experiment
以下方法用来测定本公开化合物对MIA PaCa-2细胞增殖的抑制活性。实验方法简述如下：The following method was used to determine the inhibitory activity of the disclosed compounds on the proliferation of MIA PaCa-2 cells. The experimental method is briefly described as follows:
MIA PaCa-2细胞(ATCC，CRL-1420)用含有10％胎牛血清(Corning，35-076-CV)和2.5％马血清(碧云天生物技术，C0262)的DMEM/HIGH GLUCOSE(GE，SH30243.01)培养基(即完全培养基)进行培养。实验第一天，使用完全培养基将MIA PaCa-2细胞以500个细胞/孔的密度种于96孔板，每孔90μL细胞悬液，放置37℃，5％CO 2细胞培养箱培养过夜。第二天，每孔加入10μL用完全培养基配制的梯度稀释的待测化合物，化合物的终浓度是从10μM开始进行5倍梯度稀释的9个浓度点，设置含有0.5％DMSO的空白对照，孔板放置37℃、5％CO 2的细胞培养箱培养72小时。第五天，取出96孔细胞培养板，每孔加入50μL发光细胞活性检测试剂(
Figure PCTCN2022128914-appb-000105
Luminescent Cell Viability Assay)(Promega，G7573)，室温放置10分钟后，使用多功能微孔板酶标仪(PerkinElmer，EnVision2015)读取发光信号值。用Graphpad Prism软件计算化合物抑制活性的IC 50值。 MIA PaCa-2 cells (ATCC, CRL-1420) were treated with DMEM/HIGH GLUCOSE (GE, SH30243) containing 10% fetal bovine serum (Corning, 35-076-CV) and 2.5% horse serum (Beyond Biotechnology, C0262). .01) medium (i.e. complete medium) for cultivation. On the first day of the experiment, MIA PaCa-2 cells were seeded in a 96-well plate at a density of 500 cells/well using complete medium, 90 μL of cell suspension per well, and cultured overnight in a 37°C, 5% CO 2 cell incubator. On the second day, add 10 μL of the compound to be tested in a gradient dilution prepared with complete medium to each well. The final concentration of the compound is 9 concentration points of 5-fold gradient dilution starting from 10 μM. A blank control containing 0.5% DMSO is set, and the wells are Plates were placed in a cell culture incubator at 37°C, 5% CO 2 for 72 hours. On the fifth day, the 96-well cell culture plate was taken out, and 50 μL of luminescent cell activity detection reagent (
Figure PCTCN2022128914-appb-000105
Luminescent Cell Viability Assay) (Promega, G7573), after standing at room temperature for 10 minutes, the luminescent signal value was read using a multi-functional microplate microplate reader (PerkinElmer, EnVision2015). The IC50 value of the inhibitory activity of the compound was calculated with Graphpad Prism software.
表3 本公开化合物对MIA PaCa-2细胞增殖的抑制活性Table 3 The compounds of the present disclosure inhibit the proliferation of MIA PaCa-2 cells
化合物编号Compound number IC 50(nM) IC 50 (nM)
2-p1和2-p2中较短保留时间对应的化合物Compounds corresponding to shorter retention times in 2-p1 and 2-p2 1.811.81
结论：本公开化合物对MIA PaCa-2细胞增殖具有抑制作用。Conclusion: The disclosed compound has inhibitory effect on the proliferation of MIA PaCa-2 cells.

Claims (21)

  1. 一种通式(I)所示的化合物或其可药用的盐：A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof:
    Figure PCTCN2022128914-appb-100001
    Figure PCTCN2022128914-appb-100001
    其中：in:
    X选自CR aR b、NR s和氧原子； X is selected from CR a R b , NR s and an oxygen atom;
    Y选自(CR cR d) r、NR t-CR eR f、CR eR f-NR t、O-CR eR f和CR eR f-O； Y is selected from ( CRcRd ) r , NRt - CReRf , CReRf - NRt , O - CReRf and CReRf - O ;
    Z 1和Z 2相同或不同，且各自独立地为CR u或氮原子； Z 1 and Z 2 are the same or different, and are each independently CR u or a nitrogen atom;
    环A为芳基或杂芳基；Ring A is aryl or heteroaryl;
    R a、R b、R c、R d、R e和R f相同或不同，且各自独立地选自氢原子、卤素、烷基、卤代烷基、羟烷基、烷氧基、卤代烷氧基、烯基、炔基、羟基和氰基； R a , R b , R c , R d , R e and R f are the same or different, and each independently selected from hydrogen atom, halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, hydroxyl and cyano;
    R s和R t相同或不同，且各自独立地选自氢原子、烷基、卤代烷基、羟烷基、烯基和炔基； R s and R t are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a haloalkyl group, a hydroxyalkyl group, an alkenyl group and an alkynyl group;
    R 1选自氰基、
    Figure PCTCN2022128914-appb-100002
    R 1 is selected from cyano,
    Figure PCTCN2022128914-appb-100002
    各个R 2相同或不同，且各自独立地选自氢原子、卤素、氰基、烷基、烷氧基、羟基和氨基，其中所述的烷基和烷氧基各自独立地任选被选自卤素、氰基、氨基和羟基中的一个或多个取代基所取代； Each R is the same or different, and is independently selected from a hydrogen atom, a halogen, a cyano group, an alkyl group, an alkoxy group, a hydroxyl group, and an amino group, wherein each of the alkyl and alkoxy groups is independently selected from One or more substituents in halogen, cyano, amino and hydroxyl;
    R 3、R 4、R 5和R u相同或不同，且各自独立地选自氢原子、卤素、氰基、烷基、烯基、炔基、-NR 7aR 7b、-C(O)R 8、-OR 8、-S(O) pR 8、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、烷基、卤代烷基、氰基、-NR 7cR 7d、-OR 8a、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； R 3 , R 4 , R 5 and R u are the same or different, and each independently selected from hydrogen atom, halogen, cyano, alkyl, alkenyl, alkynyl, -NR 7a R 7b , -C(O)R 8 , -OR 8 , -S(O) p R 8 , cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl Each group is independently selected from one or more of halogen, alkyl, haloalkyl, cyano, -NR 7c R 7d , -OR 8a , cycloalkyl, heterocyclyl, aryl and heteroaryl Substituents are substituted;
    各个R 6相同或不同，且各自独立地选自氢原子、卤素、氰基、烷基、烯基、炔基、-NR 9aR 9b、-C(O)NR 9aR 9b、-C(O)R 10、-C(O)OR 10、-OC(O)R 10、-OR 10、-S(O) pR 10、-S(O) pNR 9aR 9b、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、烷基、卤代烷基、氰基、-NR 9cR 9d、-OR 10a、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Each R 6 is the same or different, and each independently selected from hydrogen atom, halogen, cyano, alkyl, alkenyl, alkynyl, -NR 9a R 9b , -C(O)NR 9a R 9b , -C(O )R 10 , -C(O)OR 10 , -OC(O)R 10 , -OR 10 , -S(O) p R 10 , -S(O) p NR 9a R 9b , cycloalkyl, heterocycle radical, aryl and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently selected from halogen, alkyl, haloalkyl, cyano, - NR 9c R 9d , -OR 10a , cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
    R 11、R 12、R 13和R 14相同或不同，且各自独立地选自氢原子、卤素、烷基、-NR 15aR 15b、-OR 16、氰基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、氧代基、烷基、卤代烷基、烷氧基、卤代烷氧基、氰基、-NR 15cR 15d、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； R 11 , R 12 , R 13 and R 14 are the same or different, and are each independently selected from hydrogen atom, halogen, alkyl, -NR 15a R 15b , -OR 16 , cyano, cycloalkyl, heterocyclyl, Aryl and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently selected from halogen, oxo, alkyl, haloalkyl, alkoxy One or more substituents in radical, haloalkoxy, cyano, -NR 15c R 15d , hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
    R 8、R 8a、R 10、R 10a和R 16相同或不同，且各自独立地选自氢原子、烷基、羟烷基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、烷基、烯基、炔基、氧代基、烷氧基、卤代烷基、卤代烷氧基、氰基、-NR 17aR 17b、羟基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； R 8 , R 8a , R 10 , R 10a and R 16 are the same or different, and are each independently selected from a hydrogen atom, an alkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclic group, an aryl group and a heteroaryl group, wherein The alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, oxo, alkoxy, haloalkyl, One or more substituents in haloalkoxy, cyano, -NR 17a R 17b , hydroxyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
    R 7a、R 7b、R 7c、R 7d、R 9a、R 9b、R 9c、R 9d、R 15a、R 15b、R 15c、R 15d、R 17a和R 17b相同或不同，且各自独立地选自氢原子、烷基、羟烷基、环烷基、杂环基、芳基和杂芳基，其中所述的烷基、环烷基、杂环基、芳基和杂芳基各自独立地任选被选自卤素、氧代基、羟基、氰基、烷基、烷氧基、卤代烷基和卤代烷氧基中的一个或多个取代基所取代； R 7a , R 7b , R 7c , R 7d , R 9a , R 9b , R 9c , R 9d , R 15a , R 15b , R 15c , R 15d , R 17a and R 17b are the same or different, and each independently selected From a hydrogen atom, an alkyl group, a hydroxyalkyl group, a cycloalkyl group, a heterocyclyl group, an aryl group and a heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group are independently optionally substituted by one or more substituents selected from halogen, oxo, hydroxy, cyano, alkyl, alkoxy, haloalkyl and haloalkoxy;
    或者R 7a和R 7b与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 7a and R 7b together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
    或者R 7c和R 7d与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 7c and R 7d together with the attached nitrogen atom form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
    或者R 9a和R 9b与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 9a and R 9b form a heterocyclic group together with the connected nitrogen atom, wherein the heterocyclic group is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
    或者R 9c和R 9d与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 9c and R 9d form a heterocyclic group together with the connected nitrogen atom, wherein the heterocyclic group is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
    或者R 15a和R 15b与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 15a and R 15b together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
    或者R 15c和R 15d与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 15c and R 15d together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
    或者R 17a和R 17b与相连的氮原子一起形成杂环基，其中所述杂环基任选被选自卤素、氧代基、烷基、烷氧基、卤代烷基、卤代烷氧基、氰基、氨基、硝基、羟基、羟烷基、环烷基、杂环基、芳基和杂芳基中的一个或多个取代基所取代； Or R 17a and R 17b together with the attached nitrogen atoms form a heterocyclyl, wherein the heterocyclyl is optionally selected from the group consisting of halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano , amino, nitro, hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are substituted by one or more substituents;
    r为1或2；r is 1 or 2;
    s为0、1、2、3、4、5或6；s is 0, 1, 2, 3, 4, 5 or 6;
    t为0、1、2、3、4或5；且t is 0, 1, 2, 3, 4 or 5; and
    p为0、1或2。p is 0, 1 or 2.
  2. 根据权利要求1所述的通式(I)所示的化合物或其可药用的盐，其中X为氧原子。The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein X is an oxygen atom.
  3. 根据权利要求1或2所述的通式(I)所示的化合物或其可药用的盐，其中Y为CH 2或CH 2-CH 2。 The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein Y is CH 2 or CH 2 -CH 2 .
  4. 根据权利要求1至3中任一项所述的通式(I)所示的化合物或其可药用的盐，其中s为0。The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein s is 0.
  5. 根据权利要求1至4中任一项所述的通式(I)所示的化合物或其可药用的盐，其为通式(II)所示的化合物或其可药用的盐：According to the compound represented by the general formula (I) or its pharmaceutically acceptable salt according to any one of claims 1 to 4, it is the compound represented by the general formula (II) or its pharmaceutically acceptable salt:
    Figure PCTCN2022128914-appb-100003
    Figure PCTCN2022128914-appb-100003
    其中：in:
    m为0或1；m is 0 or 1;
    环A、Z 1、Z 2、R 1、R 3、R 4、R 5、R 6和t如权利要求1中所定义。 Ring A, Z 1 , Z 2 , R 1 , R 3 , R 4 , R 5 , R 6 and t are as defined in claim 1 .
  6. 根据权利要求1至5中任一项所述的通式(I)所示的化合物或其可药用的盐，其中环A为环内含有1、2或3个选自氮、氧和硫的杂原子的8至10元双环杂芳基。According to the compound represented by general formula (I) or its pharmaceutically acceptable salt according to any one of claims 1 to 5, wherein ring A contains 1, 2 or 3 rings selected from nitrogen, oxygen and sulfur 8- to 10-membered bicyclic heteroaryl of heteroatoms.
  7. 根据权利要求1至6中任一项所述的通式(I)所示的化合物或其可药用的盐，其中R 1为
    Figure PCTCN2022128914-appb-100004
    其中R 11、R 12和R 13如权利要求1中所定义。     According to the compound represented by the general formula (I) or its pharmaceutically acceptable salt according to any one of claims 1 to 6, wherein R is
    Figure PCTCN2022128914-appb-100004
    wherein R 11 , R 12 and R 13 are as defined in claim 1 .
  8. 根据权利要求1至7中任一项所述的通式(I)所示的化合物或其可药用的盐，其为通式(III)所示的化合物或其可药用的盐：The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, which is a compound represented by the general formula (III) or a pharmaceutically acceptable salt thereof:
    Figure PCTCN2022128914-appb-100005
    Figure PCTCN2022128914-appb-100005
    其中：in:
    W为C(CN)或N；W is C(CN) or N;
    t为0、1、2或3；t is 0, 1, 2 or 3;
    m为0或1；m is 0 or 1;
    Z 1、Z 2、R 3、R 4、R 5、R 6、R 11、R 12和R 13如权利要求1中所定义。 Z 1 , Z 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 and R 13 are as defined in claim 1 .
  9. 根据权利要求1至8中任一项所述的通式(I)所示的化合物或其可药用的盐，其中Z 1和Z 2均为氮原子。 The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, wherein Z 1 and Z 2 are both nitrogen atoms.
  10. 根据权利要求1至9中任一项所述的通式(I)所示的化合物或其可药用的盐，其中R 3、R 4和R 5相同或不同，且各自独立地选自氢原子、卤素、C 1-6烷基和C 1-6卤代烷基。 The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 9, wherein R 3 , R 4 and R 5 are the same or different, and are each independently selected from hydrogen atom, halogen, C 1-6 alkyl and C 1-6 haloalkyl.
  11. 根据权利要求1至10中任一项所述的通式(I)所示的化合物或其可药用的盐，其中各个R 6相同或不同，且各自独立地选自氢原子、卤素、氰基、-NH 2、C 1-6烷基和C 1-6卤代烷基。 The compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, wherein each R is the same or different, and each independently selected from a hydrogen atom, a halogen, a cyanide group, -NH 2 , C 1-6 alkyl and C 1-6 haloalkyl.
  12. 根据权利要求1至11中任一项所述的通式(I)所示的化合物或其可药用的盐，其中R 11为氢原子。 The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, wherein R 11 is a hydrogen atom.
  13. 根据权利要求1至12中任一项所述的通式(I)所示的化合物或其可药用的盐，其中R 12为氢原子。 The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, wherein R 12 is a hydrogen atom.
  14. 根据权利要求1至13中任一项所述的通式(I)所示的化合物或其可药用的盐，其中R 13为氢原子。 The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein R 13 is a hydrogen atom.
  15. 根据权利要求1至14中任一项所述的通式(I)所示的化合物或其可药用的 盐，其选自以下化合物：According to the compound represented by the general formula (I) described in any one of claims 1 to 14 or its pharmaceutically acceptable salt, it is selected from the following compounds:
    Figure PCTCN2022128914-appb-100006
    Figure PCTCN2022128914-appb-100006
  16. 一种通式(Ia)所示的化合物或其盐：A compound or salt thereof represented by general formula (Ia):
    Figure PCTCN2022128914-appb-100007
    Figure PCTCN2022128914-appb-100007
    其中：in:
    环A、X、Y、Z 1、Z 2、R 2、R 3、R 4、R 5、R 6、s和t如权利要求1中所定义。 Rings A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , s and t are as defined in claim 1 .
  17. 化合物或其盐，其选自以下化合物：A compound or a salt thereof selected from the following compounds:
    Figure PCTCN2022128914-appb-100008
    Figure PCTCN2022128914-appb-100008
  18. 一种制备通式(I)所示的化合物或其可药用的盐的方法，其包括：A method for preparing a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, comprising:
    Figure PCTCN2022128914-appb-100009
    Figure PCTCN2022128914-appb-100009
    通式(Ia)化合物或其盐(优选二2,2,2-三氟乙酸盐)和通式(X)化合物或其盐发生反应得到通式(I)化合物或其可药用的盐；General formula (Ia) compound or its salt (preferably two 2,2,2-trifluoroacetic acid salt) and general formula (X) compound or its salt react to obtain general formula (I) compound or its pharmaceutically acceptable salt ;
    其中：in:
    L为卤素；优选地，L为Cl；L is halogen; preferably, L is Cl;
    R 1为
    Figure PCTCN2022128914-appb-100010
     R1 is
    Figure PCTCN2022128914-appb-100010
    环A、X、Y、Z 1、Z 2、R 2、R 3、R 4、R 5、R 6、R 11、R 12、R 13、R 14、s和t如权利要求1中所定义。 Ring A, X, Y, Z 1 , Z 2 , R 2 , R 3 , R 4 , R 5 , R 6 , R 11 , R 12 , R 13 , R 14 , s and t are as defined in claim 1 .
  19. 一种药物组合物，所述药物组合物含有根据权利要求1至15中任一项所述的通式(I)所示的化合物或其可药用的盐，以及一种或多种药学上可接受的载体、稀释剂或赋形剂。A pharmaceutical composition, which contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, and one or more pharmaceutically acceptable carrier, diluent or excipient.
  20. 根据权利要求1至15中任一项所述的通式(I)所示的化合物或其可药用的盐或根据权利要求19所述的药物组合物在制备用于抑制KRAS G12C的药物中的用途。According to the compound represented by the general formula (I) or its pharmaceutically acceptable salt according to any one of claims 1 to 15 or the pharmaceutical composition according to claim 19 in the preparation of medicines for inhibiting KRAS G12C the use of.
  21. 根据权利要求1至15中任一项所述的通式(I)所示的化合物或其可药用的盐或根据权利要求19所述的药物组合物在制备用于治疗和/或预防肿瘤的药物中的用途；优选地，所述的肿瘤为癌症；所述的癌症优选选自肺癌、胰腺癌、***、食管癌、子宫内膜癌、卵巢癌、胆管癌、结直肠癌、肝癌、乳腺癌、***癌、甲状腺癌、胃癌、尿路上皮癌、睾丸癌、白血病、皮肤癌、鳞状细胞癌、基底细胞癌、膀胱癌、头颈癌、肾癌、鼻咽癌、骨癌、淋巴瘤、黑色素瘤、肉瘤、外周神经上皮瘤、胶质瘤、脑瘤和骨髓瘤；更优选选自肺癌、胰腺癌、***、食管癌、子宫内膜癌、卵巢癌、胆管癌和结直肠癌。According to the compound represented by the general formula (I) or its pharmaceutically acceptable salt according to any one of claims 1 to 15 or the pharmaceutical composition according to claim 19 in the preparation for the treatment and/or prevention of tumor Preferably, the tumor is cancer; the cancer is preferably selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer, colorectal cancer, liver cancer , breast cancer, prostate cancer, thyroid cancer, gastric cancer, urothelial cancer, testicular cancer, leukemia, skin cancer, squamous cell carcinoma, basal cell carcinoma, bladder cancer, head and neck cancer, kidney cancer, nasopharyngeal cancer, bone cancer, Lymphoma, melanoma, sarcoma, peripheral neuroepithelial tumor, glioma, brain tumor and myeloma; more preferably selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, cholangiocarcinoma and node cancer rectal cancer.
PCT/CN2022/128914 2021-11-01 2022-11-01 Nitrogen-containing tetracyclic compound, and preparation method therefor and use thereof in medicine WO2023072297A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111284258.5 2021-11-01
CN202111284258 2021-11-01

Publications (1)

Publication Number Publication Date
WO2023072297A1 true WO2023072297A1 (en) 2023-05-04

Family

ID=86159097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/128914 WO2023072297A1 (en) 2021-11-01 2022-11-01 Nitrogen-containing tetracyclic compound, and preparation method therefor and use thereof in medicine

Country Status (2)

Country Link
TW (1) TW202325298A (en)
WO (1) WO2023072297A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912723B2 (en) 2022-02-09 2024-02-27 Quanta Therapeutics, Inc. KRAS modulators and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190177338A1 (en) * 2017-12-08 2019-06-13 Astrazeneca Ab Chemical compounds
CN110603258A (en) * 2017-05-11 2019-12-20 阿斯利康(瑞典)有限公司 Heteroaryl compounds that inhibit G12C mutant RAS proteins
CN112074520A (en) * 2018-05-08 2020-12-11 阿斯利康(瑞典)有限公司 Tetracycloheteroaryl compounds
CN112300194A (en) * 2019-07-30 2021-02-02 上海凌达生物医药有限公司 Condensed ring pyridone compounds, preparation method and application
CN112300195A (en) * 2019-08-02 2021-02-02 上海济煜医药科技有限公司 Tetra-fused ring compound and preparation method and application thereof
CN113508118A (en) * 2019-03-05 2021-10-15 阿斯利康(瑞典)有限公司 Fused tricyclic compounds useful as anticancer agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110603258A (en) * 2017-05-11 2019-12-20 阿斯利康(瑞典)有限公司 Heteroaryl compounds that inhibit G12C mutant RAS proteins
US20190177338A1 (en) * 2017-12-08 2019-06-13 Astrazeneca Ab Chemical compounds
CN112074520A (en) * 2018-05-08 2020-12-11 阿斯利康(瑞典)有限公司 Tetracycloheteroaryl compounds
CN113508118A (en) * 2019-03-05 2021-10-15 阿斯利康(瑞典)有限公司 Fused tricyclic compounds useful as anticancer agents
CN112300194A (en) * 2019-07-30 2021-02-02 上海凌达生物医药有限公司 Condensed ring pyridone compounds, preparation method and application
CN112300195A (en) * 2019-08-02 2021-02-02 上海济煜医药科技有限公司 Tetra-fused ring compound and preparation method and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912723B2 (en) 2022-02-09 2024-02-27 Quanta Therapeutics, Inc. KRAS modulators and uses thereof

Also Published As

Publication number Publication date
TW202325298A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
CN107108611B (en) Tetrahydro-pyrido [3,4-b ] indole estrogen receptor modulators and uses thereof
CN102171214B (en) Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
CN113980032B (en) Fused tetracyclic derivative, preparation method thereof and application thereof in medicines
WO2022247816A1 (en) Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines
WO2022228543A1 (en) Bridged ring compound, preparation method therefor, and application thereof in medicine
WO2021098811A1 (en) Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof
CN116199703A (en) Fused tetracyclic heterocyclic compound, preparation method thereof and application thereof in medicine
CN115385938A (en) Benzopyrimidine compounds, preparation method thereof and application thereof in medicines
WO2023072297A1 (en) Nitrogen-containing tetracyclic compound, and preparation method therefor and use thereof in medicine
WO2023066371A1 (en) Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof
JP6554480B2 (en) Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
WO2023116862A1 (en) Hydrogenated indole compound, and preparation method and medical use therefor
CN115594695A (en) Macrocyclic compound, preparation method and medical application thereof
TW202321263A (en) Sulfonamide derivatives, their preparation methods and their medical use
WO2022002243A1 (en) Imidazopyrimidine derivative, preparation method therefor and medical use thereof
CN113912608B (en) Pyrimidopyrimidinone derivatives, preparation method thereof and application thereof in medicines
CN116640154A (en) Polycyclic compounds, process for their preparation and their use in medicine
WO2024046420A1 (en) Fused bicyclic compound, and preparation method therefor and use thereof in medicine
WO2021143821A1 (en) Fused heteroaryl derivative, preparation method therefor, and application thereof in medicine
WO2024041643A1 (en) Fused tricyclic compound, preparation method therefor, and medical use thereof
WO2023185793A1 (en) Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
WO2024022444A1 (en) Fused ring compound, preparation method therefor and medicinal application thereof
WO2022161447A1 (en) Dicarboxamide compound, preparation method therefor, and pharmaceutical use thereof
WO2023174374A1 (en) Fused heterocyclic compound, and preparation method therefor and medical use thereof
WO2022166810A1 (en) Fused azatricyclic derivative, preparation method therefor, and application thereof in medicine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22886172

Country of ref document: EP

Kind code of ref document: A1